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1 Introduction: Blindness and Glaucoma with focus on de-
veloping countries 
Loss of vision and blindness is an individual as well as a global health issue of major 
relevance. WHO estimated the global prevalence of blindness in 2010 with a world 
population of 6.7 billion. The number of visually impaired people is estimated to be 
285.4 million (4.24%), 39.4 million (0.58%) of these are blind, and 246 million (3.65%) 
have low vision. (WHO 2010, 2014) Blindness seems to correspond to economic wealth 
of regions, as 90% of all blindness cases are found in developing countries, the largest 
numbers in the least developed countries, mostly Asia and Sub-Saharan Africa (SSA). 
(Resnikoff & Pararajasegaram 2001) (WHO 2012a) It was estimated that 1% of Africa’s 
population was blind in 2001. (Lewallen 2001)  
In many regions of the world, glaucoma ranks second among blindness causing diseas-
es. (Foster & Resnikoff 2005) As the development of glaucoma is related to age, this 
pathology is of major relevance especially in developing countries, because of the rising 
life expectancy which is currently seen in these countries. (Tham et al. 2014) 
The following chapters are an introduction to blindness and glaucoma. Main facts and 
figures will be indicated with special focus on developing countries, especially Africa. 
The last part of the introduction will present objectives and aims of the present research.    
1.1 Blindness 
The following sections deal with blindness on a global scale, especially with numbers 
from Africa and Malawi. Furthermore, a definition of blindness is given as well as 
global causes of blindness, with differences between developing and developed coun-
tries. The term “avoidable blindness” is introduced. Positive trends and difficulties in 
the development of blindness prevalence are described.       
1.1.1 Prevalence of blindness in Africa 
SSA carries a great load of global blindness. While the population constitutes 12% of 
the global population, it accounts for 15% of the world’s visual impairment (VI). This 
2 
 
 
discrepancy is especially due to high numbers of ocular infectious diseases, e.g. tracho-
ma and onchocerciasis, but also due to untreated cataracts. Often, preventable VI ranks 
as a major cause of disability in this part of the world. (Budenz et al. 2012) (Pascolini & 
Mariotti 2012)  
There are regional differences occurring within the African continent, as B/VI in Nai-
doo’s survey was highest in West Africa and lowest in southern and central Africa.  
(Naidoo et al. 2014) A WHO data extrapolation indicates 1% of Malawians are blind, 
while 80% of those are supposed to be 50 years and older. A “Rapid Assessment of 
Avoidable Blindness” (RAAB) in Malawi from 2009/10 in the course of Vision 2020 
planning calculated that 3.3% of people aged 50 and older are affected by blindness in 
southern Malawi. (Kalua et al. 2011) 
Furthermore, an age above 50 and female gender are two factors associated with a 
higher risk of developing visual impairment. For example, 65% of those visually im-
paired and 82% of blind people are 50 years or above and it is predicted that by 2019, 
84% of all people with VI will be 50 years or older. Speaking about gender differences 
globally, women form a larger part of B/VI. (Naidoo et al. 2014) (Resnikoff, S. et al. 
2004) (WHO 2012a) (WHO 2013) This difference is most likely due to women’s longer 
life expectancy and lack of access to health services in many poorer societies. (Quigley 
& Broman 2006) (WHO 2007) In Africa, prevalence of moderate and severe vision 
impairment (MSVI) among men was 3.8%, but 4.2% for women. While 4.1% of men 
and 4.7% of women in West Africa had MSVI, in southern Africa the prevalence for 
men was only 2.0% and for women 2.3%. (Naidoo et al. 2014) Also in Malawi, age and 
female gender seem to be associated with blindness. People in the age group above 70 
years as well as women seem to be more often affected by blindness. (Courtright 2003) 
1.1.2 Definition of blindness 
There are several definitions of blindness. The one used throughout this thesis is the 
definition used in abovementioned WHO data and most articles dealing with blindness. 
It is based on ICD-10, an internationally acknowledged health care classification sys-
tem, maintained by WHO. It defines blindness as being present at vision of less than 
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3/60. In general, this classification of visual impairment comprises the following cate-
gories 0 to 5: (WHO 2015) 
 Category 0 is mild or no visual impairment with vision of 6/18 or better.  
 Categories 1 is MSVI with less than 6/18 and equal to or better than 6/60            
(<6/18 to ≥6/60).  
 Category 2 is MSVI with less than 6/60 and equal or better than 3/60 (<6/60 to 
≥3/60).  
Categories 1 and 2 are combined as “low vision”. Blindness is described in categories 3 
to 5:  
 Category 3 blindness is between 3/60 and 1/60 or finger counting at one meter     
(<3/18 to ≥1/60).  
 Category 4 blindness ranges between less than 1/60 and light perception. 
 Category 5 blindness has no light perception at all. 
 
1.1.3 Causes of blindness 
Various pathologies can be traced as underlying causes of blindness. As a major influ-
encing parameter, ageing plays a role in the development of blindness. In the industrial-
ised world, age-related macular degeneration (AMD) accounts for the largest proportion 
of blindness. On a global scale, though, about half of all blindness cases (51%) are 
caused by cataract, which is also mainly an age-related disease. Although there have 
been great improvements in the delivery of cataract surgery in developing countries, it is 
still the number one reason of blindness. In terms of VI in general, uncorrected refrac-
tive errors account for 42% of all cases and again cataract plays a major role, causing 
33% of VI. (WHO 2010, 2012a) (Resnikoff, S. et al. 2004) 
The second leading cause of blindness worldwide is glaucoma, with numbers indicated 
to cause between 8-12% of blindness. (Foster & Resnikoff 2005) (Pascolini & Mariotti 
2012) (WHO 2010) In Cook’s study looking at the prevalence of blindness due to glau-
coma in different African countries, glaucoma represents the second leading cause with 
up to 30%. (Cook 2009) In the RAAB for southern Malawi, including the district of 
Blantyre, in which the research of this thesis was conducted, glaucoma was also record-
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ed as the second most common cause of blindness with 15.8%, after untreated cataract 
with 48.2%.  
Another cause of blindness in Malawi is non-trachomatous corneal scarring with 12.3%. 
Trachoma has a rather low prevalence with 4.4% and onchocerciasis was not recorded 
at all. (Kalua et al. 2011) AMD comes third globally with 5%. In developed countries, 
though, it ranks first. Childhood blindness and corneal opacities cause 4% each, uncor-
rected refractive errors and trachoma 3% each, and diabetic retinopathy 1% of all blind-
ness. Despite all research, 21% of blindness have undetermined causes. (WHO 2012a) 
Numbers from 2010 regarding SSA depict a slightly different picture, in which glauco-
ma appears later in the list: cataract 35%, other or unidentiﬁed causes 33.1%, refractive 
error 13.2%, macular degeneration 6.3%, trachoma 5.2%, glaucoma 4.4%, and diabetic 
retinopathy 2.8%. (Naidoo et al. 2014) 
It is worth mentioning, that most of abovementioned causes of blindness and visual 
impairment are treatable eye diseases. Hence, a large proportion of present blindness 
could have been or can be avoided with timely diagnose and treatment. Estimations by 
WHO state, that 75% of all blindness worldwide in 1996 could have been avoided, an 
assumption which gave rise to the term “avoidable blindness”. (WHO 2007) The WHO 
action plan 2014-2019 for universal eye health speaks of 80% of all causes of visual 
impairment which are preventable or curable. (WHO 2013) In accordance with this 
number, the RAAB in southern Malawi indicates that 75.4% of blindness is due to 
avoidable causes like glaucoma. (Kalua et al. 2011) 
1.1.4 Decrease of blindness cases overall 
A reduction of B/VI appears feasible knowing the fact that many causes are treatable 
and avoidable. In accordance with this hypothesis and despite previous figures about 
missed opportunities to save eyesight, there are positive trends in the development of 
global blindness, as explained in the following sections.  
In response to the awareness  of blindness as a health issue of worldwide impact, there 
have been international initiatives by WHO and associated partners such as the Interna-
tional Agency for the Prevention of Blindness (IAPB) to strive for a reduction or even 
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elimination of avoidable blindness. The “Global Initiative for the Elimination of Avoid-
able Blindness” from 1999 is also known as “VISION 2020: the Right to Sight”, with 
an action plan, revised in 2006 and 2013. It contains the joint aims of eliminating the 
main causes of avoidable blindness, and halting the doubling of the number of blind 
people by the year 2020, which is projected by researchers. On a national level they try 
to increase awareness and facilitate the implementation of eye health services. They 
have also tried to gain insight into causes of blindness and vision impairment (B/VI) in 
Africa. A major difficulty in realizing this attempt is the scarcity of epidemiological 
data, resulting in a call by WHO in 2004 for intensified research on eye disease preva-
lence in Africa. (Naidoo et al. 2014) (Resnikoff, S. et al. 2004) (IAPB 2010) 
A comprehensive data set shows a worldwide decline of blindness prevalence over the 
last 20 years. International agencies see this as a success resulting from the fight against 
avoidable blindness, launched in VISION 2020. (IAPB 2013) In a WHO article compar-
ing global data, a reduction of VI for example in the age group of 50 and older is seen, 
despite the rapid growth of this part of the population. The decline of VI in the elderly 
goes hand in hand with an improved socio-economic situation, as well as governmental 
and international efforts to contribute to eye health. (WHO 2012a)  
Taking existing numbers from Africa, prevalence of B/VI has been substantially re-
duced between 1990 and 2010. Blindness (age-standardised prevalence) was reduced by 
32% from 1.9% in 1990 to 1.3% in 2010 and MSVI decreased by 25% from 5.3% to 
4.0% between 1990 and 2010. Statistically, absolute numbers of blindness and MSVI in 
Africa at all ages increased by 16% from 4.1 million blind in 1990 to 4.7 million in 
2010 and 13 million with MSVI in 1990 to 16.6 million people in 2010. Nonetheless, 
there has been a general reduction of blindness prevalence due to the fact that the over-
all African population increased by 66% during the same time span. It is also a success 
regarding the fact that the African population is constantly ageing. (Bourne et al. 2013) 
(Naidoo et al. 2014)  
Successful actions to achieve a reduction of blindness worldwide have been taken ada-
mantly against blinding infectious diseases, such as trachoma, onchocerciasis, or against 
cataract with highly effective surgeries. In Malawi a reduction of blindness cases was 
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realized, most likely due to the increase of cataract surgeries from around 300 per mil-
lion populations in 2003 to approximately 850 per million populations per year in 2010. 
(Kalua et al. 2011) Despite this positive trend of decreasing total blindness numbers, 
problem solution and prevention of blindness caused by glaucoma proves to be more 
challenging.  
Different authors claim that tackling blindness from glaucoma is a bigger challenge in 
comparison to cataract for several reasons. The main reason is that cataract is easier to 
diagnose in comparison to glaucoma. The latter is not only asymptomatic at least in the 
first few years, but also more demanding in its detection, diagnosis, and treatment. 
Further, blindness caused by glaucoma is irreversible, as visual fields cannot be re-
gained, whereas in cataract, surgery can usually reduce or even reverse visual impair-
ment, which makes its treatment more effective. (Kingman 2004) (Kayange et al. 2014) 
Therefore, presentation patterns, treatment and impacts of glaucoma are important fields 
for research and public health if they want to contribute to the prevention of avoidable 
blindness caused by glaucoma, as shown in the next chapter. 
1.2 Glaucoma 
The following passages introduce the prevalence of glaucoma and blindness caused by 
the disease worldwide, with a focus on developing countries. The chapters elaborate on 
problems in the detection and awareness of glaucoma, general aspects like definitions, 
pathophysiology and risk factors. The two major types of glaucoma are introduced. 
These aspects are crucial for the study design, results and discussion of this thesis. 
Treatment, on the other hand, is not considered in the study and therefore not included 
in detailed elaborations. For theoretical basics on treatment see relevant scientific litera-
ture (e.g. (Kanski & Burk 1996) (Pfeiffer 2005) (Flammer 2001)).  
The sections stress geographical variations in glaucoma prevalence. Despite decreasing 
numbers of blindness by chronic eye diseases, glaucoma is becoming an increasing 
burden to global and national economies and health systems. Therefore, one of the main 
questions of this thesis is the rationale for a glaucoma screening. This topic is dealt with 
in chapter 1.2.7. 
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1.2.1 Prevalence of glaucoma 
The prevalence of glaucoma is part of the following section. There is divergent infor-
mation about prevalence and because glaucoma is intimately associated with age, many 
prevalence indications are given in relation to it. On a worldwide scale, 1% of people 
older than 50 years are said to be affected by glaucoma, according to Adio and Onua 
2012. (Adio & Onua 2012) Another pooled prevalence estimate by Tham et al is given 
for the population of 40 to 80 years in the year 2013, where the global prevalence of 
glaucoma in this age group is indicated as 3.54% (range 1.69-5.27). (Tham et al. 2014) 
Numbers are rising with higher age, which is particularly true for people of African 
descent. (Adio & Onua 2012)  
Worldwide people are affected mainly by two major glaucoma types. 74% of patients 
globally suffer from primary open-angle-glaucoma (POAG) and 26% from angle-
closure glaucoma (ACG). According to Quigley and Broman this corresponds to a 
global prevalence of 1.96% in POAG as well as 0.69% of ACG in 2010, giving 2.65% 
combined. While 80% of ACG patients are Asians, POAG is most prevalent in Africa 
and among people with African descent. (Quigley & Broman 2006) (Lawan 2013) 
Tham et al give differing numbers and indicate that worldwide glaucoma (POAG and 
ACG combined) prevalence is 3.54%, as mentioned above, of which ACG makes 0.5% 
and POAG makes 3.05%. (Tham et al. 2014) Conclusively, there is a range of 1% to 
3.54% global glaucoma prevalence in the cited literature. Differences might result from 
varying glaucoma definitions, criteria and age ranges among other reasons.  
It is estimated that in Africa the prevalence of glaucoma in people of 40 years and older 
is about 4%, (Cook 2009) but numbers vary in different regions and ethnic groups and 
also in between literature, but are especially high in West Africa, as shown in Table 1 
below.  
Tham’s literature review stresses the geographical variations regarding glaucoma. Com-
paring different world regions, glaucoma prevalence ranked highest on the African 
continent with 4.79% (range 2.63-8.03). Thereof POAG makes 4.2% (range 2.08-7.35) 
and ACG 0.6% prevalence. (Tham et al. 2014) In Ghana, POAG affected 8.5% of peo-
ple aged 40 years and older in 2010, up to 13 to 18% in people older than 64 years, but 
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also 7.7% in patients between 30 and 40 years of age. (Ntim-Amponsah et al. 2004) 
These numbers rank among the highest in the world. (Gyasi et al. 2010) Budenz states 
that preventable vision loss from glaucoma is a major problem in the Ghanaian popula-
tion. (Budenz et al. 2012)  
Table 1 outlines the geographical variance within Africa and gives examples of glauco-
ma prevalence and/or types in South Africa, Tanzania, and Ghana. 
Table 1 Variance of glaucoma prevalence in different African regions (modified after (Cook 2009)) 
First Author 
Salmon 
(Salmon 1993) 
Rotchford 
(Rotchford et 
al. 2003) 
Buhrmann 
(Buhrmann et al. 
2000) 
Ntim-Amponsah 
(Ntim-Amponsah 
et al. 2004) 
Year of publica-
tion 
1993 2003 2000 2004 
Country 
South Africa 
(Western Cape) 
South Africa 
(North-West) 
Tanzania 
Ghana 
(West Africa) 
 
Number of 
participants 
987 839 3268 1785 
Age group 
40 years or 
older 
40 years or 
older 
40 years or older 40 years or older 
All Glaucoma 
prevalence 
- 5.3 4.16  - 
Primary open 
angle glaucoma 
prevalence 
1.5 2.9  3.1  8.5 
Primary closed 
angle glaucoma 
prevalence 
2.3 0.5  0.59 - 
Secondary glau-
coma prevalence 
- 2.0  0.47 - 
 
Glaucoma prevalence is rising, but nevertheless the first phase of VISION 2020 starting 
in 1999 did not focus on glaucoma yet. It was therefore not listed among the top five 
eye diseases, which were cataract, trachoma, onchocerciasis, childhood blindness, and 
uncorrected refractive errors – diseases with easier and more effective and promising 
9 
 
 
treatment options. (Babalola 2011) WHO claims that most glaucoma forms can be 
managed successfully and it is therefore advisable to consider it in national VISION 
2020 programmes. In the meantime, as shown in the next passage, glaucoma is now one 
of WHO’s focus points in VISION 2020 and also on WHO’s list of priority eye diseas-
es. (WHO 2015b) (WHO 2015a) 
Rising numbers of glaucoma support the importance of tackling the issue in internation-
al and national health programmes. In 2010, more than 60 million people (aged 40-80) 
were expected to suffer from glaucoma worldwide. 60.5 million affected people in 2010 
were projected by Quigley and Broman in 2006 and 64.3 million according to Tham et 
al. (Quigley & Broman 2006) (Tham et al. 2014) Calculations show that glaucoma will 
increase to about 80 million in 2020. (Quigley & Broman 2006) A systematic review 
and meta-analysis projects a rise of people affected by glaucoma to 111.8 million by 
2040, a 74% increase compared to 64.3 million in 2013. (Tham et al. 2014) 
Most ponderous are increasing numbers in Africa and Asia, whereof Asia will shelter 
the largest number of POAG and ACG. Africa’s number of glaucoma cases will in-
crease by 130.8% (10.9 million) from 2013 to 2040, developing from 8.29 million in 
2013 to 10.31 million in 2020 to 19.14 million people with glaucoma in 2040. In Eu-
rope, northern America and Oceania there will only be a minor growth in numbers. 
(Tham et al. 2014) 
This upsurge in glaucoma cases can mostly be explained by ageing populations all over 
the world. Increasing life expectancy will be most strikingly in Africa and Asia, while 
in the western world age structures are rather stable. (Tham et al. 2014) (Budenz et al. 
2012) Tham et al. found that people living in urban areas were 58% more likely to 
present with POAG than people in rural areas. Possible explanations in the article are 
the higher incidence of myopia among urban populations and a difference in lifestyle, 
regarding stress, pollution, physical activity or diet. (Tham et al. 2014) 
Glaucoma is not only important in terms of prevalence, but because of the detrimental 
effects of vision loss on an individual’s personal and professional life and consecutively 
on a country’s economy. 
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1.2.2 Blindness from glaucoma 
Approximately 8% of all blindness is due to glaucoma, the second leading cause 
worldwide, as mentioned in . (Pascolini & Mariotti 2012) (WHO 2010) Quigley and 
Broman compare several surveys and find differing numbers. Previous studies gave a 
number of 4.4 million (12%) of blindness caused by glaucoma, while another suggests 
8.4 million (>20%) bilaterally blind from glaucoma in 2010 and 11.1 million in 2020. 
The reason for this discrepancy, as Quigley and Broman explain, is a difference in 
methodology of prevalence surveys. Many underestimate glaucoma numbers by focus-
ing more on “treatable” diseases as causes of blindness, such as cataract. (Quigley & 
Broman 2006) Adio and Onua claim glaucoma to cause as much as one third of current 
blindness. (Adio & Onua 2012) 
The risk of blindness resulting from glaucoma varies among individuals, ethnic groups, 
and regions, but it is particularly high in patients from developing countries. (Chen 
2004) (Quigley 1996) (Ramchandani 2006) In SSA glaucoma caused 4.4% of blindness 
in 2010, according to Naidoo et al., while Resnikoff et al. speak of 15%. (Naidoo et al. 
2014) (Resnikoff, S. et al. 2004) 
Table 2 demonstrates the percentages of blindness due to the main causes, namely 
glaucoma, as well as cataract, trachoma, and macular degeneration in different African 
regions and Africa in total compared to global data. 
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Table 2: Blindness in Africa and worldwide by causes (modified after (Naidoo et al. 2014)) 
Region 
Glaucoma      
Blind (%) 
Cataract         
Blind (%) 
Macular 
degeneration 
Blind (%) 
Trachoma       
Blind (%) 
1990     
Central Africa 3.3  41.0  4.8  0.94 
East Africa 2.9  35.4  4.1  13.5 
Southern Africa 5.4  34.0  6.9  1.6  
West Africa 2.9  37.1  4.1  7.3  
Africa 3.1  36.5  3.8  8.9  
World 4.4  38.6  4.9  2.8  
2010     
Central Africa 5.2  34.8  6.9  0.44 
East Africa 4.0  36.7  5.8  8.1  
Southern Africa 7.3  31.2  9.7  0.69 
West Africa 4.4  33.8  6.2  3.6  
Africa 4.4  35.0  6.3  5.2  
World 6.6  33.4 6.6  1.4  
 
Also Table 3 shows that regional differences of blindness owing to glaucoma within 
Africa are tremendous. Interregional discrepancies are large among all cited authors, 
with over 30% in a Nigerian study compared to 6% in a South African research. In 
many studies though, as already mentioned above, glaucoma ranks second among all 
causes of blindness. The regional variance proves the importance of research within the 
different parts of the world for better and more targeted health programmes. The strong 
differences especially regarding blindness levels might be partially due to the large time 
difference. Registration of blindness cases in the late 1980s and 1990s might not have 
reached all parts of the population.  
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Table 3: Prevalence of Blindness, Proportion owing to Glaucoma, Ranking  (modified after Cook 2009) 
First 
Author 
Year  Country Surveyed Ages  
Overall 
Blindness 
Prevalence, 
%  
Proportion of 
Blindness Owing 
to Glaucoma (%) 
Ranking of 
Blindness 
Owing to 
Glaucoma 
Bucher 1988 South Africa All ages 0.57  6.0 Fourth 
Balo 1989 Togo All ages 0.82 6.0 Second 
Negrel 1990 Congo All ages 0.30 9.0 Second 
Cook 1993 South Africa All ages 1.00  22.9 Second 
Negrel 1995 Benin All ages 0.6 15.0 Second 
Melese 2003 Ethiopia 
40 years and 
older 
7.9  7.6 Third 
Guzek 2005 Ghana 
40 years and 
older 
4.4 20.6 Second 
Adegbe-
be-
hingbe 
2006 Nigeria 
60 years and 
older 
5.6 32.4 Second 
Ona-
kpoya 
2007 Nigeria All ages 1.1 14.3 Second 
The high risk of going blind from glaucoma in developing countries has multiple ori-
gins. Firstly, the awareness among affected individuals is low. Therefore, individuals 
present late to specialists, often already blind in at least one eye upon first presentation. 
Secondly, infrequency of ophthalmologic check-ups leads to advanced stages. (Ntim-
Amponsah et al. 2005) Thirdly, among Africans the disease is more aggressive and 
leads to earlier blindness. (Kyari et al. 2013) And lastly, the number of ophthalmolo-
gists in developing countries is very low in comparison to more developed, industrial-
ised countries, which reduces the chance of regular medical examinations. (Gyasi et al. 
2010) Further reasons for the high risk of becoming blind from glaucoma especially in 
Africa will be discussed in chapter 1.2.6. 
As discussed in the previous chapter, glaucoma was not put on the VISION 2020 priori-
ty list of eye diseases, which was mainly due to uncertainty or inability to detect and 
manage this pathology. (Cook 2009) Nevertheless, recent efforts show that tackling the 
problem of this blinding disease gained importance internationally and in Africa. In 
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2010 Ghana hosted the World Glaucoma Association’s (WGA) first Africa glaucoma 
summit. Its participants stressed to improve glaucoma management, training, and educa-
tion, and include them into existing national programmes. In 2012, the Kampala Resolu-
tion constituted another reminder for those in glaucoma care to raise awareness of the 
disease and incorporate it into eye care services and policies. (WGA 2010) (PBU 2012) 
Despite the blinding effect of glaucoma, which arises typically late in the progress of 
the disease, the lack of symptoms and knowledge often leads to unawareness among 
affected people, as discussed in the following section.  
1.2.3 Detection and awareness 
Globally only a limited proportion of glaucoma patients are diagnosed or treated. Preva-
lence surveys suggest that in the developed world, about half of all cases are likely to be 
diagnosed. However, in developing countries, especially in very remote and medically 
underserved parts, the number of detection is probably closer to one in ten or less. 
(Ntim-Amponsah et al. 2004) (Rotchford 2005) 
Glaucoma is sometimes called the “thief of sight”. This name stems from the asympto-
matic progression and nature of the disease, which leads to patients being unaware of 
their potentially blinding disease and doctors having difficulties detecting it. (Faal 2012) 
Kyari et al. underline the low awareness of glaucoma by scrutinizing several articles 
comparing awareness, attitudes, and knowledge of glaucoma patients in different Afri-
can settings. (Kyari et al. 2013) 
The high rate of undiagnosed glaucoma may further be due to the complex diagnosis 
and poor availability of adequate eye care facilities, staff, and equipment. (Olawoye et 
al. 2013) Mermoud, a Swiss ophthalmologist and founder of the charity “Vision for 
all”, names the lack of well-trained eye doctors to be the main limiting factor in diag-
nosing and managing glaucoma patients in the developing world. He continues to elabo-
rate on the disproportion between doctors and patients. Whereas in Europe one oph-
thalmologist serves 10 000 patients, in India there is one eye doctor for 400 000, while 
in Africa it is one or even less for a million patients. (Kingman 2004) 
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Nevertheless, diagnostic technology and thus detection are improving, which might in 
part explain the increasing numbers of glaucoma prevalence. (Cedrone et al. 2008) This 
is true for settings of industrialised environments, and may also be applicable for devel-
oping countries. The next chapter introduces possible definitions, classifications, patho-
physiology, and diagnostics of glaucoma. It highlights special features of the African 
setting and creates a base for the following presentation and discussion of results.    
1.2.4 Definition and classifications  
There has not yet been an international definition of glaucoma. (Pfeiffer 2010) This 
uncertainty makes diagnosis and comparison of various epidemiological studies diffi-
cult, because they often use different definitions which can lead to considerably varying 
numbers and outcomes. (Weinreb et al. 2008)  
It is crucial to stress that glaucoma in general is now considered a group of diseases, not 
one disease alone. Therefore, Pfeiffer speaks of glaucoma in plural (German: Glau-
kome). (Pfeiffer 2005) In a review of studies on how to define chronic open-angle 
glaucoma (OAG), the authors found different combinations of mainly three parameters 
“glaucomatous optic nerve appearance”, “visual field defect” and “elevated intraocular 
pressure (IOP)”. These three features played a major role in most studies. (Spry & 
Sparrow 2005) The following paragraphs are a brief summary of three existing glauco-
ma definitions. 
One example is the definition by the UK National Screening Committee (UK NSC), 
defining glaucoma as “a chronic, age-related optic neuropathy characterised by at least 
one eye having a defined visual field abnormality combined with an optic disc appear-
ance compatible with the functional loss.” (Spry & Sparrow 2005) 
In 1998, the International Society of Geographical and Epidemiological Ophthalmology 
(ISGEO) suggested a standard definition and classification system for glaucoma, which 
takes different diagnostic possibilities into consideration. This seems a practical ap-
proach given the fact that firstly, not all examinations are possible in each patient and 
secondly, not all tools may be present at different settings, e.g. in many developing 
countries. ISGEO defines glaucoma as structural optic nerve damage with functional 
deficit. Three levels of evidence describe the disease, without considering angle fea-
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tures. The highest level presents the assessment of structural damage in terms of a large 
vertical cup-to-disc ratio (VCDR), ≥97.5th percentile of the VCDR of the normal popu-
lation and functional damage in terms of visual field defects. Level two has stronger 
optic disc damage >99.5
th
 percentile, or asymmetry, if visual field testing is unavailable. 
Level three, if cup-to-disc ratio (CDR) and visual fields cannot be assessed, IOP >99.5
th
 
percentile of the normal population, visual acuity (VA) less than 3/60 and medical 
history of glaucoma could help in defining glaucoma. (Kyari et al. 2013) (Foster et al. 
2002)  
A further category is glaucoma suspect. These individuals either have glaucoma suspi-
cious optic discs with IOPs below 22 millimetre of mercury (mmHg) with an unsuspi-
cious visual field, or borderline optic discs with IOPs above 21 mmHg, or further risk 
factors or borderline optic discs with non-accessible or non-utilisable visual fields. 
(BVA & DOG 2006) 
A concluding remark regarding definitions by Kyari et al. relativises the theoretical 
discussion and puts focus on the practical consequences. He claims that although sur-
veys vary in definitions and methodologies and are thus not totally comparable, the 
main conclusion is “that glaucoma is a public health problem in SSA”, (Kyari et al. 
2013) and therefore the topic needs further consideration and research. 
In summary, after introducing different definitions and classifications, it can be defined 
as usually bilateral, often asymmetric disease, which shows the following features in at 
least one eye: glaucomatous optic nerve damage, glaucomatous visual field defect, 
repeatedly IOPs above 21 mmHg, a disease onset during adulthood and absence of any 
secondary reasons for glaucoma. Nevertheless, 15% of all POAG patients constantly 
present with IOPs below 21 mmHg and thus are diagnosed with so called normal ten-
sion glaucoma (NTG). (Kanski & Burk 1996) 
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1.2.5 Pathophysiology and diagnostics 
Glaucoma, as defined above, is not one disease but a set of pathologies with some 
common and some varying pathologic and diagnostic features, explained at length in 
respective text books. A few special aspects arise in the African context and are ex-
plained below.   
In glaucoma, a still incompletely understood underlying pathologic process is silently 
and gradually destroying retinal nerve fibres of the optic nerve. This results in nerve 
fibre loss, which first strikes the optic nerve head. (Flammer 2001) A large quantity of 
nerve fibres may already be destroyed before a patient consciously perceives visual 
impairment in the form of a reduced visual field. Twenty percent ganglion cell loss 
corresponds to five decibel sensitivity loss and ten decibel sensitivity reduction with 
already 40% ganglion cell loss. (Quigley et al. 1989)  
CDR is genetically determined and in most eyes it is 0.3 or below. Ratios above 0.3 in 
one eye, or a difference in the ratios of more than 0.1 between both eyes should be 
regarded as suspicious. (Kanski & Burk 1996) For diagnostics among an African popu-
lation it has to mentioned, that these often present with larger optic discs. This has to be 
respected in CDR assessments. (Nangia et al. 2013)  
The origins and risk factors of the abovementioned nerve fibre loss will be discussed in 
more detail in section 1.2.6. One relevant factor, though, is IOP. Normal values range 
between 10 and 21 mmHg (average 16 mmHg) and fluctuate within a 4 mmHg-range in 
healthy eyes, depending upon daytime, blood pressure and other factors. Glaucomatous 
eyes may even vary within a 10 mmHg-range. In general terms, IOP is now considered 
to be normal if it does not harm the eye and is thus individually determined. (Kanski & 
Burk 1996) 
For diagnostics of glaucoma, all these pathologic features should be assessed. It is 
further important to assess the optic nerve head by funduscopy through a dilated pupil. 
Findings should be documented by drawing or photograph for better comparison during 
follow-up and judgment of progression. As a final examination, visual field should be 
assessed by perimetry. (Kanski & Burk 1996) In African settings visual field tests are 
often “unavailable and unnecessary”, as Bowman and Kirupananthan write in their 
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article on “How to manage a patient with glaucoma in Africa”. (Bowman & Kirupanan-
than 2006) This lack of visual field diagnostics in developing countries may result in an 
underestimation of glaucoma prevalence. One alternative which can be useful in devel-
oping countries is funduscopy with optic disc assessment in combination with a drawing 
of the fundus. This method is subjective and far from ideal, but it allows getting an 
approximate prevalence of glaucoma, detecting advanced disease stages and giving at 
least some (drawn) documentation for a better follow-up. (Foster et al. 2002)  
1.2.6 Risk factors 
In the African context of the current study an accumulation of several individual risk 
factors for the development of glaucoma is found. This phenomenon may in part be an 
explanation for the importance and high prevalence of this pathology. 
The AAO has published guidelines on Preferred Practice Patterns® for POAG. This 
paper itemises the following risk factors associated with POAG: (AAO 2010b) 
 Increased intraocular pressure 
 Old age 
 Family history of glaucoma 
 African ancestry or Latino/Hispanic ethnicity 
 Thin central cornea thickness 
 Low ocular perfusion pressures 
 Type II diabetes mellitus 
 Myopia 
 Genetic mutations 
Flammer distinguishes between risk factors for increased IOP values (e age, familial 
predisposition, race, arteriosclerosis, and myopia), from risk factors for glaucomatous 
damage. The latter are increased IOP, vascular dysregulation with arterial hypotension 
and vasospasm, female gender, and race. (Flammer 2001) Risk factors which are of 
importance in the setting of this thesis will be elucidated in more detail in the following 
paragraphs.  
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Increased intraocular pressure levels are a well-known and widely discussed poten-
tial and potent risk factor in the development of glaucomatous damage. The higher the 
pressure, the greater is the likelihood to develop optic nerve damage. Variation of pres-
sure with spikes may even be more harmful to the optic nerve than high pressure alone, 
and patients with undulating IOPs are more likely to have severe glaucoma progression. 
The duration of elevated pressure is crucial. An acute rise, as e.g. during a glaucoma 
attack, does not necessarily cause harm if the IOP is lowered promptly, in comparison 
to a detrimental chronic elevation. 
Stewart stresses the relevance of increased IOP for glaucoma damage and the progres-
sion of disease especially in eyes with mean IOP higher than 21 mmHg. (Stewart et al. 
1993) (Stewart et al. 2000) The Ocular Hypertension Treatment Study (OHTS) men-
tions that lowering IOP leads to a significant reduction of disease progression. (OHTS 
& EGPS 2007) If this opportunity is missed, as in many cases in the developing world, 
a chance to avoid optic nerve damage is lost. Leske et al. found in follow-ups on treated 
and untreated POAG patients that initial IOP reduction was most important regarding 
the outcome, since every lower or higher mmHg in IOP occurred with approximately 
10% decrease or increase in the risk for progression of visual field defects. (Leske et al. 
2003) Spry and Sparrow also found that the higher the IOP, the higher the risk of pro-
gression of the disease to end-stage nerve damage. (Spry & Sparrow 2005)  
Nevertheless, 30% of people have glaucomatous nerve damage without detectable IOP 
elevation, whereas almost 80% of patients with increased IOP levels never progress on 
to glaucomatous damage. (Flammer 2001) Therefore, IOP is a potential but not neces-
sary risk factor for the development of glaucomatous damage to the optic nerve. 
Ageing plays an important role in glaucoma for several reasons. Firstly, with lifetime 
ageing processes occur in the trabecular meshwork, and IOP average will increase. 
Secondly, because life expectancy rises worldwide, age-related diseases occur more 
frequently. Thereby, the development of increased IOPs and further glaucoma with age 
can be expected to pose an increasing burden on eye care services throughout the Afri-
can continent and elsewhere. The majority of patients with increased IOP and POAG 
are above 40 years and do not only show the physiologically occurring rise of IOP with 
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age, but a more severe increase of pressure. The reasons might be genetic, but are not 
yet fully understood. In most glaucoma patients, IOP starts to rise between the ages of 
40 to 50. If no treatment is initiated at this stage, which is often the case in developing 
countries, the pressure is likely to rise further. Thirdly, the lifetime of elderly patients 
leads to an accumulation of nerve fibre damage. Therefore, visual field defects com-
monly become apparent with age even without an elevated IOP. (Flammer 2001) 
(Kingman 2004) 
Familial predisposition can be responsible for increased IOP and progression of glau-
coma. The tolerance of an eye for high IOP levels and the individual limit is only in-
completely understood. The risk for glaucomatous damage in individuals with affected 
family members is comparably high and those patients should be monitored carefully. 
(Flammer 2001) (Tielsch et al. 1994) In developing countries, though, family history of 
a disease is often unknown and patients are unaware of it. Thus, such factors are often 
difficult to assess and hard to act accordingly. 
In line with hereditary factors, race or African ancestry are named among major risk 
factors for high IOP, as well as glaucoma development. Epidemiological studies illus-
trate a dramatic increase of glaucoma with age, especially among patients of Hispanic 
and African descent. (AAO 2010b)  
This reinforces the statement of innate risk factors being present in the sample popula-
tion of the present study, as geographical, ethnic, or genetic origins put them at higher 
risk for developing glaucoma. Flammer portends it is often difficult to fully distinguish 
between hereditary and socioeconomic reasons or living conditions. Nevertheless, in 
Africans, high IOP occurs more frequently and at an earlier age and also the chance of 
developing optic nerve damage at a given IOP is higher. (Flammer 2001) 
Other authors support the finding that between Caucasians and Africans, there is a 
different dynamic in glaucoma development. In Africans glaucoma tends to occur at an 
earlier age. Further, it is often associated with higher IOP, it may be more rapidly pro-
gressive and patients present later in the course of their disease, with up to 50% of 
patients already blind in one eye at the point of first presentation. (Cook et al. 2009) 
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(Olawoye et al. 2013) (Buhrmann et al. 2000) (Budenz et al. 2013) (Cedrone et al. 
2008) (Kyari et al. 2013)    
This fact was first recognized in the US by examining the American population, finding 
differences between white Americans and Afro-Americans. A study states that preva-
lence rates for POAG in black people were four to five times higher than in whites. 
(Tielsch et al. 1994; Tielsch 1991)  
Another innate glaucoma risk factor is gender. Studies report opposing gender differ-
ences. (Tham et al. 2014) (Quigley & Broman 2006) (Adio & Onua 2012) A US-study 
found no difference in rates of POAG between men and women for either blacks or 
whites. (Tielsch 1991) (Cedrone et al. 2008) Whereas no difference is found in IOP 
levels between both sexes, the following study described differences in the prevalence 
of the individual types of glaucoma. In general, more women than men were said to be 
presently and prospectively affected by glaucoma. For 2010 it was estimated that fe-
males would comprise 55% of POAG, 70% of ACG, and 59% of all glaucoma. Respec-
tively, women were more likely to fall ill with ACG and NTG, while men more often 
presented with pigment dispersion glaucoma. (Quigley & Broman 2006) Furthermore, 
women seemed to be extremely sensitive to higher pressures, as they commonly devel-
oped glaucomatous damage if affected with POAG. A reason for the higher incidence of 
NTG in women might be the higher incidence of vasospastic disorders in females. 
(Flammer 2001) Conclusively, no clear gender bias can be seen. 
Central corneal thickness (CCT) is a considerable parameter and relevant part of 
glaucoma discussions, especially as it is considered to be an independent risk factor for 
glaucoma development. (AAO 2010b) (Boehm 2011) Corneal thickness varies among 
individuals, among ethnic groups, and differs within ophthalmologic pathologies.  
Depending on the measurement technique, the human eye possesses an average CCT of 
540 µm. Doughty and Zaman recommend that if a +/- 1 standard deviation (SD) esti-
mate of acceptable population variance is used, CCT values between 503 and 565 µm in 
adult eyes should be considered normal, from a clinical and also a clinical research 
perspective. (Doughty & Zaman 2000) (Rosentreter 2011) Another comparable average 
is given with 550 µm. The average of patients with POAG was reported to be 545 µm, 
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in NTG it is about 510 µm and those with ocular hypertension about 595 µm. (Neu-
burger et al. 2011)  
Furthermore, a relevant fact for the present study sample is that Africans as well as 
Afro-Americans, in comparison to Caucasians or other ethnic groups, are known to 
have thinner corneas with approximately 534 µm average. (Lawan 2013) (Leite et al. 
2010) (Aghaian et al. 2004) In the current study population of Malawi, Hohmann de-
tected one of the lowest CCT-measurements among all available study data on people of 
African descent with an average in a non-glaucomatous sample of 509.83 µm. 
(Hohmann 2011) This feature will also be part of the discussion. 
To summarize, the study sample consisting of people from Malawi in South-East-Africa 
comprises several innate risk factors. Based on the African origin, which can be associ-
ated with higher IOP and thus a predisposition to develop glaucoma early and aggres-
sively, the population also seems to be prone to thin CCTs, another crucial risk factor in 
the development of glaucoma. Thus, the special preconditions and pre-existing risk 
factors in this population make glaucoma research a crucial scientific and medical un-
dertaking in this setting. 
1.2.7 Rationale for glaucoma screening 
The biggest challenge, as well as opportunity in blindness caused by glaucoma is inher-
ent in the fact that this irreversible blindness can be prevented or delayed through timely 
diagnosis, effective treatment, and regular clinical follow-ups. A logic conclusion is 
trying to detect the disease as early as possible before irreversible damage has occurred. 
One such method is screening.  
Screening was defined in 1951 by the United States Commission of Chronic Illness as 
“the presumptive identification of unrecognised disease or defect by the application of 
tests, examinations, or other procedures which can be applied rapidly. Screening tests 
ought to sort out persons who probably have a disease from those who probably do not. 
A screening test is not intended to be diagnostic. Persons with positive or suspicious 
findings must be referred to their physicians for diagnosis and necessary treatment.” 
(Commission on Chronic Illness 1957)  
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Spry and Sparrow evaluate POAG as a major cause of visual loss, which consequential-
ly deserves consideration for screening despite the need to possibly use more than one 
test. Their elaboration refers back to the 22 criteria of the United Kingdom National 
Screening Committee (UK NSC), which are a framework regarding condition, test, 
treatment, and screening for glaucoma. (Spry & Sparrow 2005) (UK NSC 2015) The 
UK NSC criteria are a variant of the classic WHO screening criteria published in 1968 
by Wilson and Jungner, known as “Wilson criteria”: (Wilson & Jungner 1968)  
1. The condition sought should be an important health problem 
2. There should be an accepted treatment for patients with recognized disease 
3. Facilities for diagnosis and treatment should be available 
4. There should be a recognizable latent or early symptomatic stage 
5. There should be a suitable test or examination 
6. The test should be acceptable to the population 
7. The natural history of the condition, including development from latent to de-
clared disease, should be adequately understood 
8. There should be an agreed policy on whom to treat as patients 
9. The cost of case-finding (including diagnosis and treatment of patients diag-
nosed) should be economically balanced in relation to possible expenditure on 
medical care as a whole 
10. Case-finding should be a continuing process and not a “once and for all” pro-
ject 
Spry and Sparrow come to the conclusion that in case of POAG the criteria are largely 
even, though not completely met. (Spry & Sparrow 2005) German ophthalmic experts 
(„Berufsverband der Augenärzte Deutschlands e.V.“ (BVA) and „Deutsche Ophthal-
mologische Gesellschaft e.V“ (DOG)) conclude that in case of POAG the main criteria 
for screening are fulfilled. However, according to Lawan, the nature of the disease 
(point 7) cannot be regarded as fully understood. (Lawan 2013) 
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As elaborated in chapter 1.2.1 and 1.2.2, glaucoma can be considered a problem of 
global and national public health especially in regions with increasing life expectancy 
(point 1). Risk factors and treatment options for the disease are known to a large extent. 
Tests for diagnostics and monitoring are available. Therefore, points 1 to 4 are met, but 
point 5 is not fully agreed on.  
A prevailing challenge in diagnosing glaucoma is to identify a test with which to relia-
bly diagnose glaucoma in its early stage and could thus be used for screening. Three 
tests - tonometry, optic disc/nerve ﬁbre layer examination and visual ﬁeld testing - are 
essentially used in the diagnosis of POAG. They have also been considered potential 
and well-accepted screening tools. (Spry & Sparrow 2005) According to Rotchford and 
the present state of knowledge, none of these have high enough levels of sensitivity and 
speciﬁcity, so that a large number of false positives are referred. (Rotchford 2005) 
(Mowatt et al. 2008) (Lawan 2013) 
Hohmann suggests that in a setting like Africa, in which the number of unidentified 
glaucoma cases is even higher than in other parts of the world, with low density in eye 
clinicians, difficult work conditions, and a low degree of health education, a simple 
screening method such as the mobile ICare tonometer (ICT) device would provide 
substantive benefit. Further, IOP measurements were recommended as a screening 
method in developing countries, since it is one of the few simple options at present to 
detect (advanced) glaucomatous eyes among a healthy population. According to Hoh-
mann, it enables to filter out patients with very high IOP values and some remaining 
vision. These can then be transferred to larger hospitals for further examination. 
(Hohmann 2011) Although this seems a realistic practicable action, the inevitable con-
troversy in this suggestion is the fact that a great amount of glaucoma cases will be 
missed by tonometry alone as they present with IOPs in the normal range. (Cook 2009) 
The right tool, timing and target group are challenges for screening. Regarding glauco-
ma in low-income countries, WHO in the action plan on the prevention of visual im-
pairment advices that opportunities for diagnosing glaucoma should be identified, e.g. 
during refraction testing, or before/after cataract surgery. (WHO 2007) Essuman and 
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Ntim-Amponsah recommend using every opportunity that presents itself for diagnosing 
glaucoma cases. (Essuman & Ntim-Amponsah 2012)  
Transferred to a setting with populations at risk like Africa, a comprehensive eye evalu-
ation including glaucoma assessment, e.g. during community eye outreach programmes, 
offer a realistic chance for earlier diagnosis. (Cook 2009) A Nigerian study concluded 
that community eye outreach programmes appeared highly useful in the earlier detec-
tion of glaucoma in SSA. It is often during routine ocular examinations that diseases 
without early symptoms, like glaucoma, are detected. (Olawoye et al. 2013) Presently in 
the United Kingdom, glaucoma is also usually detected opportunistically by optometric 
case finding. (Spry & Sparrow 2005) 
Nevertheless, with the current state of knowledge and diagnostic tools, a general glau-
coma screening of a whole population for early detection is not cost-effective and not 
used anywhere in the world. In the future, though, if technologies for glaucoma screen-
ing advance, population-based screening might become a beneficial procedure. At 
present, if screening programs target populations at risk, namely people of old age, with 
a genetic predisposition or certain heritage, e.g. African Americans or Hispanics, it can 
be considered a useful and cost-effective tool. (AAO 2010b) The AAO suggests, espe-
cially among older populations, that screening for glaucoma during general eye disease 
screenings could be pursued. (AAO 2010b) 
One of the major questions of this thesis, as will be outlined in the next chapter, are 
about the rationale of screening, as well as possible screening options and guidelines in 
the population under study, which are elaborated in chapter 4.5 and 4.6 according to 
results presented in this thesis. Possible age and IOP cut-offs will be discussed in chap-
ter 4.5.2 and 4.6, as currently there are no universal guidelines in this respect. (Spry & 
Sparrow 2005) 
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1.3 Research objectives and aims 
After dealing with the main terms and issues important for the study, general research 
objectives will be formulated. These objectives are in accordance with abovementioned 
questions and challenges, which make research in this field a crucial undertaking. 
A major aim of this research was to document baseline parameters of healthy and glau-
comatous eyes in a geographic region in which data is scarce. Specific aims were to 
investigate the prevalence of raised IOPs above 21 mmHg, and especially the preva-
lence of glaucoma with subtypes, and associated risk factors among patients presenting 
at Lions Sight First Eye Hospital (LSFEH) in Blantyre, Malawi. This aim is consonantly 
with the call by WHO in 2004 for intensified research on eye disease prevalence in 
Africa, due to the scarcity of epidemiological data, also stated by other literature. (Nai-
doo et al. 2014) (Resnikoff, S. et al. 2004) (IAPB 2010) 
The study aims at creating a database for the respective geographical region with infor-
mation regarding features of healthy and glaucomatous eyes, with a focus on IOP, optic 
disc appearance and corneal thickness. It aids at understanding and knowing characteris-
tic presentation patterns of glaucoma, enabling more effective detection, and manage-
ment of glaucoma in this region. As IOP in normal eyes varies not only inter- and intra-
individually but also between populations, data analysis, as well as any screening test 
based on tonometry, has to take the specific IOP levels in a particular population into 
account. (Rotchford 2005)
 
It is therefore important to create baseline ocular data for as 
many regions as possible.  
It was further a central goal to evaluate the attained database regarding the usefulness of 
a glaucoma screening programme in Malawi or at LSFEH and define a guideline pro-
posal for glaucoma management at LSFEH and possibly other tertiary institutions in 
Malawi. It is of interest, if the statement given in chapter 1.2.7 that population-based 
screenings are not useful (in Western countries) is equally true for developing countries. 
If IOP levels or prevalence of glaucoma in Malawi varied greatly from other settings, 
different conclusions regarding the usefulness of a screening programme in that region 
could be drawn. If for example the data set revealed that in Malawi, many people are 
found with highly elevated IOPs and large glaucomatous papillary excavations, this 
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could help in screening for and diagnosing the disease at an earlier stage than is possible 
e.g. European countries. Therefore, the dataset was analysed regarding these questions, 
also by relating the data back to the WHO criteria for a population-based screening 
mentioned in the previous chapter. 
As suggested by Kyari et al. in review of literature on glaucoma in SSA: “More popula-
tion-based research is needed to clarify the nature of glaucoma in many more popula-
tions in Africa, to determine reasons for its variation and to better define target risk 
groups.” (Kyari et al. 2013) The research therefore contributes to more knowledge and 
information about glaucoma in yet another region in Africa. 
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2 Materials and Methods 
The following discourse first explains the instruments used for patient examinations 
throughout the studies. The second part outlines study designs, procedures and details 
about patient samples. Lastly, statistical analysis will be described.  
2.1 Instruments for examination 
This chapter gives an overview of instruments and material used for examining the 
study sample. Visual acuity assessment by visual chart and the tool for funduscopy is 
explained. Further, theory about optical coherence tomography and the two tonometers 
of this study are described.  
2.1.1 Visual chart, indirect ophthalmoscopy and Anterior-segment Optical 
Coherence Tomography  
Visual chart. To determine patients’ visual acuity, a tumbling E chart was used at 6 
meter distance to the patient. As many patients were illiterate, this chart offers a useful 
tool. They were asked to tightly cover one eye with one hand and point to the direction 
or state to which direction the limbs of the E are pointing (up, down, left, right). This 
test was done under good lighting condition, for both eyes, if applicable. Visual acuity 
(VA) was examined relative to 6/6 (metres) with the following grades: 6/6, 6/9, 6/12, 
6/18, 6/24, 6/36, 6/60, 5/60, 4/60, 3/60, 2/60, 1/60, hand movement (HM) and no per-
ception of light (NPL).  
Indirect ophthalmoscopy. Funduscopy was done by using a 90 dioptres funduscopy 
lens (Volk, USA) after dilatation of the pupil.  
Anterior-segment Optical Coherence Tomography (ASOCT). The ASOCT used was 
a Slit Lamp Optical Coherence Tomography (SL-OCT™), Software Version 1.0.2.0 by 
Heidelberg Engineering. The instrument enables in vivo non-contact, high resolution 
imaging and measuring of anterior segment structures. Anterior chamber angles (ACA), 
anterior chamber depth (ACD), objective digital gonioscopy or thickness of cornea can 
be measured. Our study focused on CCT, ACD and ACA. Relevant information is 
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obtained, e.g. about angle configuration, saving patients from undergoing an unpleasant 
direct gonioscopy, which is further a subjective method in comparison to OCT. 
The device consists of an OCT scanning unit combined with an HAAG-STREIT BD 
900 Slit Lamp, a height-adjustable table, computer, monitor, keyboard, and mouse. It 
enables to store patient data and displays or prints images in grey scale or false colour.  
The anterior segment OCT is technically based on the time-domain-OCT (TD-OCT)-
interferometer with a mobile reference mirror. The OCT utilizes short-coherent infrared 
light from a superlumniscence diode with a central wavelength of approximately 1310 
nanometre. After leaving the source, the light beam is divided into two – one sample 
and one reference beam. While the sample beam enters the eye and is reflected, the 
reference beam traverses a delay line. Eventually, both beams are brought back together 
and the calculation of interferences results in the actual OCT-signal. The beam is di-
rected across the eye, creates, and later combines several axial scans (A-scans), which 
give two-dimensional cross-sectional images, similar to ultrasound diagnostics. The 
reference mirror moves for each A-scan to determine the eye’s anatomical structure's 
depth. Scanning quality reaches a width of 15 millimetre (mm) and depth of 7 mm at a 
scanning speed of 200 Hertz. During measurement taking software quality checks en-
sure correct alignment for measurement accuracy. (Heidelberg Engineering 2008) 
2.1.2 Goldmann-Applanation-Tonometer and ICare-Tonometer  
Goldmann first described the method and limitations of tonometry which is still consid-
ered the gold standard. (Goldmann & Schmidt 1957) All types of tonometer applanate 
the cornea and correlate the force necessary to reach a certain level of deformity with 
intraocular pressure. As the tonometer presses against the ocular cornea, a corneal influ-
ence on the measurement technique and findings is evident. It is often complex to inter-
pret the IOP findings, as they are dependent on many parameters, especially corneal 
configuration. (Neuburger et al. 2011) Furthermore, they are prone to different sources 
of errors, may it be examiner-, patient-, or instrument-based. (Rosentreter et al. 2011) 
Furthermore, it is true for all non-invasive IOP measurement techniques that the real 
IOP is not 100% known, unless it is correlated to an intracameral measurement of the 
same eye. (Boehm 2011) The following sections are an explanation of the two tonome-
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ter used in this study, with a focus on examiner-, instrument-, or patient-associated 
sources of errors.  
Slit lamp and GAT. The device used throughout the study was a Haag Streit Applana-
tion-Tonometer AT 900 type R (BD-900). GAT is the gold standard in IOP assessment 
for more than 50 years. The ophthalmic physics which Goldmann based his technique 
on was the Imbert-Fick-law. It states that the power F necessary to applanate surface A 
of a sphere equals the product of existing intraspherical pressure P and the applanated 
surface A (F = P x A). The law is valid for endlessly thin and perfectly spherical and 
flexible surfaces without any rigidity. These theoretical prerequisites, though, are only 
partly encountered in the human eye ball, which is not perfectly spherical, not endlessly 
thin, or flexible and has some volume changes during measurements. Further, the cover-
ing tear film possesses an inert tension, which pulls the tonometer probe towards the 
cornea. At least corneal rigidity B and capillary force of the tear film S have to be con-
sidered in the equation, resulting in a change of the Imbert-Fick-law: F = P x A + (B – 
S). (Rosentreter et al. 2011)  According to a written statement by an employee of Haag-
Streit, the Imbert-Fick-law is incorporated in the device, yet hysteresis and corneal 
rigidity are not considered.  
Goldmann first described his procedure in 1955. (Goldmann & Schmidt 1957) It uses a 
slit lamp with disinfected tonometer head and a double prism, using illumination 
through a cobalt blue filter. By adding fluorescent topical anaesthetics to the tear film, 
the corneal surface can be applanated by the examiner approaching the probe towards 
the cornea. Upon touching the surface with the tonometer front, a double prism optically 
divides the tear menisci into two green semi circles. Using a tension spring adjusted at 
the slit lamp, the applanated pressure can be finely adjusted until the two menisci touch 
one another on their inner margins. At this position, IOP can be read off the tension 
spring in mmHg. This method actually measures a force in meganewton (mN), not a 
pressure. Therefore, Goldmann calibrated the tonometer in grammeforce (1 
grammeforce = 9.8 mN). When reading the tonometer results, 1 grammeforce is equated 
with 10 mN and directly indicated in mmHg. (Rosentreter et al. 2011)   
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It is important to add that there are various sources of error in this technique, which 
shall briefly be recorded here. Rosentreter et al. divide them into examiner-, instrument- 
or patient-associated influencing variables: (Rosentreter et al. 2011) Several factors can 
be responsible for examiner-associated errors. Firstly, applied anaesthetics for appla-
nation can alter the pressure needed. Thus, a large amount of drops can result in higher 
measures and too little drops in lower values. The pressure applied by the examiner to 
help patients opening their eye, e.g. with cotton buds or touching eyelids or lashes with 
the probe, may result in falsely high values. Inaccuracy in reading off the results can 
occur due to the 2 mmHg range, which is seen on the tension spring. Further, the exam-
iner may take slight eccentric measurements, repeat them several times or applanate the 
surface for more than 30 seconds, which can, according to the authors’ citation in their 
article, reduce the applanated IOP for 2 to 4 mmHg.  
Instrument-based errors may result in systemic measurement errors. These can occur 
if calibration of GAT is not done regularly. Further, tonometer probes may be damaged, 
which leads to measurement inaccuracies and damage of the corneal surface.  
Several patient-associated parameters have an influence on IOP and its readings, leading 
to patient-based errors. Pulse, breathing, or blink reflex can be visible as pulsating 
menisci. Bending forwards towards the slit lamp with reclination of the neck, holding 
breath, or wearing tight collars may bring elevated venous pressure and IOPs. An in-
crease in IOP levels of several mmHg can be explained by patients looking upwards 
during examination, especially those with endocrine orbitopathy, or forced activity of 
levator palpebrae muscle for intense opening of the eyes. Lastly, corneal characteristics, 
most importantly CCT, which is focused on within several levels in this thesis, play an 
important role in correctly interpreting IOP measurements. Corneal astigmatism can 
lead to imprecise GAT measures. Abnormal corneal epithelium is a current source of 
error. Oedematous epithelium is said to be applanated easier than normal epithelium and 
thus results in falsely low values. Thin CCTs and eyes after photorefractive surgery can 
lead to drastically lower IOP measurement. Opposing, thick CCTs rather result in high 
IOP values. (Rosentreter 2011) (Neuburger 2011) This phenomenon will be further 
elaborated in chapter 4.4 in the discussion of this thesis.  
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ICT. The tonometer used throughout the study was an Icare® TA01i by Icare Finland. 
The handheld instrument is based on the rebound phenomenon and was launched in 
2003. Induction of rebound tonometry was developed in the end of the 1990s in Finland 
and quickly won recognition in the clinical routine. Its major advantage is that no spe-
cial expertise and no local anaesthetics like in GAT are needed. The method is therefore 
readily accepted by children. The battery-driven, portable, handheld Icare® tonometer 
is one variant of rebound instruments present at LSFEH. During measurement a single-
use tonometer head gets catapulted against the patient’s cornea, slowed down, and 
rebounds. Acceleration of the probe is induction-based through two coaxial inductors, 
whereas slowing down and mechanical rebounding is measured by changes in poten-
tials. This is converted into intraocular pressure, appearing in digital readouts. The 
deceleration of the probe depends on the IOP. A higher IOP leads to a faster decelera-
tion of the probe and a shorter contact time. Six measurements are taken, supported by 
acoustic signals, and a mean is generated and indicated as a digital number (P followed 
by IOP result), accompanied by a longer beep. (Boehm 2011) (Neuburger et al. 2011)  
If there is an erroneous measurement, the tonometer will beep twice and display an error 
message. Thereby, different cases can occur: If “P” is blinking, standard deviation (SD) 
of the measurements is greater than normal. “P_” indicates SD of the different meas-
urements has a slightly greater value than normal, but the effect on the result is likely to 
be irrelevant. “P-“ means SD of the different measurements is clearly greater than nor-
mal, but may not have a relevant effect on the result, but a new measurement is recom-
mended if the IOP is over 19 mmHg. “P
-
“ signals that SD of the different measurements 
is great and a new measurement is recommended. According to the producer, the effec-
tive range of the tool is 7 to 50 mmHg, but display range is from 0 to 99 mmHg, with 
the limitation that beyond the effective measurement range, IOP is only estimated. Its 
weight is 250 g including 4 batteries. (Icare Finland 2015) 
The very light probe weighs 26.5mg, is 40 mm long, made of stainless steel, slightly 
magnetic, and provided with a 1.7 mm plastic covering at its top. Velocity of the probe 
towards the cornea is at 0.25-0.4 m/s, which is low enough not to harm the cornea, but 
faster than the corneal reflex. This explains why no anaesthetics are needed. Thereby, 
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the procedure is barely noticed by patients as only momentary contact happens. (Icare 
Finland 2012) (Hohmann 2011) 
As indicated in the manufacturer’s manual, accuracy of the instrument with 95% toler-
ance interval relative to manometry is ±1.2 mmHg (≤20 mmHg) and ±2.2 mmHg (>20 
mmHg). Repeatability (coefficient of variation) is <8%. According to literature, 84% of 
measurements are within ±3 mmHg variance compared to GAT, in a range of 6 to 48 
mmHg. (Iliev et al. 2006) In comparison to GAT in general, ICare values tend to be 0.6 
to 1.6 mmHg higher than GAT values. (Martinez-de-la-Casa et al. 2005) (Martinez-de-
la-Casa et al. 2006) (Hohmann 2011) (Neuburger et al. 2011) (van der Jagt, Liane H. & 
Jansonius 2005) In the manual a mean paired difference and standard deviation (Gold-
mann-Icare) is given from a study with 158 patients with -0.4 mmHg and 3.4 mmHg. 
(Icare Finland 2015)  
Obligatory for good measurement outcomes is a correct distance of the instrument to the 
cornea, central-orthogonal touching of the cornea by the probe, little tearing. Further, 
for correct interpretation, CCT should be known. ICT has to be applied in an upright 
position of the patient and held horizontally. A disadvantage is thus that it cannot be 
performed in patients lying in bed. For better positioning, a forehead support adjusting 
wheel is integrated. A major disadvantage is that in case of corneal pathologies like 
scars, rebound tonometry cannot be regarded as sufficiently accurate in its measure-
ments. (Neuburger et al. 2011)  
Since IOP control at certain individual target pressures is especially crucial for stopping 
the progress of the disease, a most accurate IOP determination is of utter importance. 
Despite many different measurement techniques and machines it cannot be said with 
certainty, if the measured IOP corresponds to the actual pressure inside the eye. (Boehm 
2011) Only direct intracameral measurements can indicate real pressures and compara-
tive studies were done e.g. by Ehlers et al. and Kohlhaas et al. (EHLERS et al. 1975) 
(Kohlhaas et al. 2006) For ICT there are no intracameral studies comparing ICT meas-
urements to real IOPs, but it is reported by some authors that CCT, like GAT, may be 
influenced and dependent on CCT with up to 4 mmHg per 100 µm. (Boehm 2011) 
(Jorge et al. 2008) The ICare serves in the field of diagnosis, follow up, and screening 
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of glaucoma. (Icare Finland 2015) Its simple and fast applicability can explain the broad 
clinical acceptance.  
2.2 Research design 
For the literature research on existing studies and information on the topics of this thesis 
the PubMed US National Library of Medicine and publicly available online information 
were used.  
The clinical research part consisted of three separate studies, each with own objectives 
and aims. Nevertheless, they had some identical features which will be described in the 
following lines. All three were cross-sectional studies and carried out between August 
and October 2014 at the outpatient department (OPD) of Lions Sight First Eye Hospital 
(LSFEH) in Blantyre, Malawi. LSFEH is the largest of five eye hospitals in Malawi, 
serving about 6 million people. It is under jurisdiction of Queen Elizabeth Central Hos-
pital (QECH). LSFEH serves as teaching eye hospital for the College of Medicine as 
part of the University of Malawi. (Kayange et al. 2014)  
As there is no computer-based patient documentation at LSFEH, we relied on patient’s 
narrative history and information given in their health passports, which every person in 
Malawi carries to each medical visit, containing a brief medical history and important 
diagnoses, such as tuberculosis or HIV status. All findings, e.g. IOP level or glaucoma 
diagnosis in these health passports, were documented and every book was marked with 
a coloured sticker to avoid double registration of this patient in the study. 
Prior to the research we applied for ethical approval by the College of Medicine Re-
search and Ethical Committee (COMREC) of Malawi in April 2014 and were granted 
admission in June 2014. (see appendix 9.4) 
The following definitions and diagnostic guiding values were underlying:  
IOP was considered “elevated/increased” at values above 21 mmHg in at least one eye. 
If available, pressure analysis was based on GAT-findings, the gold standard in tonome-
try. In other cases, IOP values were collected by ICT measurements.  
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In this setting with a limited availability of technical devices as visual field, good fun-
dus photography and optic disc documentation such as OCT or HRT we had to rely on 
our clinical evaluation of the optic nerve head. Even though a CDR of >/= 0.8 is very 
suspicious for glaucoma we diagnosed those patients as “healthy” who had a large optic 
disc without focal thinning of the rim, optic disc haemorrhages and intact ISNT-rule. 
This was in accordance with the knowledge that the optic disc appearance varies be-
tween Caucasian and African, with African having larger discs with larger CDR. For 
example Nangia et al. describe that large optic discs are commonly found in black 
patients and might lead to an over-diagnosis of glaucoma. (Nangia et al. 2013) As the 
examinations were a subjective assessment we had to rely on the grading of our experi-
enced African colleagues in cases of doubt regarding the diagnosis of glaucomatous 
optic neuropathy.  
In our study people were diagnosed with glaucoma, if one of the typical features was 
present: 
 Glaucomatous optic disc damage (abnormal inferior-superior-nasal-temporal 
(ISNT)-rule of the neuroretinal rim or abnormally large cup in a small optic 
disc) + IOP >/= 22 mmHg or  
 IOP elevation above 35 mmHg without a corresponding nerve fibre defect or  
 Optic nerve damage with a CDR >= 0.8 that can be clinically related to 
glaucoma and is far advanced even without an elevated IOP (except those cases 
related to large optic discs (as mentioned above)  
The diagnosis of “glaucoma suspect” was made according to the following criteria: (in 
accordance with (Pfeiffer 2005)) 
 IOP >/= 22 mmHg 
 VCDR >/= 0.6 with a normal disc size 
 Diffuse or focal thinning of neuroretinal margin 
 Papillary haemorrhages in accordance with glaucomatous optic neuropathy 
The unavailability of visual field diagnostics made definitive diagnoses by perimetry 
impossible. Limitations are obvious since perimetry is a major diagnostic tool in 
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abovementioned definitions in 1.2.4. Therefore, a limited validity of the glaucoma 
diagnosis in the absence of perimetric data has to be taken into account. Like in other 
studies with limited technical options, CDR of the optic nerve head provided the base of 
staging severity of glaucoma. Asymmetry of CDR between both eyes was not consid-
ered suspicious as such, only in combination with suspicious optic disc appearance.  
After giving clear definitions and explanations of the study design, the following chap-
ters are descriptions of each of the three conducted studies. Study A was the first one, 
examining “healthy” Malawians. Study B was second in which ICT measurements were 
taken on a large scale. Study C consisted of thorough examination of those individuals 
referred from study B due to elevated IOPs. 
2.2.1 Study A: Baseline survey 
Objectives. The first study to be carried out was a two-week research period in August 
2014 in which 200 people were examined. The aim of this study was to comprehensive-
ly examine patients with no history of high IOP or glaucomatous changes, or complete-
ly healthy individuals outside the hospital. The aim of examining “healthy” – meaning 
individuals without a history of glaucoma – was to gather data of average Malawian 
eyes as a baseline for further studies. Furthermore, results should indicate the preva-
lence of increased IOP above 21 mmHg and the number of glaucoma cases among 
them. Lastly, prevalence of glaucoma among patients with IOPs below 21 mmHg 
(NTG) was of interest. 
Sample size. There is not much local data available regarding the prevalence of elevat-
ed IOP and glaucoma in this geographic area. With the collection of data from 200 
“healthy” patients, no detailed description of the glaucoma prevalence and types was 
expected. It was rather considered a pilot study to collect baseline data and for interpret-
ing consecutive studies. Since study A was a pilot study it was agreed on with the statis-
tics office at the University of Tuebingen on the number of 200 patients. Not all param-
eters could always be collected of all 200 individuals, due to corneal ulcers, opaque 
discs or other ocular disturbances. The exact numbers of measurements can be cross-
checked in appendix 9.3.2. 
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Study population and inclusion criteria. We recruited patients at the OPD and healthy 
individuals who were on the premises of the eye hospital, e.g. as “guardians” – usually 
family members of patients who accompany and care for the patient during the time of 
admittance. The main inclusion criteria were age above 18 without a history of glauco-
ma or increased IOP.  
Exclusion criteria. Patients with the following features were excluded: known case of 
glaucoma, previous glaucoma surgery, patients on anti-glaucomatous medication, cor-
neal abnormalities, e.g. ulcerations, scars etc. as they might interfere with measure-
ments, children and young people below the age of 18 or lack of consent. Verbally 
given information was confirmed by cross-reading patients’ health passport in which 
medical data is recorded. 
Data collection. Study subjects were asked to take part randomly. Before starting ex-
aminations, an information sheet and consent form were handed out (see appendix 
9.5) explaining the necessary background of the study in simple words in English or the 
national language Chichewa. Afterwards patients had time to think about their participa-
tion and ask questions. Examinations were performed only after patients had agreed and 
signed the forms. For illiterate participants there was the possibility of giving consent 
by thumbprint. 
Findings were collected on a questionnaire form (see appendix 9.5) in the following 
order: 
 Ocular medical history: history of eye surgery, glaucoma and present complaint 
 Monocular visual acuity (tumbling E chart) at 6 meter distance, if possible, in 
both eyes, and without correction; in case of low vision, the examiner tested 
finger-counting at 6 down to 1 meter distance (6/60 to 1/60), below 1 meter hand 
movement directly in front of the patient or light perception were tested  
 ASOCT examination evaluating CCT, ACA, ACD 
 Slit lamp examination of anterior chamber depth and condition of lens (clear, 
mild cataract, mature cataract, intraocular lens (IOL)), pigment dispersion. No 
exact grading of cataract other than mild or mature was done.  
 IOP measured by ICT 
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 IOP measured by GAT  
 Pupillary dilatation (after exclusion of the risk for occlusion or already closed 
ACAs with SL-OCT) by application of mydriatic eye drops, waiting 15 to 20 
minutes for maximum dilatation 
 Assessment of pseudoexfoliation (PEX) under slit lamp  
 Assessing fundus and determining condition of the optic nerve head, particularly 
CDR and other pathologic findings 
After finishing all examinations, patients were informed about results and given treat-
ment if needed, including the prescription of medication, referral to further investigation 
and follow-ups, or admittance to ward. In those cases in which glaucoma was newly 
diagnosed, patients were thoroughly educated about the disease, implications, treatment, 
and importance of follow-up visits. Complete examination per patient took on average 
30 minutes. 
A local study assistant (final year medical student) recruited patients and explained the 
purpose and content of the study. He took history as well as visual acuity, and translated 
results and treatment to the patients. ACOCT and ICT were done by the author. Slit 
lamp examination by funduscopy and the final decision about diagnose and treatments 
were done by the German ophthalmologist Dr. med. Johanna Müller. 
2.2.2 Study B: IOP assessment 
Objectives. The second study aimed at getting a maximum number of IOP measure-
ments at the OPD of LSFEH, to come up with a strong indicator for average IOP in a 
Malawian eye clinic, and the prevalence of increased ocular pressures.  
Sample size. Because only little data is available regarding the prevalence of elevated 
IOP and glaucoma in this geographic area, it was a pilot study like study A to collect 
baseline data. ICT measurements of 1,112 patients in total were taken. As mentioned for 
study A, not IOPs could always be collected of all 1,112 individuals, due to ulcers or 
other corneal disturbances. The exact numbers of measurements can be cross-checked in 
appendix 9.3.3. 
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Study population and inclusion criteria. IOPs were measured by ICT on all patients 
above 18 years of age waiting in line at the OPD of LSFEH according to exclusion 
criteria.  
Exclusion criteria. No ICT-measurements were taken in the following cases: corneal 
abnormalities, e.g. ulcerations, scars etc., children and young people below the age of 
18, or lack of consent. There was no patient who denied the measurement. This broad 
IOP assessment also included patients with a known history of glaucoma. Information 
was taken from patient’s statements and health passports. 
Data collection. Before collecting patient data, a local study assistant explained in 
simple words in Chichewa the purpose of our measurements, the concept of ocular 
pressure, and the risk of an unnoticed elevated pressure. Patients were encouraged to 
ask questions at any moment. They were informed that in case of pressures over 21 
mmHg, a comprehensive eye examination (study C) would follow, in which their pre-
sent complaints and also possible glaucomatous findings were looked at. Age, (family) 
history of eye disease or blindness, and ICT measurements were taken after each pa-
tient’s verbal consent. All examined patients received a sticker on their health passport 
to avoid double assessment in future OPD visits, and results were marked on a paper 
form as well as in the individual’s health book. In case of pressures above 21 mmHg 
ICT-measurements were repeated three times to rule out mistakes. If numbers were 
above 21 mmHg in at least one eye in all three measurements, patients’ health passports 
were marked with a red sticker. They were invited to proceed to a study room for com-
prehensive investigation, in which a thorough eye exam with special attention to elevat-
ed pressure and related pathologies would follow.  
2.2.3 Study C: Increased IOP examination 
Objectives. As described above, in a second step following ICT measurements of study 
B, examination was performed on all those with increased IOP in three consecutive 
ICT-measurements in at least one eye, who agreed to participate. This enabled to not 
only detect the prevalence of increased IOP at an OPD setting in Malawi (objective of 
study B), but also find out the actual prevalence of glaucoma or glaucoma suspects 
among those with increased pressures (objective of study C). 
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The focus on prevalence of glaucomatous findings among those with elevated pressures 
was aimed at getting results to further draw conclusions regarding the usefulness of an 
ICT screening at this or comparable settings.  
By including patients with a history of glaucoma, a database was expected to be estab-
lished with glaucomatous ocular findings to further investigate possible characteristics 
and correlations. For this purpose, the same details as in study A were registered on the 
questionnaire form (see appendix 9.5). 
Sample size. The number of patients was determined continuously by findings of study 
B. In total 106 patients, who presented with ICT measures above 21 mmHg in study B, 
were included and fully examined. As valid for studies A and B, not all parameters 
could always be collected of all 106 individuals, due to corneal ulcers, opaque discs or 
other ocular disturbances. The exact numbers of measurements can be cross-checked in 
appendix 9.3.4. 
Study population. All 154 patients of study B who presented with IOP above 21 
mmHg in three consecutive ICT measurements in at least one eye were encouraged to 
join. 106 of those joined the study.  
In- and exclusion criteria. Criteria for in- and exclusion were the same as in study B as 
this was the continuation. Due to lack of time or scepticism on the patient’s part, not 
every patient meeting inclusion criteria was examined. 
Data collection. In the course of study B, patients were already informed by a Mala-
wian study assistant (Herbert Thole or Boston Zimba) about the research and the mean-
ing of an IOP above 21 mmHg. Patients with this certain finding were asked to join for 
a comprehensive examination in a separate study room. They were then given further 
explanations and had to sign (with thumbprint if illiterate) the same consent form as in 
study A (see appendix 9.6).  
Examinations and data collection followed the order of study A and were noted on the 
same form (see appendix 9.5). After explanations, history taking, and visual acuity, 
followed ASOCT picturing, slit lamp examination including GAT and administration of 
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mydriatic eye drops. Funduscopy for CDR evaluation and final diagnosis with treatment 
were made by Malawian ophthalmologists.  
2.3 Statistical Analysis 
All data was treated confidentially and is kept in a password-protected file. All study 
data was recorded on standard questionnaire forms, checked for completeness, and 
entered into a database sheet using Microsoft Office Excel 2010. 
Data included the date of examination, patient number (assigned by author), gender, and 
age. Examination findings included VA, subjective ACD and lens in slit lamp examina-
tion, IOP measurements with ICT and GAT, presence of PEX or pigment dispersion, 
lens, fundus, CDR of the optic disc, as well as ACA, ACD and CCT by SL-OCT exam-
ination. 
All data was exported to IBM SPSS Statistics Version 22. Subgroups were formed in 
SPSS, including female or male gender, patients above and patients below 40 years, 
patients with CDR above 0.8 or glaucoma diagnosis among others.   
Results were evaluated in mean, median, standard deviation, minimum-maximum-
ranges, frequencies, or percentages. All relevant variables were examined for normal 
distribution. If a normal distribution was not given, as in many cases, median and range 
with minimum and maximum are indicated. All relevant results were transferred to 
Excel sheets. 
Descriptive analysis of all relevant variables was done, followed by Spearman bivariate 
correlational analysis between age, IOP, CCT, and CDR using SPSS programme. 
Spearman (rho) was considered appropriate due to the non-normal distribution of at 
least one variable in all correlations. A correlation of -1.0 to -0.5 or 1.0 to 0.5 was con-
sidered strong, -0.5 to -0.3 or 0.3 to 0.5 moderate and between -0.3 and -0.1 or 0.1 to 0.3 
was considered as weak, whereas values between -0.1 and 0.1 meant no correlation.   
Further, sensitivity and specificity as well as positive and negative predictive value were 
calculated for study A regarding ICT detection of glaucoma cases. 
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Bland-Altman-analyses were carried out for the comparison of measurements generated 
by the two tonometry methods (ICT and GAT) and depicted in scatter-plots (see chapter 
3.6).  
Statistical analyses and results are presented in the form of tables or bar graphs as appli-
cable.  
In accordance with the German statistical consultant, no statistical tests with non-metric 
variables were done. The reason is that sample size estimations were not possible in 
advance due to the lack of available data for this region. Consecutively, testing would 
result in high error rates, depriving the study of its persuasive power. We therefore only 
calculated correlations and summarized the descriptive statistics, which can give rise to 
further studies and research in the future.  
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3 Results 
The following chapters present the results of each study separately with their specific 
focus and questions. Ocular characteristics and study findings are presented and ana-
lysed. In study A and C these are age and gender distribution, IOP levels with preva-
lence of increased IOPs, CCT, CDR, ACD, ACA, VA and blindness, cataract and 
prevalence of glaucoma. In study B, main findings are gender and age distribution, IOP 
levels and the prevalence of increased IOP levels.  
POAG is the most prevalent glaucoma type in SSA. Therefore this subtype was focused 
on during the research of this study. All POAG patients with their specific patterns are 
combined in chapter 3.4. This allows a detailed analysis of POAG presentation patterns 
in Malawi. A special focus is put on glaucoma presentation patterns. Possible correla-
tions between metric parameters, such as age, IOP, CCT, or CDR are analysed in chap-
ter 3.5. Furthermore, Bland-Altman-analysis is done to compare ICT with GAT meas-
urements, with possible implications on ICT cut-off points, as outlined in chapter 3.6.  
The division of visual impairment and blindness follows the ICD-10 definitions de-
scribed in chapter 1.1.2. Certain age group structuring was applied, which is briefly 
explained as follows: Group 1 comprised people of 18 to 24 years of age. 18 years was 
the minimum age for inclusion in all studies. The upper limit of 24 years was chosen, 
because 25 is mentioned in literature, e.g. in (Essuman & Ntim-Amponsah 2012), as a 
good age to start screening. It is part of the discussion in chapter 4.5.2. For comparative 
reasons, this cut between 24 and 25 was set.  
Group 2 was formed by people between 25 and 39 years of age, because comparable 
studies, which are also part of chapter 4.5.2, e.g. (Ntim-Amponsah et al. 2004) or 
(Ntim-Amponsah et al. 2005), often contrast samples below and above 40 years. For 
comparative reasons, 39 years was regarded an appropriate cut-off point.  
Group 3 included ages 40 to 59, as this was equally seen in comparable studies, e.g. 
(Kyari et al. 2013). Group 4 was formed from ages 60 to 79, and group 5 from 80 years 
and above. The last two categories have been chosen for comparable age ranges. These 
two were the smallest samples due to low life expectancy in Malawi, which is 58 years 
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for men and 60 years for women. (WHO 2012b) Results of study A, B, C, and of POAG 
patients are summarized in Table A 1 of the appendix under 9.3.1, which can be used 
for orientation and comparison.  
3.1 Study A: Baseline survey, “healthy” sample 
As explained in chapter 2.2.1, the aim of study A was to gather data of Malawian eyes 
as baseline for further studies. Therefore, allegedly healthy individuals, with “healthy” 
meaning no history or unaware of high IOP or glaucomatous changes, were comprehen-
sively examined. Furthermore, prevalence of IOPs above 21 mmHg, and the number 
and types of glaucoma cases detectable during a random screening of a “healthy” sam-
ple were determined. The full list of results from study A is attached in appendix 9.3.2. 
3.1.1 Description of sample size, gender ratio, age distribution, mean IOP, CCT, 
CDR, ACA, cataract and visual acuity 
A total number of 200 “healthy” individuals without a known-history of glaucoma were 
randomly recruited on the hospital premises (if meeting inclusion criteria) for a thor-
ough eye examination. As mentioned in 2.2, due to ulcers, scars or other corneal opaci-
ties, the number of measured right eyes was 191 and of left eyes it was 188. (Compare 
appendix 9.3.2)  
Table 4 summarizes the main findings. These parameters can serve as a baseline of 
ocular parameters for the Malawian population. 
The sample consisted of 53% women (number (n) =106) and 47% men (n=94). The 
rather equal distribution was aimed for by the researchers in order to avoid bias for one 
gender and to get equal amounts of baseline data on each.   
The mean age was 35.3 years (median 32; range 18-78), where a majority of 67.5% 
belonged to the group of under 40 years and 32.5% were 40 years or older.  
Figure 1 shows the distribution of age groups in study A. Almost half of all people 
(47.5%) represented group 2 (25-39 years), whereas 20% formed group 1 (18-24 years), 
26% group 3 (40-59 years), 6.5% group 4 (60-79) and none in group 5 (80 years and 
above). 
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Table 4: Main ocular findings in healthy Malawian population 
Parameter Unit Results 
Total number  200 
Gender distribution (male : female) % 47 : 53 
Age mean / median  Years 35.3 / 32 
IOP (ICT/GAT) mean mmHg 16.6  / 15.4 
IOP (ICT/GAT) median mmHg 16 / 15 
IOP >21 mmHg % 11.5  
CCT mean / median µm 509.2 / 507.5 
CDR mean / median   0.3 / 0.3 
CDR > 0.8 (at least one eye) % 2.0 
Cataract bilateral % 16.3 
Blindness unilateral / bilateral % 1.0 / 0 
Glaucoma prevalence % 2.5 
 
 
Figure 1: Age group distribution in percentages of healthy sample, n=200; age group 1 (18-24 years), 2 (25-39 years), 
3 (40-59 years), 4 (60-79) 
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IOP was measured first with ICT and then with GAT, which is indicated as ICT/GAT. 
Mean ICT and GAT values for right eyes were 16.5/15.3 mmHg (median 16/15, range 
8/8-31/27 mmHg) and in left eyes 16.6/15.5 mmHg (median 16/15, range 10/9-51/53 
mmHg) respectively. In conclusion, total mean for both eyes in ICT/GAT was 16.6/15.4 
and median in ICT/GAT was 16/15 mmHg. ICT values of over 21 mmHg in at least one 
eye were recorded in 11.5% and above 22 mmHg in 10%.  
CCT measurements in both eyes showed normal distribution. Mean CCT in 190 right 
eyes was 509 µm (SD 35.7) and in 188 left eyes 509.5 µm (SD 37.1). Total mean CCT 
for both eyes was 509.2 µm. Total median was 507.5 µm.  
Figure 2 and Figure 3 shows CCT distributions for both eyes separately. As the differ-
ence between eyes did not show a clinical significance in the examined parameters, both 
eyes are regarded together in the on-going text. 
 
 
 
Figure 2: Right eye, central corneal thickness (CCT) in healthy study population, n=10ß, frequency numbers (no.) 
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Figure 3: Left eye, central corneal thickness (CCT in healthy study population), n=188, frequency numbers (no.) 
 
CDR assessment gave a left-skewed distribution. Mean as well as median CDR in both 
eyes was 0.3 (right eye range 0.1-0.8, left eye range 0.1-1.0). The amount of patients 
with at least one eye presenting with a CDR of 0.8 or worse was 2% (n=4).  
In those four people with a minimum CDR of 0.8, 50% (n=2) were newly diagnosed 
with glaucoma, and 25% (n=1) were declared suspects. Furthermore, the mean age of 
those with CDR of at least 0.8 was 56 years (median 61, range 23-78), the presence of 
bilateral cataract was high (75%). Mean and median ICT/GAT-values were higher than 
in the average sample (mean ICT/GAT of 20.1/19.5 mmHg versus 16.6/15.4 and medi-
an ICT/GAT of 17.8/17.3 mmHg versus 16/15 mmHg). 
ACD mean in both eyes was 2.95 mm (SD 0.3 both eyes). ACA means for all angles 
(nasal, temporal) in both eyes were 38° (range 18-60°). 16.3% (n=31) of people pre-
sented with bilateral cataract. As described in chapter 2.2.1, no exact grading of cataract 
other than mild or mature was done.  
Regarding visual acuity, no patient was bilaterally blind. All 190 right eyes (100%) 
studied had a vision of 3/60 or better. 99% of 188 left eyes had 3/60 vision or better, 
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only 1% (n=2) presented with left eye, unilateral blindness with visual acuity of less 
than 3/60, one with hand movement and one with NPL.  
3.1.2 Glaucoma prevalence and types in healthy study sample 
In an initially “healthy” sample of 200 people, five (2.5%) of these were newly diag-
nosed with glaucoma. POAG was the leading subtype with 60%, PEX and NTG formed 
20% each. Out of the 23 patients detected by the ICT with IOPs above 21 mmHg four 
patients were finally diagnosed with glaucoma, whilst the NTG was by definition not 
detected by the ICT. Table 5 shows the subdivision. 
Table 5: ICare tonometer (ICT) fourfold table 
  Glaucoma Healthy 
Positive test result 4  19  
Negative test result 1  176   
 
This corresponds to ICT sensitivity in detecting glaucoma by increased IOP levels 
(above 21 mmHg) of 80% with a specificity of 90%. Yet, the positive predictive value 
(PPV) of the ICT was only 17% and the negative predictive value (NPV) 99.4%. This 
result is due to the very few positives compared to many negatives, which needs to be 
taken into consideration when interpreting these results.  
Another five (2.5%) of all were marked as glaucoma suspicious due to their ocular 
findings and advised for follow up visits. This adds up to 5% (n=10) glaucomatous 
people among the “healthy” sample. 
All definitive POAG cases of study A and C combined are analysed separately in chap-
ter 3.4 to represent a larger sample, and exclude secondary glaucoma cases with very 
different findings, leading to distortion of the data regarding e.g. cornea, vision, and 
IOP. 
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3.1.3 Study A excluding glaucomatous eyes 
Study A was an allegedly healthy – meaning non-glaucomatous – sample, among which 
2.5% (n=5) glaucoma cases and 2.5% (n=5) glaucoma suspects were newly diagnosed.  
Discounting these ten individuals from the sample, results in a data set which is 100% 
non-glaucomatous. Thus it was thought to represent the Malawian non-glaucomatous 
population better than the original sample A, which included some glaucomatous eyes. 
The same data analysis was done on the remaining 95% of the original data set to see 
possible differences. However, results were similar.  As there was only a minor differ-
ence between 100% “healthy” and 95% healthy sample, all further descriptions of study 
A refer to the full data set including five glaucoma cases and five suspects, if not said 
otherwise. 
Gender distribution was almost equal with 54.7% females and 45.3% males. Median 
age was the same (32 years), as well as age group distribution. IOP medians were also 
equal to the original data, but instead of 11.5%, only 9.5% had increased IOP levels.  
The median CCT value with 506.8 µm was slightly thinner than in the full sample 
(507.5µm). Bilateral cataract was less prevalent in the non-glaucomatous data set 
(14.7% instead of 16.3%).    
3.1.4 Characteristics and glaucoma prevalence in patients with raised IOP  
11.5% (n=23) in the non-glaucomatous, healthy study sample presented with an IOP of 
over 21 mmHg. 52% were female and 48% male. Mean age was 41 years (median 39; 
range 22-78), compared to 35.3 years in the total sample. Equally to the total sample, 
almost half of all (47.8%) belonged to age group 2 between 25 and 39 years.  
Median ICT/GAT-values were 23/20.5 mmHg. Median CCT for both eyes was 515µm 
(right range 440-613; left range 434-610), which was thicker than that of the total sam-
ple (507.5 µm) described in chapter 3.1.1. A median CDR of 0.3 was found in both 
eyes, which equals the complete sample. Twenty-four percent showed cataract in both 
eyes and 9% of people presented with unilateral blindness, which was clearly higher 
than the 1% in the total healthy sample.  
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Whereas 2.5% of the whole study sample was diagnosed with glaucoma, in the group of 
elevated IOPs the proportion was 17.4%. This finding gives incentives for further dis-
cussion regarding the usefulness of ICT screening, as discussed in chapter 4.5.1 and 
chapter 4.6.  
3.1.5 Comparison between gender and different age groups  
The intended equal proportion of male to female participants (47:53) allows the com-
parison of results. Female median age was 35 years (mean 35.1; range 18-64), male 
median age was 31 years (mean 35.5; range 18-78). Females over 40 years were 34.9%, 
while males over 40 years represented 29.8%. Age group distribution by gender is 
illustrated in Figure 4. In summary, men exceeded women in the young age group be-
tween 25 and 39 years and also in the age group above 60 years.  
 
Figure 4: Age group distribution by gender in study A (%) 
 
Median IOP of males was in average 1 mmHg above female values. Median IOP in 
male eyes was 16.5/15.3 mmHg in ICT/GAT (range 8-53) versus 16/14 mmHg in 
ICT/GAT of female eyes (range 8-29). Both genders showed the same proportion of 
people above 21 mmHg in at least one eye, with 11.7% of men and 11.3% of women.  
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Mean CCT values did not vary much between genders, although males had slightly 
thinner CCT median values. In median values males had 505 µm and females 508.4 µm. 
ACD and ACA means were similar between genders. ACD in both eyes of males was 
3.0 mm, for women it was 2.8 mm for both eyes. ACA means for males were 38 to 39°, 
and in females 36 to 38°. CDR medians in both genders were 0.3, while 1% of women 
and 3.4% of men showed CDR of 0.8 or more in at least one eye. No major difference 
was detectable in the presence of cataract or visual impairment.  
Despite finding only five glaucoma cases, the gender distribution was strongly unequal. 
Four out of the five cases were male, representing 4.3% of all men and 0.9% of all were 
women. Also among suspects the gender ratio varied, with 4.3% and 0.9% respectively. 
Comparing features of participants above and below the age of 40 demonstrated more 
differences than comparing gender. There were slightly more females (56.9%) in the 
group over 40 years compared to men (43.1%), than in the group below 40 (51.1% 
female versus 48.9% male). IOPs did not differ much in both groups with medians 
around 15 and 16 in both groups. Nevertheless, more over 40 than below age 40 pre-
sented with IOPs above 21 mmHg (13.8% versus 10.4%). CDR median in both groups 
was 0.3.  
Large differences appeared in the remaining features, in which the elderly showed lower 
and respectively worse values. Median CCT values of those below 40 years was 509.5 
µm (range 428-613), whereas in those over 40 years CCT was lower with median 502 
µm in both eyes (range 423-582). Mean ACDs in the older group was lower, with 2.8 
mm versus 3.0 mm in the younger. ACAs were narrower, with means of around 34-35° 
in the older group and 38-40° in the younger group. As cataract is a phenomenon main-
ly of age, a difference was also seen in these two groups. Twenty-four percent had 
cataract in both eyes in the group over 40 years, against 5% in the younger group. Vi-
sion in both groups was mostly above 3/60. Only in the group above 40 years of age, 
there was 3% with unilateral blindness with vision below 3/60.  
A large gap could be seen in terms of new glaucoma diagnosis. Whereas 1.5% of those 
younger than 40 years were newly diagnosed, in those above 40 it was 4.6%. In sum-
mary, elderly individuals presented with more advanced findings concerning VA, cata-
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ract, and CDR, and were more often diagnosed with glaucoma. The following chapter 
3.1.6 is a concluding summary, joining the most important findings of study A. 
3.1.6 Summary of study A 
Study A resulted in baseline data of 200 healthy, non-glaucomatous Malawian patients, 
with 400 eyes. The study population had an almost 50:50 male-female ratio. Mean age 
was 35.3 years (median 32; range 18-78), with 67.5% belonging to the group of under 
40 years. Total mean for both eyes in ICT/GAT was 16.6/15.4 mmHg and median in 
ICT/GAT was 16/15 mmHg. The prevalence of increased IOP in the healthy sample 
was 11.5%.  
Mean CCT for both eyes was 509.2 µm, median was 507.5 µm. Mean as well as median 
CDR in both eyes was 0.3. The number of patients with at least one eye presenting with 
a CDR of 0.8 or worse was 2%, with a mean age of 56 years. Of those with CDR of 0.8 
or worse, 50% were newly diagnosed with glaucoma, 25% were suspects and 25% were 
classified as healthy. No patient was bilaterally blind.  
2.5% of study A was newly diagnosed with glaucoma, where POAG was the leading 
subtype with 60%. Another 2.5% of all were glaucoma suspects. Of the 11.5% present-
ing with ICT-levels above 21 mmHg, 17.5% were diagnosed with glaucoma. This cor-
responds to ICT sensitivity in detecting glaucoma by increased IOP levels (above 21 
mmHg) of 80% with a specificity of 90%. The PPV of the ICT was 17% and the NPV 
99.4%.  
Looking at those with glaucoma diagnosis, median CCT was slightly thicker (515 µm 
than in the total sample of study A (507.5 µm). Median age (39 versus 32 years) was 
higher in those with glaucoma diagnosis versus the total sample.   
Men and women did not differ much in terms of ocular parameters such as IOP, CCT, 
or CDR. A difference though existed in the proportion of males and females diagnosed 
with glaucoma, which was a 4:1 male-female ratio. This indicated a male majority in 
this subgroup, although the number of cases was too small to deduce a general state-
ment from it.  
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Differences were detected when comparing individuals below and above 40 years of 
age. Those above 40 presented with thinner CCT, narrower ACAs, less ACD and lower 
VA, as well as more cataracts. In terms of new glaucoma diagnosis, 1.5% of younger 40 
years were newly diagnosed, while in those above 40 it was 4.6%.   
3.2 Study B: IOP assessment 
After the thorough eye examination of study A, the aim of study B was to get a maxi-
mum number of IOP measurements at the outpatient department (OPD) of LSFEH. This 
was meant to generate a strong indicator for the average IOP, and the prevalence of 
increased ocular pressures in Malawian patients at an eye clinic. A summarized list of 
findings is attached in 9.3.3 of the appendix.  
3.2.1 Description of sample size, gender ratio, age distribution and mean IOP 
The IOP of 1,112 patients at the OPD of LSFEH were measured with an ICT. As men-
tioned before, due to ulcers and other corneal disturbances, 1,099 right eyes and 1,090 
left eyes were measured (compare appendix 9.3.3). Age, gender, and IOPs were docu-
mented for both eyes. Main findings are summarized in Table 6. 
Table 6: Main ocular findings of patients at outpatient department of LSFEH 
Parameter Unit Results 
Total number No. 1,112 
Gender distribution (male : female) % 41.8 : 58.2 
Age mean / median  Years 41.2 / 36 
IOP (ICT) mean  mmHg 16.6 
IOP (ICT) median  mmHg 15.5 
IOP >21 mmHg % 13.8  
New glaucoma diagnosis % 2.4 
Gender distribution at the OPD was 58.2% females and 41.8% males. The average age 
was 41.2 years (median of 36 years) with a minimum of 18 and an alleged maximum 
age of 112, as claimed by the patient and her attenders (without proof of birth certifi-
cate). The distribution within the defined age groups is seen in Figure 5: Age group 1 
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from 18 to 24 years of age were 17.4%, group 2 from 25 to 39 years was 38.1%, group 
3 from 40-59 years represents 25.4%, group 4 from 60-79 years was 17.1% and group 5 
from 80 years onwards comprised 2% of patients. 
 
Figure 5: Age group distribution (in %) at outpatient department of Lion Sight First Eye Hospital, Malawi 
Mean age of women was 40 years and of men 42.8 years, whereas 42% of women and 
48% of men were older than 40 years. As in study A, the difference between both eyes 
showed no clinical significance so that they will be described together in the text below. 
Total mean/median ICT for both eyes was 16.6/15.5 mmHg (range 3-81). The preva-
lence of patients with raised ICT values above 21 mmHg was 13.8% and will be further 
described in chapter 3.2.3.   
3.2.2 Glaucoma presentation patterns, known and new diagnosis 
3.1% of patients (n=34) seen at the OPD had a known history of glaucoma. Of those 34 
patients, male-female ratio was 59:41, opposing the 40:60 distributions in the total study 
population. Thus results showed a male dominance.  
Known glaucoma patients on average were older. Mean age was 58.2 years (median 62; 
range 18-81), with 11.8% below the age of 40 and 88.2% above. Their mean IOP was 
30.8 mmHg and median was 26 mmHg.  
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Anticipating the results from the thorough examination of study C, a total of 2.4% 
(n=27) of all 1,112 patients were newly diagnosed in the study with glaucoma. The 
mean age of those 27 new glaucoma patients was 53 years. Another four out of the 
1,112 patients were seen by other specialist and also newly diagnosed with glaucoma, 
making 2.7% of the OPD population.  
3.2.3 Characteristics and glaucoma prevalence in patients with raised IOP  
The vast majority of all 1,112 OPD patients presented with ICT values below 21 
mmHg. The prevalence of patients with raised ICT values above 21 mmHg was 13.8%, 
as mentioned in chapter 3.2.1, whereas not all could be fully examined afterwards. 9.5% 
(n=106) instead of 13.8% (n=154) received full eye examinations.  
Of those 154 patients with raised IOPs, 46.8% were female and 53.2% were male. So 
despite the fact that there was a female majority in the OPD pool, male gender had a 
tendency to present more often with IOP values above 21 mmHg.  
The mean age of all 154 patients with increased IOP was 47.9 years (median 47; range 
18-82 years; SD 18.04). A majority (61.7%) was in the age group of 40 years and 
above. Another age division showed that age groups 2-4 (group 2 (25-39 years): 26.6%; 
group 3 (40-59 years): 27.9%; group 4 (60-79 years): 32.5%) approximately comprised 
one third of all patients each. Only 11.7% fell into group 1 (below 25 years) and 1.3% 
into group 5 (from 80 years onwards), which was also the smallest study population due 
to the low life expectancy in the country. This distribution among the five age groups is 
illustrated in Figure 6 and can give possible hints as in how to structure screening pro-
grammes.  
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Figure 6: Age group distribution of patients with IOP >21 mmHg by ICare measurement at outpatient department of 
LSFEH 
In those 154 individuals with elevated ICT measurements mean IOP was 27.7 mmHg 
(median 25; range 6-81). About one fifth (20.9%, n=32) of those found with raised IOPs 
at the OPD already had glaucoma diagnosed and mostly had IOD values far above 21 
mmHg, while only two known glaucoma patients had an IOD below 21 mmHg. . Of 
those 106 patients who were fully examined and included in study C, 25.5% (n=27) 
were later newly diagnosed with glaucoma. These results will be discussed in chapter 
4.5.  
3.2.4 Comparison between gender and different age groups 
The comparison of males and females showed a slightly higher age of males presenting 
at the OPD. The mean age of men was 42.8 years (median 38; range 18-87) and 40.0 
years in females (median 35; range 18-112). 40.6% of women were found in age group 
2 (25-39 years) and 34.6% of men, while male patients were better represented in the 
older age groups. The age group 4 (60-79 years) had 20.2% male and 14.8% female 
patients. In age group 5 (80 years onwards) males were twice as many as females (2.8% 
versus 1.4%).  
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Whilst 4.3% of men indicated a known glaucoma diagnosis, only 2.2% of women did 
so. Whereas 17.6% (n=82) of all males presented with increased IOP above 21 mmHg, 
elevations were only found in 11.1% (n=72) of women. Accordingly, more males 
(11.2%) than females (8.3%) were fully examined and included in consecutive study C. 
Nevertheless, no difference was found in the median ICT values, with 15.5 mmHg in 
both genders.  
In respect to age above and below 40, in the group below 40 years 60.8% were wom-
en and 39.2% were men. The group above 40 years consisted of 54.9% females against 
45.1% of males. ICT median was 15.5 mmHg in both age groups. The mean ICT value 
in the group above 40 years was higher with 17.3 mmHg (range 3-81) in those above 40 
years against 16.0 mmHg (range 3-61) in the younger age group.  
In terms of elevated IOP readings, the age group of 40 and above showed a stronger 
tendency for elevated values. In this group 19.2% came with IOP elevations, while in 
those below 40 years 9.6% had elevated IOPs. Correspondingly, the number of people 
with known glaucoma was higher in the elderly patients, with 6.1% of people above 40 
years against 0.6% of patients under 40. 
3.2.5 Summary of study B 
In study B – the IOP assessment among 1,112 patients at the OPD - gender distribution 
was 58.2% female and 41.8% male. The average age of study B was 41.2 years. Women 
presented at a younger age with 40.6% between 25 and 39 years against 34.6% of men. 
Adding up the two age groups of 18 to 24 years with 25 to 39 years results in 57.9% 
women and 52% men, which shows an overall younger female study sample. 
Total mean/median for both eyes was 16.6/15.5 mmHg respectively. The prevalence of 
patients with raised ICT values above 21 mmHg was 13.8%, while male gender had a 
higher tendency to present with IOP values above 21 mmHg. The mean age of all with 
increased IOP was 47.9 years, and age groups 2 to 4 each comprised approximately one 
third of all patients (25-39: 26.6%; 40-59: 27.9%; 60-79: 32.5%). 
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About one fifth (20.9%, n=32) of those found with raised IOPs at the OPD already had 
glaucoma diagnosed and most had IOD values far above 21 mmHg, while only two 
known glaucoma patients had an IOD below 21 mmHg.  
3.1% of patients had a known history of glaucoma, with male dominance (male-female 
ratio of 59:41). Known glaucoma patients on average were older, with a mean age of 
58.2 years, as 88.2% were above the age of 40. Their mean IOP was 30.8 mmHg and 
median was 26 mmHg for both eyes. A total of 2.4% (n=27) of all 1,112 patients were 
further on diagnosed in study C with glaucoma at a mean age of 53 years.  
In respect to gender, males at the OPD presented at a higher age (median 38 versus 35 
years in female), whereas the median ICT was equal (16 and 15 mmHg) in both gen-
ders. In total numbers, more males than females presented with known glaucoma (4.3 
versus 2.2%), or elevated IOPs above 21 mmHg (17.6 versus 11.1%). In retrospect, also 
more male patients were newly diagnosed with glaucoma (3.4 versus 1.7%).  
Regarding the difference in patients below or above 40 years of age, it can be seen that 
older patients showed a higher IOP mean of 17.3 mmHg against those below 40 years 
with 16.5 mmHg. Medians for both groups were 15.5 mmHg. More people above 40 
years (19.2%) than below (9.6%) presented with elevated IOPs.  
The association between glaucoma and age was underlined by the average age of people 
with a known glaucoma diagnosis of 58.1 years. Further, 1.1% of those below 40 years 
against 4% of those over 40 years were later diagnosed with glaucoma.  
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3.3 Study C: Increased IOP examination 
In a second step following ICT measurements of study B, all those with increased IOP 
above 21 mmHg were comprehensively examined to find out the actual prevalence of 
glaucoma, or suspects among those with increased pressures. A detailed documentation 
of results is added in 9.3.4 of the appendix. For a short comparison see Table 7.  
One aim of this study was to draw conclusions regarding the usefulness of an ICT 
screening at this specific setting, which is part of chapter 4.5. By including patients with 
a history of glaucoma, a database to investigate possible characteristics and correlations 
in glaucomatous eyes was established.  
3.3.1 Description of sample size, gender ratio, age distribution, mean IOP, CCT, 
CDR, ACA, cataract and VA 
A total of 154 patients were referred to take part in study C. These were detected with 
IOPs of over 21 mmHg during the large IOP assessment of study B. As described in 
chapter 3.2.3 due to logistical reasons (lack of time or unwillingness of patients), 106 
instead of 154 individuals with increased IOP received full eye examinations. As also 
previously mentioned, not all parameters could always be collected of all 106 individu-
als, due to corneal ulcers, opaque discs or other ocular disturbances. The exact numbers 
of measurements can be cross-checked in appendix 9.3.4. 
The sample of study C consisted of 50.9% women (n=54) and 49.1% men (n=52). This 
almost 50:50-distribution occurred randomly without intention. The sample also includ-
ed 12.3% (n=13) with a known history of glaucoma, as this helped in collecting more 
data on glaucomatous eyes in this setting, as mentioned in 2.2.3. The main findings of 
study C are summarized below in Table 7. Mean age was 46.6 years (median 43 years; 
range 19-81), of which 41.5% belonged to the group under 40 years and 58.5% to the 
group of 40 years or older. According to age groups, 13.2% formed group 1 (18-24 
years), whereas about one third made up group 2 (25-39 years: 28.3%), group 3 (40-59 
years: 28.3%) and group 4 (60-79 years: 29.2%). A minor part (0.9%) was found in 
group 5 (80 years and above). The distribution was thus comparable to the one found in 
study B (shown in chapter 3.2.3), which sample C is formed of.     
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Table 7: Main ocular findings in study C, people with IOP > 21 mmHg 
Parameter Unit Results 
Total number No. 106 
Gender distribution (male : female) % 49.1 : 50.9  
Age mean / median  Years 46.6 / 43 
IOP (ICT/GAT) mean mmHg 26.7 / 25.9 
IOP (ICT/GAT) median mmHg 24.5 / 24 
CCT mean / median µm 527.8 / 527 
CDR mean / median   0.45 / 0.4 
CDR > 0.8 (at least one eye) % 18.7 
Cataract bilateral % 28.3 
Blindness unilateral % 21.7 
Blindness bilateral % 3.8 
Glaucoma prevalence % 25.5 
 
Among all 106 patients mean ICT/GAT-values for both eyes were 26.7/25.9 mmHg 
(range 11-81) and the median was 24.5/24 mmHg. Total median CCT for both eyes was 
527 µm respectively. This was higher than the median CCT-values in the healthy study 
sample of study A (507.5 µm). 
Excavations of the optic disc were slightly larger than in healthy eyes, with median 
CDR of 0.4 (compared to 0.3). 18.7% showed CDRs of 0.8 or worse against 2% in 
sample A. Of those with a CDR of 0.8 or more, 50% were diagnosed with glaucoma 
according to the definition given in 2.2. Their optic nerve damage could be clinically 
related to glaucoma or was far advanced even without an elevated IOP. As discussed in 
2.2 the optic disc appearance in Africans differs from the one in Caucasians in the sense 
that they are often larger and thus have a bigger excavation. (Nangia et al. 2013) In 
accordance to the opinion of our African colleagues, who are more familiar with the 
optic disc appearance of the Malawian population, they were classified as non-
glaucomatous optic discs but were advised to come for follow ups.  
ACD and ACA did not show different results to the healthy sample. Mean ACD was 2.8 
mm for both eyes and ACA means clustered around 38° (range 0-68°). Unilateral blind-
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ness (VA less than 3/60) was present in 21.7% (39% in the right eye, 61% in the left 
eye). 3.8% (n=4) were bilaterally blind.   
As mean age was higher, there was a large portion of people with cataract. 28.3% had 
bilateral cataract, of which 40% were diagnosed with glaucoma, 23.3% already had 
glaucoma diagnosed, and another 10% were glaucoma suspects or known suspects. This 
large percentage of people with common cataract and glaucoma gives implication for 
discussion in chapter 4.5.3. 
3.3.2 Glaucoma prevalence and types in raised IOP sample 
In this sample of 106 people, 25.5% (n=27) were newly diagnosed with glaucoma and 
12.3% (n=13) already had glaucoma diagnosed. POAG was the leading subtype as 
already in study A, with an even higher prevalence of 70.4%. Secondary glaucoma was 
found in 18.5% and PEX in 11.1%. By the nature of the study (only people with ICT 
above 21 mmHg included), no NTG was detected. 17.9% of all were considered glau-
coma suspicious and one person was already declared a suspect.  
Of those with the diagnosis of glaucoma, 59.3% were male, mean age was 53 years and 
44.4% belonged to age group 4 (60-79 years). 44.5% presented unilaterally blind 
(33.3% in the right eye, 66.6% in the left eye). One person (3.7%) in the sample was 
bilaterally blind. All POAG cases will be analysed separately in the next chapter 3.4 as 
mentioned before.   
3.3.3 Comparison between gender and different age groups  
The unintended almost equal proportion between 52 male and 54 female participants 
(49:51 ratio) allows a comparison of results. Female median age was 39 years (mean 
44.1; range 20-79), and male age was higher with a median of 48 years (mean 49.2; 
range 19-81). Of all females, 51.9% were over 40 years. Males over 40 represented 
65.4%. Women were strongly present in the younger age group 2 between 25 and 39 
(37%), and none in group 5 of 80 years and older. Males dominated in group 4 between 
60 and 79 (35%), and also 1.9% in the oldest group of 80 and above.   
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Median IOP was almost equal in both genders. Men had a median ICT/GAT of 25/24 
mmHg (range 11-81) versus ICT/GAT in females of 24.5/23.5 mmHg (range 11-72). 
Mean and median CCT values did not vary much between genders, although males had 
a slightly thinner CCT median. Median CCT for male eyes was 525.5 µm. Women 
presented a median CCT of 530.5 µm. ACD and ACA means were almost equal in both 
genders as in study A. ACD mean in both eyes of males and females was 2.8 mm. ACA 
means for males were between 38 and 39°, and in females 37° to 38°, the same as in the 
healthy study sample.  
The CDR median for males was 0.4 in both eyes and 0.35 in women. A marked gender 
discrepancy was found in the amount of people with CDR values of 0.8 or more in at 
least one eye. While 11.1% of women fell into this category, 26.9% of men had CDR of 
0.8 or worse. 
While bilateral cataract was present in 25.9% of females, in males it was detected in 
30.8%. 20.4% of women were unilaterally blind (27.3% on the right, 72.7% on the left 
eye) and 1.9% bilaterally blind. In contrast, 23.1% of men were unilaterally blind (50% 
on the right and 50% on the left eye), and 5.8% presented with bilateral blindness.  
There were more men diagnosed with glaucoma, but more women declared as suspects. 
20.4% of women were diagnosed with glaucoma upon examination, primarily with 
POAG, and 22.2% were described as suspects. 1.9% was diseased with PEX and 1.9% 
with secondary glaucoma. In men, almost one third (30.8%) was diagnosed with glau-
coma, mainly POAG (19.2%), as well as secondary glaucoma (7.7%), and 3.8% PEX. 
13.5% were determined as glaucoma suspects.  
Comparing features of younger and older sample populations in study C, below and 
above 40 years, demonstrated more differences than comparing gender. In total num-
bers there were more men in the group over 40 years (54.8%) than women (45.2%), 
whereas in the group younger 40 years there was a female preponderance with 59.1% 
against 40.9%.   
IOPs did not differ much in both groups. Medians for both eyes combined of those 
under 40 years were 25/23.8 mmHg in ICT/GAT, and among those over 40 years it was 
24.3/24 mmHg. CDR median was higher in the older age group, with 0.5, while in the 
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group below 40 years it was 0.3 for both eyes. The elderly had a higher incidence of 
CDRs of 0.8 or worse, which was 29% in those over 40 years versus 4.6% in the 
younger.  
There were further distinct findings between age groups. Like in study A, older patients 
showed lower median CCT values. Median CCT of those older 40 years was 511.5 µm 
(range 439-635) while in those younger 40 years it was 535.5 µm (range 451-623). 
Mean ACDs in the older group was lower, with 2.7 mm versus 3.0 mm in the younger, 
which was almost equal to the healthy group (2.8 versus 3.0 mm). ACA means were 
between 35-37° in the older group and 39-43° in the younger group (in healthy 34-35° 
and 38-40°).  
Cataracts affected the older age group more (46.8% bilaterally versus 2.3% in the 
younger group). Likewise, vision deteriorated with age. 9.1% of the younger 40 years 
group were unilaterally blind (50% right, 50% left eye) and none was bilaterally blind. 
In the age group over 40 years, 6.5% presented with bilateral and 30.7% with unilateral 
blindness (36.8% right, 63.2% left eye blindness).  
A disparity appears in terms of new or known glaucoma diagnosis. Those above 40 
were given a definitive glaucoma diagnosis (mainly POAG) in 32.3%, which was twice 
as often as in the younger group with 15.9%. Vice versa, those below 40 years of age 
were considered suspects three times as often as the elderly, with 30% versus 10%. 
Furthermore, all people with a known diagnose of glaucoma (n=14, including one 
known suspect) were over 40 years and none below.  
To repeat the concluding words of study A and B, the findings gave an indication that 
higher IOP values and glaucoma are closely associated with age. In respect to gender, 
men were older on average, presenting with more advanced glaucomatous findings and 
diagnosed more often with glaucoma and. The statistical correlation of these parameters 
will be demonstrated in chapter 3.5. 
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3.3.4 Summary of study C 
Study C examined individuals with increased ICT measurements at the OPD. In the 
sample of 106 people with a median age of 43 years, almost 60% were 40 years or 
older. With an almost 50:50 gender distribution, 25.5% (n=27) were newly diagnosed 
with glaucoma, and 12.3% (n=13) already had glaucoma diagnosed. POAG was the 
leading subtype with 70.4%. Among those diagnosed with glaucoma, the mean age was 
53 years and 59.3% were males. 
Total mean ICT/GAT for both eyes was 26.7/25.9 mmHg, and total ICT/GAT medians 
for both eyes were 24.5/24 mmHg. Total median CCT for both eyes was 527 µm re-
spectively. Excavation of the optic disc had a median of 0.4 in both eyes (compared to 
0.3 in the healthy sample of study A). A very high number (18.7%) showed CDRs of 
0.8 or more. 50% among those were newly diagnosed with glaucoma. A marked gender 
discrepancy was found regarding CDR values of 0.8 or more in at least one eye in 
women with 11.1% and men 26.9%.  
3.8% of people with visual impairment and blindness were bilaterally blind, mainly in 
the age group above 40 years. Concurrently with high median age, 28.3% showed bilat-
eral cataract. 
Patients above 40 years had a higher incidence of CDRs of 0.8 or worse. 4.6% in those 
below 40 years contrasts 29% in those over 40 years presenting with a CDR of 0.8 or 
worse. Likewise, the elderly were diagnosed twice as often with glaucoma as their 
younger counterparts (32.3% versus 15.9%). Vice versa, those below 40 years of age 
were considered suspects three times more frequently than the elderly (30 versus 10%). 
All people with a known diagnosis of glaucoma were older than 40 years. In respect to 
gender, men on average were older and showed advanced glaucomatous findings.  
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3.4 Characteristics of POAG patients from study A and C 
With POAG as the main glaucoma type in Africa, the following chapter focuses on this 
type. All 22 patients newly diagnosed with POAG in study A and C are presented com-
bined in the following chapter. Of these 22 POAG patients, three are from study A, 
found among an allegedly healthy study population, and 19 from the sample of in-
creased IOP levels of study C. Those patients with a known history of glaucoma have 
been excluded, as it was not sure that the same definition of glaucoma was taken for 
diagnosis and also because they were partially under treatment, which could distort the 
numbers and figures. The detailed table of results throughout the following chapters are 
found in Table A 5 in the appendix 9.3.5. 
3.4.1 Total number of POAG patients, gender ratio, age distribution, mean 
IOP, CDR, CCT, ACA, ACD, cataract and visual acuity 
Among all 22 POAG patients the male gender outnumbered the female with 54.5 to 
45.5%, while in the total sample of study A and C there was a slight dominance of the 
female gender. A brief summary of main findings are summarized in Table 8. 
Table 8: Main ocular findings of POAG patients at LSFEH 
Parameter Unit Results 
Total number No.  22 
Gender distribution (male : female) % 54.5 : 45.5  
Age mean / median  Years 52 / 54 
IOP (ICT/GAT) mean mmHg 30.2  / 30.3 
IOP (ICT/GAT) median mmHg 27 / 26 
CCT mean / median µm 504.7 / 505  
CDR mean / median   0.7 / 0.7 
CDR > 0.8 (at least one eye) % 45.5 
Cataract bilateral % 45.5 
Unilateral blindness % 31.8 
Blindness bilateral % 4.5 
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The median age was 54 years (mean 52 years; range 20-78). The majority of 72.7% 
belonged to the group of 40 years and older, where 27.3% were 40-59 years (group 3), 
and almost half (45.5%) of all were 60-79 years old (group 4). There was none 80 years 
or older. The group younger than 40 years comprised mostly people from 25-39 years 
(18.2%; group 2), and only 9.1% were younger 25 (group 1), shown in Figure 7.    
 
Figure 7: Age group distribution of POAG patients (%), n=22 
Median ICT/GAT was 27/26 mmHg and total mean ICT/GAT 30.2/30.3 mmHg (range 
18-69 mmHg). These medians were above the average of study C, in which total medi-
ans were 24.5/24 mmHg with ICT/GAT.  
Median CDRs among POAG patients were increased with 0.7 in both eyes, and 45.5% 
were detected at a very advanced stage with 0.8 or worse. Total median CCT was 505 
µm and thereby was thinner in POAG patients than in the healthy population (507.5 
µm). Mean CCT in all 22 POAG patients was 516.2 µm, but these included three pa-
tients with IOP values above 40 mmHg and one immeasurable IOP. Excluding these 
four from the calculation, because of their extreme IOP and thereby most likely thick-
ened CCT values, results in a mean CCT of 504.7 µm, which is shown in Table 8, be-
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cause this was regarded as the more accurate value. The mean ACD of 2.75 mm and the 
mean ACA between 36° to 39° did not differ much from the healthy sample. 
31.8% of all POAG affected patients showed unilateral blindness (28.6% in the right 
and 71.4% in the left eye), whereas 4.5% (n=1) presented with bilateral blindness 
(among the healthy sample, no one was bilaterally blind; in the increased IOP sample 
3.8% were bilaterally blind). Bilateral cataract was present in 45.5% of POAG patients. 
Due to only incipient to medium stage cataracts present, glaucoma seemed to be the 
cause of blindness in these patients, given their large CDRs or very elevated IOP values. 
3.4.2 Comparison between gender and different age groups 
The following paragraphs describe similarities and differences between results for both 
genders, and in between age groups, mainly patients below and above 40 years of age. 
A gender comparison among POAG cases shows that out of ten women 70% were 40 
years and older. Among twelve men 75% were 40 or older. Men had a higher median 
age (68 years) with 50% being over 60 years in comparison to women (48 years) with 
30% above 60 years of age. 
IOPs in ICT/GAT measurements were about equal between both genders. In total, 
results show a higher IOP median in men. Median ICT/GAT for men was 27.5/26.5 
mmHg and for women 25.8/24.8 mmHg. Male POAG patients had thinner CCTs com-
pared to females. Total median CCT for men was 494.5 µm (range 439-568) versus 
509.3 µm 458-541) in women. CDR findings in men are higher than in women. Median 
CDR in both eyes of men were 0.8 (range 0.4-1.0). In women, median CDR was 0.7 
(range 0.4-0.8). While in women 30% had 0.8 or worse, in men it was 58.3%.  
Cataract was also more prevalent in men. Bilateral cataract was twice as common (30% 
versus 58.3%). Concurrently, male VA was less than female VA. Women with POAG 
had 20% unilateral blindness (all in the left eye) and no bilateral blindness. Twice as 
many men - 41.7% - were unilaterally blind (40% in the right and 60% in the left eye), 
and 8.3% (n=1) were bilaterally blind.  
Comparing ages below and above 40, there were almost three times as many POAG 
patients detected with age over 40 (n=16) compared to those who were younger than 40 
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(n=6). In those younger than 40, gender distribution was 50:50. In those over 40 female-
male ratio was 44:56.  
ICT/GAT IOPs did not vary much between the two age groups. The total median 
ICT/GAT in those younger than 40 was 27.5/25.5 mmHg, and 26.8/26.3 mmHg in those 
above 40 years. There was a difference between CCT values of under and over 40-year-
old people, as in previous studies. Under 40 years, CCT mean/median was 530.5/529 
µm, whereas over 40 years mean/median was 494.5/493 µm, which is again in accord-
ance with the fact of physiological decrease in CCT with age.  
Resembling the results of the previous gender comparison, median CDR findings were 
mildly higher in the age group over 40. Median CDR was 0.65 in those younger than 40 
years and 0.73 in those above 40 years of age. Half of all over 40 years presented with 
CDR findings of 0.8 or worse, against 33.4% of those below 40 years of age. This dis-
closes that advanced stages often develop with increasing age. No cataract was found 
among those aged below 40, while 62.5% above the age of 40 presented with bilateral 
cataract. Accordingly, VA was worse with increasing age.  
Male participants had a higher median age and presented with worse ocular findings, 
showing more risk factors for the development of glaucoma, such as high IOP, worse 
CDR, and thinner CCTs. The same was true for the older age group. These findings 
need to be interpreted in the light of the age distribution of the whole sample B of 1,112 
patients. The majority of participants (58.2%) were female and 41.8% male. At the 
same time, the male population was older with 48% above 39 years, against 42% of 
women.  The fact of an older male sample and the correlation between the development 
of glaucoma with age may contribute to the predominance of males in terms of patho-
logic glaucomatous findings. Furthermore, the correlations shown in chapter 3.5 will 
also indicate aforementioned associations.  
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3.4.3 Summary of findings in POAG patients 
In general, POAG patients presented with high median age and share in patients above 
60 years of age. Ocular parameters showed the highest IOP medians, thinnest medians 
in CCTs, more advanced CDR findings as well as low VA in comparison to the healthy 
sample of study A and the sample of increased IOP of study C. In general terms, rather 
advanced glaucoma stages were detected among POAG patients.  
The median age was 54 years (range 20-78). Male gender with 54.5% outnumbered the 
female gender (45.5%). The majority (72.7%) among POAG patients belonged to the 
group above 39 years. While both age groups (above and below 40 years) had compara-
ble median IOP values of 26.3 mmHg and 25.5 mmHg respectively, the younger POAG 
patients with advanced glaucoma stages presented with a higher CCT median (530.5 
µm)  than their older counterparts (493 µm) and also than the healthy population sample 
of study A (507.5 µm).  
Median ICT/GAT-values were 27/26 mmHg. Median CDR among POAG patients was 
0.7 and 45.5% of cases were detected at an advanced stage with CDR of 0.8 or worse. 
Total mean CCT was 516.2 µm and total median CCT 505 µm. Bilateral cataract was 
present in 45.5% of POAG patients. VA was on average worse than in the previous 
studies and 4.5% (n=1) presented bilaterally blind. 
A gender comparison pinpointed a male majority in terms of older age and more ad-
vanced glaucoma stages. As glaucoma development is closely associated with ageing, 
the fact of an older male sample may contribute to the dominance of males in terms of 
pathologic glaucomatous findings. Male median age was 68 years versus 48 years in 
women. Men also showed larger CDRs, lower VA findings, and had thinner CCT val-
ues (median 494.5 µm) than women (509.3 µm).   
Comparing POAG patients of older and younger than 40 years of age showed a CCT 
median of the elderly of 493 µm, which was thinner than in those below 40 years, where 
median was 530.5 µm. Vision was also worse in the latter group. CDRs were slightly 
more advanced in the older age group. CDR median was 0.65 in those younger 40 years 
and 0.73 in those above 40 years of age.  
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3.5 Correlations of ocular parameters 
In order to determine how different features of interest are associated, correlation analy-
sis was done, using metric parameters, namely age, ICT, GAT, CCT, and CDR. Fur-
thermore, correlations were calculated for the dichotomous variables gender and age 
with the diagnosis of glaucoma. Statistical correlations were measured for each study by 
coefficient of correlation. Because the metric parameters were not normally distributed, 
Spearman’s correlation coefficient (rho) was chosen. The correlation coefficient ranges 
from -1.0, indicating perfect negative relation to +1.0, indicating perfect positive rela-
tion. The closer results come towards zero, the less two parameters are correlated. As 
already outlined in chapter 2.3 correlation of -1.0 to -0.5 or 1.0 to 0.5 is considered a 
strong correlation, -0.5 to -0.3 or 0.3 to 0.5 moderate and between -0.3 and -0.1 or 0.1 to 
0.3 it is weak, whereas values between -0.1 and 0.1 mean no correlation. The correlation 
has statistical significance (p) with a p-value of < 0.05.    
3.5.1 Correlations in study A and B 
In the healthy study sample A and taking the means of both eyes, there was a strong and 
significant correlation between ICT and GAT measurements (rho = 0.863, p = 0.000).  
Moderate and significant correlation was found between ICT and CCT (rho = 0.35, p = 
0.000).  
A weak but significant correlation was detected between GAT and CCT (rho = 0.244, p 
= 0.000) as well as very weak between age and CDR (rho = 0.13, p = 0.067). 
No associations were found between CCT and CDR (rho = -0.054), ICT/GAT and CDR 
(rho = 0.117/0.107), nor age and ICT (rho = 0.006) or age and CCT (rho = -0.071).  
In study B in which only the age and ICT measurements of patients were recorded, there 
was also no correlation between age and IOP.  
In retrospect the variable of glaucoma diagnosis was added to study B after examining 
the individuals with elevated IOPs. The dichotomous variables age and gender were 
then correlated with the variable of glaucoma diagnosis to see the possible associations. 
In the presentation of results gender and age comparisons were often made. The total 
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numbers suggested a tendency of glaucoma to occur more often at higher ages and more 
often in men.  
For gender and glaucoma diagnosis the chi-squared test gave no significant result (p = 
0.075). Thus, gender does not seem to be correlated to the development of glaucoma. In 
respect to age and glaucoma diagnosis the Pearson correlation showed a weak but sig-
nificant correlation of age and the diagnosis of glaucoma (r = 0.112, p = 0.000). There-
fore, age can be associated with the development of glaucoma and the fact of an older 
male sample may influence the results. These tests also confirm the information given 
in the introduction under 1.2.1 and 1.2.6. 
3.5.2 Correlations in study C and POAG sample 
Comparable associations were found in study C and the separate POAG sample, which 
is explained by the fact that the POAG sample is mainly a sub-entity of study C. The 
following refers to study C but also applies to the POAG sample.  
Just like in study A, strong associations with high significance were found between ICT 
and GAT (rho = 0.785, p = 0.000) for the mean of both eyes together.  
A moderate and significant correlation existed between age and CDR (rho = 0.314, p = 
0.001). 
A weak but not significant correlation was present between ICT and CDR (rho = 0.184, 
p = 0.061). A weak but significant correlation between GAT and CDR (rho = 0.283, p = 
0.004).  
There was a weak and significant negative correlation between age and CCT (rho = -
0.282, p = 0.003), as well as CDR and CCT (rho = -0.223, p = 0.022). In comparison, 
age and ICT/GAT were not (rho = 0.1) or very weakly correlated (rho = 0.194, p = 
0.05). No correlation is present between ICT and CCT (rho = 0.105) or GAT and CCT 
(rho = -0.043).   
3.5.3 Summary of correlations 
Looking at the metric variables throughout all studies, common and strong correlations 
were only found between ICT and GAT measurements. A weak positive correlation was 
71 
 
 
found in study A and C between age and CDR, indicating that higher age is associated 
with higher CDRs. In all studies no correlation could be seen between IOP measure-
ments in ICT/GAT and age. Age and glaucoma were weakly but significantly correlated 
(r = 0.112, p = 0.000). Gender was not correlated with the diagnosis of glaucoma. 
In contrast in all other variables no consistency was found among the studies regarding 
correlation. In study A there was a moderate association between ICT and CCT 
(rho=0.35, p = 0.000), which was not correlated in study C (rho=0.105). The association 
between CCT and IOP is a topic of discussion in literature and subject of discussion in 
chapter 4.4.  
The strong correlation between ICT with GAT will be further examined in the next 
chapter.  
3.6 ICT and GAT comparison in Bland-Altman-plots  
Complementary to the preceding descriptive statistics of results, the two methods for 
IOP assessment – ICT and GAT – are compared to each other in the following chapter. 
The statistical methods used are Bland-Altman-plots, done for right and left eyes of 
study A and B separately. 
The Bland-Altman-plots are scatter diagrams, displaying means of paired values from 
each method on the x-axis, and mean differences of each pair of the two measurements 
for each individual on the y-axis. Three horizontal lines are added. The medial line 
represents the bias, calculated as the mean (overall) difference in values obtained with 
two different methods of measurement, namely ICT and GAT. As the plotted results 
display ICT minus GAT method values, the bias quantifies how much higher (positive 
bias) or lower (negative bias) values are with ICT.  
The upper and lower horizontal lines represent the limits of agreement, in other words 
the confidence limit for the bias or degree of the average deviation of measured values. 
These limits are computed as bias (mean difference) plus and minus 1.96 SD of differ-
ence, resulting in upper and lower limits of agreement. The confidence limit is between 
upper and lower limits of agreement. The limit indicates the range within which 95% of 
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the differences from the bias are expected to be, if differences between the methods 
were distributed normally.  
Figure 8 and Figure 9 depict Bland-Altman-plots for right and left eyes of study A. A 
very wide distribution of scatter points can be seen in Figure 8 for the right eye, whereas 
in the left eye, depicted in Figure 9, points are clustered more narrowly.  
The 95% confidence limit of the right eye is from -3.09 to +5.57 mmHg, with a positive 
systemic bias or average difference of +1.24 mmHg, indicating that ICT measures on 
average about 1.2 mmHg higher than GAT. Evaluating the same for the left eye, it gives 
a confidence limit between -2.83 and +5.03 mmHg and a positive systemic bias of +1.1 
mmHg.  
The right eye of study A comprises nine outliers (9 of 191, 4.7%), eight above and one 
below the limits of agreement. For the left eye, the plot demonstrates ten outliers (10 of 
188, 5.3%), five above and five below the limits. So in both eyes the two methods show 
a bias, which can be rounded to 1 mmHg overestimation of ICT compared to GAT.   
 
 
Figure 8 : Bland-Altman-plot for study A, right eye (mmHg) 
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Figure 9 : Bland-Altman-plot for study A, left eye (mmHg) 
 
 
 
Figure 10: Bland-Altman-plot for study C, right eye (mmHg) 
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Figure 11 : Bland-Altman-plot for study C, left eye (mmHg) 
Figure 10 and Figure 11 illustrate Bland-Altman-plots for right and left eyes of study C, 
individuals who all presented with IOP values above 21 mmHg in at least one eye. Both 
plots show a rather wide distribution of scatter points. The 95% confidence limit of the 
right eye is wider than in study A, ranging from -5.58 to +6.62 mmHg. There is a posi-
tive systemic bias or average difference of +0.52 mmHg. This indicates that ICT-
measures were on average about 0.6 mmHg higher than GAT-measures. Values in the 
left eye give an even wider confidence limit between -6.54 and +7.84 mmHg and a 
positive systemic bias of +0.65 mmHg.  
For the right eye of study C, 7 of 105 (6.7%) outliers can be detected, four are above 
and three below the limits of agreement. For the left eye, the plot demonstrates 10 of 
105 (9.5%) outliers, seven above and three below the limits. So in both eyes, like in 
study A, the two methods show a positive systemic bias of 0.5-0.7 mmHg. This is less 
bias than in study A, but with a higher percentage of outliers.   
All have in common that the plots show a narrower scattering around the zero-point at 
lower IOP values. At higher pressure levels, distribution is wider and farther from zero. 
This indicates a larger difference between the two methods in higher pressure levels, 
suggesting that ICT is more inaccurate in measuring high IOP than in lower IOP ranges.  
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3.7 Summary of results  
The most important results and findings are summarised below. Prevalence of increased 
IOP is summarized in Table 9. It shows that study A found 11.5% of increased IOP 
levels within an allegedly healthy, non-glaucomatous population. Two and a half per-
cent were newly detected with glaucoma. Discounting these newly detected glaucoma-
tous individuals among the healthy sample, the prevalence of increased IOP was 9.5% 
for healthy, Malawian eyes.  
By screening with an ICT at the OPD of this hospital (study B), 13.8% were detected 
with raised IOP levels. Not all these could be further examined, but of those found with 
increased IOP who did get examined (study C), 2.4% were hence diagnosed with glau-
coma. 
Table 9: Prevalences of increased intraocular pressure (IOP) and glaucoma in current studies 
Study IOP >21 mmHg (%) New glaucoma diagnosis (%) 
Study A, “Healthy” sample, including 
glaucomatous cases 
11.5 2.5 
Sample A, excluding glaucomatous cases 9.5 - 
Study B, Intraocular pressure assessment  13.8 2.4 
The following Table 10 is a summary of results of studies A, B, and C regarding the 
prevalence of glaucoma and subtypes. The table shows the percentage of people newly 
diagnosed with any type of glaucoma during the study period and the percentage of 
glaucoma among all people with increased IOPs. It furthers gives a subdivision of the 
different glaucoma types that were detected.  
One finding is the difference of glaucoma detection comparing study A, B and C. In the 
non-patient sample (study A) and the OPD sample (study B) the rate of glaucoma detec-
tion was 2.5 and 2.4%, compared to the sample with increased IOP patients (study C), 
where the number of new (excluding known glaucoma) diagnoses was 25.5%. Similar-
ly, a focus on increased IOP levels in the samples of A and B led to detection of over 
17% glaucoma cases. The main glaucoma type in Malawi according to results of this 
study is POAG with 60 to 70%.  
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Table 10: Prevalence of glaucoma and subtypes in current studies 
Study 
Sample number  
(n) 
Newly 
diagnosed (%) 
Newly diagnosed 
among increased 
IOP (%) 
Glaucoma types 
(%) 
A (healthy sample) 
 
200 2.5 17.4 POAG 60.0 
PEX 20.0 
NTG 20.0 
B (IOP assessment) 1,112 2.4 17.5 - 
C (increased IOP) 
 
106 25.5 
 
 
 
- 
 
POAG 70.4 
PEX 11.1 
Secondary glaucoma 18.5 
NTG (excluded) 
Abbreviations 1: IOP, intraocular pressure; POAG, primary open-angle glaucoma; PEX, pseudoexfoliating glaucoma; 
NTG, normal tension glaucoma 
In general, mean and median CCTs in all samples were found to be low, indicating thin 
CCT findings among a Malawian population sample. An exception to low CCTs was 
the result of study B (sample with increased IOP). CCT findings and their implications 
form a major part of the discussion in chapter 4.4. POAG patients had high median age 
and IOPs, thin corneas, advanced CDR values, a high rate of cataract, and lower VA 
than their non-glaucomatous counterparts.  
Male patients, especially those above the age of 40 years and elderly patients in general 
presented with more advanced glaucoma stages than their female or younger counter-
parts. These findings need to be interpreted in the light of the age distribution where 
males also showed a higher median age. This was confirmed by the weak but significant 
correlation between age and glaucoma. Gender and the diagnosis of glaucoma were not 
correlated. Further, mainly weak associations were found. The exception was a strong 
correlation between ICT and GAT and moderate correlations between IOP (ICT or 
GAT) and CCT, as well as between CDR and age.  
A comparison between the two IOP measurement techniques ICT and GAT in Bland-
Altman-plots have shown an overestimation of approximately 1 mmHg of ICT against 
GAT-values in the healthy sample. In the sample with increased IOP values, ICT over-
estimation was 0.5 to 0.7 mmHg. Implications of this finding on possible ICT cut-off 
points are discussed in chapter 4.5.1. 
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4 Discussion 
The thesis has given an introduction to central topics of interest for this study, presented 
study designs, results and their statistical analysis. Following is a discussion of study 
results in perspective of prevailing opinions and data of the scientific world. A focus is 
put on studies from the African continent in order to have comparable samples and 
settings.    
Chapter 4.1 compares the generated baseline data of a Malawian healthy, non-
glaucomatous sample to values from other populations. Chapter 4.2 compares the preva-
lence of increased IOP levels and glaucoma in our studies to the prevalence in other 
countries. Chapter 4.3 describes glaucoma presentation patterns and is concerned with 
glaucomatous Malawian eyes, especially POAG characteristics, in comparison with 
findings in literature. The successive chapter 4.4 is dedicated to the discourse on CCT 
with related implications on IOP measurement outcomes, and the role as independent 
risk factor for development of glaucoma, as seen in the results of this and in comparable 
studies. 
One central question of the present thesis is the usefulness of a screening programme at 
LSFEH and other African or development country settings. Therefore, chapter 4.5 deals 
with this question in accordance with recommendations from literature.  
The last two chapters concentrate on the collected data in the context of Malawi, dis-
cussing the usefulness of an ICT screening for glaucoma. Firstly in chapter 4.6, all 
findings are discussed in the light of realities at LSFEH with a guideline proposal. 
Secondly, chapter 4.7 deals with the limitations of the study and data collection.  
4.1 Comparative study of results for non-glaucomatous eyes  
 
Table 4 in chapter 3.1.1 summarises main findings of “healthy”, non-glaucomatous 
Malawian eyes. These parameters serve as a baseline of ocular features in this popula-
tion. In Hohmann’s thesis conducted in the same eye hospital, the group of patients with 
IOP below 16 mmHg (group I) and the group between 16 to 23 mmHg (group II), may 
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correspond best with the non-glaucomatous, “healthy” sample of this thesis. Her total 
sample comprised patients at LSFEH including 18% glaucomatous and the remaining 
non-glaucomatous eyes. Mean ICT of group I was 13.7 and group II 19.1 mmHg. Group 
I had a mean CCT of 509.83 µm, group II mean CCT was 516.9 µm, and in total CCT 
average was 513.52 +/- 36.22 µm. (Hohmann 2011) In general, her findings correspond 
to the present results of this study with 509.2 µm as a mean CCT. Both studies from the 
same setting give a clear indication of very thin CCTs at this setting in comparison to 
data from other researches from Africa and other regions.  
Mohamed et al. conducted a comparable hospital-based cross-sectional study in Sudan. 
Their sample excluded POAG, corneal ectasia such as keratoconus, or any other corneal 
disease. They also excluded patients who had undergone any kind of surgery with cor-
neal incision, and patients with history of ocular trauma. Their sample can be referred to 
as “healthy”, non-glaucomatous and thus be compared to our findings. In the Sudanese 
setting, mean CCT was 530.2 µm. (Mohamed et al. 2009) The Barbados Eye Study 
mentions remarkably thin CCT values of 529.8 µm among Barbados black participants. 
(Nemesure et al. 2003) Table 11 gives an overview of literature cited in Mohamed et 
al.’s article, for comparison of values from different populations.  
Table 11 : Comparison of mean central corneal thickness (CCT) 
 in different populations (modified after Mohamed et al. 2009) 
Author Year Race Mean CCT (µm) 
Hoffmann et al. 2013 German 552.2  
La Rosa et al. 2001 African American 531.0-530.0 
Mohamed et al.  2009 Sudanese  530.2 
Nemesure et al.  2003 Barbados Black  
Mixed Black/White 
White 
529.8 
537.8 
545.2 
Wong et al.  2002 Chinese 555.1 
Hohmann 2011 Malawian 513.5 
Present study 2014 Malawian 509.2 
It is apparent throughout the literature, that black populations show lower CCT values 
in comparison to other populations. Yet, since measurement techniques, instruments, as 
well as examiners vary among studies, values are not entirely comparable. Nevertheless, 
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thin CCT is a risk factor for glaucoma development and therefore these findings can 
raise awareness about populations potentially at risk, as discussed in chapter 4.5.3. The 
comparison of CCT means from different populations shows highest values in Chinese 
and Germans, and thinnest in Sudanese. By far the lowest CCT findings are the ones 
found in the present thesis. Since the measurements were taken by using the ASOCT 
and Hohmann came to similar findings using SP-100 Handy Pachymeter, the results can 
be considered to be very valid. They are extreme findings which suggest further re-
search. Yet, referring back to the statement of Daughty and Zaman in chapter 1.2.6, 
CCT values between 503 to 565 µm could still be considered normal. (Doughty & 
Zaman 2000) Accordingly, Malawians would rank at the lower border of the normal 
CCT range. 
4.2 Prevalence and implications of increased IOP  
“Increased IOP”, as defined in chapter 2.2, were pressure values above 21 mmHg in at 
least one eye. In this case, findings were based on ICT measurements. As summarized 
in Table 9 of chapter 3.7, 11.5% of increased ICT values were recorded in the “healthy” 
sample (including ten glaucoma cases). Excluding those individuals results in a preva-
lence of 9.5% elevated IOP levels among a non-glaucomatous population sample. As 
there is no comparable literature about elevated IOP prevalence in the Malawian popu-
lation, data from other regions is used for discussion of the findings.  
A cross-sectional study among patients of a general practice, in a semi-rural district in 
South-Africa, assessed IOP using a Schiötz tonometer in 110 patients (87.3% white, 
10.9% black). Aim of this study by van Niekerk et al. was to investigate the prevalence 
of increased IOP (above 21 mmHg) in a general practice. Findings indicate whether 
tonometric measurements of IOP, as one diagnostic option for glaucoma, should be 
performed by the general practitioner during routine examination. Further, the study 
tried to detect associations between increased IOP and possible risk factors. They de-
tected increased IOP in 10% of the study sample (n=11 of 110). While among females 
in the general practice the prevalence of increased IOP levels was 7.3%, in men it was 
17.9%. (van Niekerk et al. 2006) The study does not give any information about the age 
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distribution in males in females, which might be an explanation for the different preva-
lence of increased IOP levels. 
A gender discrepancy towards the male can also be confirmed in the findings of stud-
ies A and B of the present thesis. In the non-glaucomatous sample (study A), increased 
IOP was present in 11.3% of “healthy” females compared to 11.7% of men. More obvi-
ously, during IOP assessment at the OPD (study B), 11.1% of females versus 17.6% of 
males had increased IOP levels. This was most likely due to the different age distribu-
tion between the genders with females being younger than males.  
Comparing van Niekerk et al.’s data to the present research, the result of approximately 
10% is in accordance with the present study data of the healthy sample. Therefore, a 
10% prevalence of increased IOP among apparently healthy populations in this African 
region is regarded as appropriate. Among ophthalmologic patients, slightly higher prev-
alence rates between 11 to 18% seem to be a realistic approximation. These percentages 
are based on the present findings. In study B, among OPD patients, the total prevalence 
of increased IOP was 13.8%, which is higher than in the unaffected sample of study A. 
These prevalence findings from Malawi may be used as a basis for further discussions 
or consecutive researches and may help in clinical planning. 
4.3 Glaucoma presentation patterns  
The previous chapters described ocular findings and characteristics of “healthy” Mala-
wians without a history of glaucoma to generate a baseline data set for this particular 
population. The subsequent chapters are concerned with glaucomatous Malawian eyes. 
Study findings will be compared with data from literature. 
4.3.1 Glaucoma prevalence and types  
Table 10 in chapter 3.7 combines the results of studies A, B, and C regarding the per-
centage of people newly diagnosed with any type of glaucoma and the different glau-
coma types detected. The prevalence of newly diagnosed glaucoma patients was 2.5% 
in study A, 2.4% at the OPD (study B) and 25.5% among those with increased pressure 
(study C). The mean age of those 27 new glaucoma patients was 53 years. Results of 
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present studies from Malawi indicate a glaucoma prevalence of 2.5% and POAG in 
1.5% in the healthy sample. This is one of major study findings, since it shows glauco-
ma prevalence among a healthy Malawian sample and may give an approximation 
towards glaucoma prevalence in the Malawian population.  
Yet as mentioned in the introduction on glaucoma prevalence, most prevalence data is 
given in respect to age. In Africa the number was 4.79% in people aged 40 to 80. In this 
study, the prevalence of glaucoma above 40 years was 4.6%, which is in accordance 
with abovementioned numbers. 
The main glaucoma type in Malawi according to study findings of this thesis is POAG 
with 60 to over 70%. This finding is in accordance with numbers from other African 
countries, visualized in Table 12.  
Table 12 : Prevalence of glaucoma subtypes in different studies 
Study Country Number Glaucoma types (%) 
(Budenz et al. 
2013) 
Ghana 5603 POAG 94.5 
Secondary glaucoma 3.0 
ACG 2.5 
(Giorgis et al. 
2012) glaucoma 
patients 
Ethiopia 602 POAG 37.7 
        PEX 26.6 
(Gyasi et al. 2010) 
glaucoma patients 
Ghana 446 POAG 77.8 
NTG 8.3 
POAG+NTG 1.1 
Secondary glaucoma 1.7 
Abbreviations 2: POAG, primary open-angle glaucoma; PEX, pseudoexfoliating glaucoma; NTG, normal tension 
glaucoma; ACG, angle-closure glaucoma 
As mentioned in the introductory section 1.2.1, prevalence of glaucoma varies among 
regions. Glaucoma, especially POAG, is found most prevalent in Africa, with 4.79% of 
glaucoma (range 2.63-8.03) and 4.2% of POAG. (Tham et al. 2014) Ghana’s glaucoma 
prevalence numbers seem to rank among the highest in the world. 8.5% of people 40 
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years and older were affected as reported by Gyasi et al. and 6% according to Budenz et 
al. (Gyasi et al. 2010) (Budenz et al. 2013) 
Kyari et al. claim the high prevalence numbers of glaucoma in Ghana to be an overesti-
mation, after comparing different prevalence studies in SSA with rather varying per-
centages. This variance results from different glaucoma definitions and diagnostic 
criteria used by different authors. (Kyari et al. 2013) The challenge of non-uniform 
definitions is further discussed in chapter 4.7. 
It has to be added to the discussion about increased glaucoma cases that ageing may 
primarily contribute to this upsurge. Yet, raised awareness through international cam-
paigns and discussions as well as research and publications, has triggered an intensified 
effort to detect more glaucoma cases. Thus, whenever a disease is particularly screened 
or looked for, its numbers automatically rise. This is due to a higher detection rate, 
including false positives.   
Regardless of the prevalence, glaucoma is the second most frequent cause of blindness 
in Malawi. (Kayange et al. 2014) (Kalua et al. 2011) Due to the deep impact on indivi-
dual and national levels, detection of affected people is of utter importance.  
4.3.2 Characteristics of eyes with POAG  
The following discourse puts the findings about POAG patients of this thesis in relation 
to literature data. Focus will be on IOP, CDR, blindness, and cataract among POAG-
affected individuals. CCT is separately dealt with in chapter 4.4. IOP, CDR and blind-
ness values in comparison are visualised in Table 13. 
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Table 13 : Charachteristics of glaucomatous eyes in literature comparison 
 
POAGs Present Study 
2014  
Kayange et al. 
2014 
Giorgis et al. 
2012 
Gyasi et al. 
2010
* 
Number 22 60 602 347 
IOP mmHg, ICT / GAT 
 
   
     Right eye, mean 29.0 / 29.3  28.5 (GAT) 39.4 (GAT) 
     Left eye, mean 31.4 / 31.3  30.6 (GAT) 39.7 (GAT) 
     Total mean (GAT) 30.3 35.5  39.5 
CDR mean 0.7    
% (n) >= 0.8, minimum one eye 45.5% (10) 78% (46) >61% 70% 
% (n) Bilaterally blind  4.5% (1) 15% (9)  34.1% 
Abbreviations 3: ICT, ICare tonometer; GAT, Goldmann Applanation tonometer; n = number;  
* While IOP data is given for POAG patients only, figures about blindness and CDR include the original study 
sample which also included NTG, secondary and mixed types and suspects with n =446. 
Kayange et al. in their study on 60 POAG patients at LSFEH in 2010, found a mean 
IOP (GAT) of 35.5 mmHg in comparison to a mean IOP (GAT) of 30.3 mmHg in the 
present study. Furthermore, the majority of patients in their research showed severely 
cupped optic discs with 77% (n=46) having a CDR of 0.8 or worse. This number is in 
contrast to 45.5% in POAG patients of the present study. 15% of POAG patients in 
Kayange et al.’s study suffered from bilateral blindness, which is three times more than 
the present results of 4.5%. The reason for this discrepancy may lie in the nature of their 
study. Chronic POAG patients were recruited, of which the majority presented a year 
after onset of visual symptoms, whereas in the present study there were several subjects 
who did not have visual problems upon time of detection and three healthy individuals. 
(Kayange et al. 2014) 
Giorgis et al.’s Ethiopian hospital-based prospective review of 602 open-angle glauco-
ma patients from 2009 presents very similar IOP results to POAG patients of the present 
study, but a higher incidence of advanced CDR stages, as shown in Table 13. (Giorgis 
et al. 2012)  
Gyasi et al.’s data originate from a review of clinical records of all first-time attendants 
newly diagnosed with any type of glaucoma (mostly POAG) at a hospital in Ghana 
between 2003 and 2005. Mean IOP (GAT) was higher than in the present study and 
Kayange et al.’s results from Malawi, and more patients presented with bilateral blind-
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ness (34.1%). Gyasi ascribes advanced glaucoma stages, including the high incidence of 
blindness from glaucoma firstly to the more aggressive nature of the pathology especial-
ly in black people. Secondly, he explains it with a late presentation to hospitals due to 
lack of awareness and education. And thirdly poor access to care as well as lack and 
inadequate distribution of ophthalmologists who are trained in trabeculectomies is 
mentioned as further reasons for advanced stages. (Gyasi et al. 2010)  
It is worth recalling the painless nature of glaucoma, resulting in unawareness of the 
disease. As pain is the “driving force in seeking medical help” (Lawan 2013) glaucoma 
is not likely to motivate people to see a doctor. This statement is also supported by other 
reviewed literature (e.g. (Lawan 2013) (Kyari et al. 2013)). Painlessness results in 
presenting at very advanced stages in Africa and other parts of the developing world, 
often with largely cupped optic discs, loss of vision in one or both eyes or both phe-
nomena combined. These features were partly also seen throughout the present study 
data.  
One last characteristic aspect of POAG patients is the presence of cataract. As explained 
in chapter 3 during presentation of results, incipient to medium cataract was present in 
a high number of patients of study C and of POAG patients. In study C, 28.3% had 
bilateral cataract, of which 40% were diagnosed with glaucoma, 23.3% were known 
glaucoma patients, and another 10% were new or known glaucoma suspect. Of all 
glaucoma cases 48% had bilateral cataract, and of POAG cases 45.5% presented with 
bilateral cataract. In respect to cataract, Kyari et al. make an important statement. They 
suggest that in areas with high numbers of cataract, glaucoma prevalence and blindness 
are underestimated. Cataract is an easily visible diagnosis, but often optic discs are 
obscured by cataract lenses. Consequently, a definitive diagnose of glaucoma cannot be 
given. (Kyari et al. 2013) In the studies of this thesis, cataract was always incipient, 
which enabled to make a definite diagnosis.  
As both diseases are associated with age, it is very likely that both occur together, which 
has implications on screening, as discussed in chapter 4.5.3. Correspondingly, mean age 
of all POAG patients with cataract (mean 63 years, median 65 years) was higher than 
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the POAG average (mean 52 years, median 54 years). The high coincidence of cataract 
and glaucoma is most likely due to ageing.  
4.3.3 Gender and age characteristics in glaucoma presentation 
In all three samples of the present research more women were registered (female/male 
percentages: study A 53% : 47%; study B 58.2% : 41.8%; study C 50.9% : 49.1%. 
Males had a higher median age and had higher glaucoma prevalence. Since the results 
in chapter 3.5 showed a weak but significant correlation between age and the diagnosis 
of glaucoma (r = 0.112, p = 0.000), it can be postulated that the higher age of the male 
study population can be partly an explanation for the higher incidence of glaucoma 
among men in these studies.  In study A and C, a moderate correlation also existed 
between age and CDR (study A: rho = 0.13, p = 0.067, study C: rho = 0.314, p = 0.001). 
In addition, no correlation was found between gender and glaucoma. Likewise, the 
Ethiopian study from the previous chapter also showed no statistically significant asso-
ciation between glaucoma stage and gender. (Giorgis et al. 2012)  
Male preponderance is found in a lot of African literature. For instance, in Kayange et 
al.’s hospital-based survey at LSFEH among newly diagnosed POAG patients, there 
were three quarters male (73.3%), resulting in a male-female-ratio of 2.75:1. He further 
sees this finding in accordance with other African literature from eye hospitals in Nige-
ria, Ghana, and Tanzania, where males made up 74%, 65%, and 72% of POAG patients. 
(Kayange et al 2014) (Lawan 2007) (Mafwiri et al. 2005) (Gyasi et al. 2010) 
Social factors may also be relevant in explaining the gender presentation patterns, as 
elderly females are more likely to stay at home, and are often financially dependent and 
worse off than men in terms of money. Also mobility, education, and thus the under-
standing of the importance to come for follow-up visits are lower in many women. 
Kayange et al. name socio-economic and cultural reasons as barriers for women, which 
result in lower health care attendance. A review of SSA-literature on glaucoma found no 
consistent association between gender and age. Nevertheless, five out of nine surveys 
showed higher male prevalence in POAG and also a higher likelihood for men to devel-
op secondary glaucoma, e.g. following trauma. (Kyari et al. 2013)  This imbalance 
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should be tackled by intervention programmes concerning glaucoma and most possibly 
any other health issue. (Kayange et al 2014) 
Regarding gender, a Ghanaian population-based study of adults of 40 years and older 
reports a higher number of males than females with glaucoma and POAG throughout all 
age groups, with a male-female-ratio of 1.5:1. They further cite a number of previous 
studies which all come to the conclusion of a higher prevalence of glaucoma in men 
than in women in Africa, Europe, and Asia with male-female ratios between 1.2 and 
1.8:1. (Budenz et al. 2013) 
Whereas in the present studies males presented with higher age and worse vision and 
higher prevalence of blindness (uni-, and bilateral), Courtright et al. present a con-
trasting gender-ratio regarding blindness in Malawi. In their examination, blindness 
was more common in women and the male-female ratio for bilateral blindness was 
1:1.94. (Courtright 2003) Further contrasting findings to results of this thesis are from a 
hospital-based study in Nigeria dealing with the economic burden of POAG for patients. 
Glaucoma was seen more often in females, although according to the authors of the 
study, there is no general gender predilection in POAG. (Adio & Onua 2012) 
Quigley and Broman in their data review on the prevalence of glaucoma worldwide, 
also come to contrary conclusions compared to the present study. They predicted in 
2006 that on a global scale, women will comprise 55% of POAG, 70% of ACG, and 
59% of all glaucoma in 2010, and thus women are disproportionately affected. The 
main explanation of the high female prevalence among ACG, especially in Asia, was 
their relatively longer life expectancy. They advise a focus on female gender in eye care 
services, because women were estimated to develop B/VI twice as often compared to 
men and therefore need special attention. (Quigley & Broman 2006) (Resnikoff, S. et al. 
2004) 
Conclusively, on the global scale, no clear indication can be given as to which gender is 
affected more by glaucoma. Also in the present studies from Malawi, no gender correla-
tion to glaucoma can be seen. 
There are diverging findings when comparing the age of POAG patients. The group 
younger than 40 years presents with less advanced ocular findings and glaucoma stages, 
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thicker CCTs, better vision and no cataract. IOP values did not differ much between 
ages above or below 40 years (see chapter 3 for details). In general, analysis of the 
findings gives clear indications of glaucoma being a disease closely associated with age, 
as more people in the age group of 40 and above were newly diagnosed with glaucoma. 
For instance, in study C, no person below the age of 40 was found with a known diag-
nosis. Therefore all were 40 years or older. Ntim-Amponsah et al. even found an expo-
nential trend line to correctly represent the prevalence of glaucoma with age in Ghana. 
(Ntim-Amponsah et al. 2004)  
Nevertheless, more than a quarter (27.3%) of all newly diagnosed with POAG through-
out our studies was younger than 40 years. In detail, these younger patients included 
9.1% (n=2) between 18 and 24 years, and 18.2% (n=4) between 25 and 39. These young 
individuals partly had very advanced glaucoma, e.g. the 21-year-old man, unilaterally 
blind and excavations of 1.0 and 0.9, or a 20 year old women with 0.7 and 0.8 cupping 
as well as a 27 year old woman with CDR of 0.6 and 0.7, who both attended the clinic 
because of itchy eyes, and all three became part of the study due to their ICT readings of 
minimum 28 mmHg. 
Tham et al. analysed the effect of age on POAG prevalence and found varying odds 
ratios (OR) across different regions. Despite the fact that POAG prevalence was highest 
in people of African ancestry at all ages, a steeper increase with age per decade was 
found in Hispanics and patients with European ancestry. (Tham et al. 2014) This find-
ing supports the suggestion that in Africa, glaucoma detection should focus on age, as 
by nature it is a disease of age. It could be useful, though, to also target younger ages, as 
among Africans it occurs more often in young people than in other populations. 
This finding is also underlined by Ntim-Amponsah et al.’s observations from Ghana, in 
which they stress that the onset of the disease is earlier and more aggressive in Africans 
than in Caucasians. The overall glaucoma prevalence in the population was 8.4% (8.2% 
in females, 8.6% in males). In the age group 30 to 64 years prevalence was 6.6% com-
pared to 16.4% above 65 years. This proves a high association of glaucoma with age. 
Nevertheless, it is noteworthy that a prevalence of 6 to 7% in the young age group of 30 
to 39 years is already high. (Ntim-Amponsah et al. 2005)  
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Not only is age a risk factor itself for the development of glaucoma, but also for blind-
ness from the disease. As an example in Kyari’s study, more elderly people were found 
blind, and the average age of blind glaucoma participants was 74.8 years in comparison 
to 65.4 years of the seeing participants. (Kyari et al. 2013) In the same line, a Ghanaian 
study reports that people of 60 years and older are twice as likely to present to the hos-
pital with advanced glaucoma stages, compared to younger ones. (Ntim-Amponsah et 
al. 2004) A finding, which is in accordance with our study results, having implications 
on screening programmes, as discussed in chapter 4.5. 
 
4.4 CCT, its influence on glaucoma development and diagnostics         
This chapter is dedicated to the discussion on CCT and its implications on glaucoma 
development and diagnostics, especially with applanation tonometry. The low CCT 
findings in the present studies and special role in the development and detection of 
glaucoma justify a separate chapter on this topic. 
4.4.1 CCT findings in comparison 
As already described in the introductory chapter 1.2.6, Hohmann detected one of the 
lowest CCT-measurements among people of African descent. (Hohmann 2011) Table 
14 gives an overview of findings from different studies for comparison.  
Table 14: Central corneal thickness (CCT) findings for glaucoma and non-glaucoma patients in comparison 
Author Year Non-/ Glaucoma Race Mean CCT(µm) 
Aghaian et al. 2004 75% Glaucoma US (all) 542.9 
   African Americans  521.0 
   Japanese 531.7 
   Chinese 555.6 
Hohmann  2011 Non-glaucoma German 561.95 
Hohmann  2011 18% Glaucoma Malawian 513.5 
Present study  2014 Glaucoma (POAG) Malawian 504.7 
Present study  2014 Non-glaucoma Malawian 509.2 
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In order to put CCT results of this study in a global context, Aghaian et al.’s retrospec-
tive study is taken for comparison. They evaluated CCT measurements by ultrasound 
pachymetry in Asian, Caucasian, Hispanic, and African American patients in a US 
glaucoma practice, including 600 glaucomatous and 201 non-glaucomatous eyes. There-
fore, values do not represent glaucomatous eyes only, but are a rough orientation as 
75% of the sample is from glaucoma patients. Mean CCT in the US glaucoma practice 
was 542.9 µm. African Americans presented with the thinnest CCT (521 µm), while all 
other groups were above, ranging between 531.7 (Japanese) and 555.6 µm (Chinese). In 
the subdivision into ethnic groups, the trend towards a comparatively thin CCT in Ma-
lawians, and most likely Africans in general, is obvious.  
Hohmann’s Malawian sample with 18% glaucomatous and the remaining non-
glaucomatous eyes presented with an average of 513.5 µm, minimum of 431 µm and 
maximum of 595 µm. She divided all patients into three groups according to their IOP. 
In group I of her sample with IOPs below 16 mmHg, mean CCT was 509.83 µm. This 
group may correspond most with the non-glaucomatous, “healthy” sample of this thesis. 
Hohmann’s German control group, mean CCT was markedly higher. (Hohmann 2011)  
In the present studies of this thesis, CCT values were found to be equally low or lower 
than Hohmann’s values. Due to the extreme findings, the numbers are outlined again in 
the following. As CCT data did not have normal distribution, medians are indicated, but 
for better comparison with literature data, means are also given. It was already ex-
plained in the presentation of results in chapter 3.4 that mean CCT of all POAGs was 
516.2 µm, including very extreme IOD values of over 40 mmHg and very oedematous 
CCTs. Therefore, the mean CCT value taken for comparison excluding these extremes 
(n=4), is indicated as 504.7 µm for POAG patients.  In the healthy sample mean was 
509.2 µm. Median for both eyes from POAG patients of 505 µm. In the healthy sample 
(study A), total median was 507.5 µm. CCT in the eyes of a healthy Malawian popula-
tion sample ranged from a minimum of 423 µm to maximum 613 µm, and in POAG 
patients from 439 to 632 µm. Therefore, while Hohmann already claimed to have found 
the thinnest CCT values ever measured on the African continent, the present data under-
scores hers and shows even lower CCT findings for Malawians.   
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4.4.2 Causes of thin CCT findings 
A first cause of thin corneal findings is the ethnic origin of patients. As already desig-
nated in the introduction on risk factors for glaucoma, (see chapter 1.2.6) Africans are 
known to have thinner corneas compared to people from other geographical descent, 
providing them with an innate potential risk factor. The abovementioned findings from 
present Malawian studies and from glaucoma patients of different ethnic origin in the 
US support this finding. The authors of the US study noticed that glaucoma suspects 
and glaucoma affected patients showed CCTs which were significantly thinner than in 
unaffected participants, especially in African Americans. (Aghaian et al. 2004) Also 
Nemesure et al. found thinnest corneas in black POAG patients from Barbados. 
(Nemesure et al. 2003)  
The German Gutenberg Health study of almost 5000 subjects found CCT to be age 
dependent, as from 35 to 44 years of age CCTs were thicker than in subjects from 45 to 
54 years. After 54 years, CCT was not decreasing further. (Hoffmann et al. 2013) Also 
Aghaian et al. found a relationship between thin corneas and increasing age. (Aghaian et 
al. 2004) Doughty and Zaman summarize in their literature review and meta-analysis 
that there was, indeed, a decrease of CCT with increasing age, especially after 60 years 
in non-caucasians (“non-whites”). In contrast, among Caucasians (“whites”) no appar-
ent influence of age on CCT was found. (Doughty & Zaman 2000) 
An age and pathology link with thin CCT values conforms to the present study data. 
The thinnest CCT values were found among POAG patients above 40 (median 493 
µm). The age-pathology and thin cornea link is obvious when comparing this data to 
healthy people below 40 (509.5 µm), and most strikingly compared to POAG patients 
below 40 years (530.5 µm). Very low median CCTs were found among all POAG 
patients (505 µm), as well as among healthy participants above 40 (502 µm). Contro-
versially in these findings, CCTs in healthy individuals below 40 years was thinner 
compared to glaucomatous, whereas thinner CCTs were expected not in healthy but in 
glaucoma patients. These findings may be explained by the presence of very high IOPs 
among glaucoma patients, which is discussed in chapter 4.4.3.  
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It is remarkable that within the same group, e.g. study A, people below and above 40 
years differ in CCT medians - 509.5 versus 502 µm – which is a 7.5 µm difference 
between age groups. In comparison, in POAG patients the difference is larger. Median 
CCT in the younger group is 530.5µm versus 493 µm, which gives 37.5µm difference. 
These findings give rise to the question if the age related decrease of corneal thickness 
is a risk factor for developing glaucoma rather than the low CCT itself. This could then 
be taken into consideration in monitoring patients.  
Thinnest corneas were documented among POAG patients above 40 (median 493 µm). 
Second thinnest corneas in the data were recorded in male POAG patients who included 
the majority of people above 40 (median 494.5 µm).  
It has to be mentioned that a decrease of corneal thickness is a physiological develop-
ment occurring with age and is not per se pathological. (Spoerl et al. 2009) Nonetheless, 
thin corneas stay an independent risk factor for glaucoma development, as described in 
chapter 1.2.6. Hence, thin CCTs and glaucoma occur especially at older ages, and “non-
white” populations seem to be especially prone to it. As this research found extremely 
thin corneas, this fact should be taken into consideration in discussions and management 
of glaucoma in this setting. The next chapter also deals with the topic of thin CCTs and 
the implication for disease development. 
4.4.3 Influence of thin CCT on the development of glaucoma 
The association of increased IOP with the development of glaucoma is widely known 
and accepted as the most important risk factor for the development of the disease. 
(Boehm 2011) High IOP can be paralleled to thin CCT as it is said that the chance to 
develop optic nerve damage is 36% in untreated patients with IOP of 26 mmHg or 
above, as well as with CCT values of 555 µm or below. In contrast, if IOP is below 24 
mmHg or CCT above 588 µm, the same risk is reduced to 2%. The OHTS – the first 
study finding this relationship between thin CCT and glaucoma progression - mentioned 
a threefold greater risk of developing glaucoma for eyes with CCT of 555 μm or less, 
compared to eyes with CCT of more than 588μm. (Gordon & Beiser, J. et al. 2002) Also 
in the European Glaucoma Prevention Study, low CCT values were found to be a pow-
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erful predictor for the development of POAG in patients with ocular hypertension (IOP 
22 to 29 mmHg). (Gordon et al. 2007)  
To refer back to the present study data, CCTs in all cases are far below the abovemen-
tioned 555 µm. IOP values in the POAG group surpassed the 26 mmHg in 77.3%. Thus, 
from both aspects (CCT and IOP values) the Malawian study population may have a 
high risk to develop optic nerve damage in the course of the disease, if not already 
present.  
In those cases in which nerve damage has already taken place, the link between thin 
CCT and glaucoma progression can be hypothesised. In study A, those with high CDR 
of 0.8 or above show very thin CCTs (median 507 µm). Yet, CDR and CCT were not 
correlated. 
In study C with IOPs above 21 mmHg, the group of CDR 0.8 or worse shows most 
remarkable CCT findings. The group is comprised of 50% newly diagnosed and 50% 
known glaucoma patients. Median for this group is 489.5 µm (mean 501.6 µm), which 
is the lowest of all study results, and is accompanied by 50% bilateral blindness in this 
group. There was a weak and significant negative correlation between age and CCT (rho 
= -0.282, p = 0.003), as well as CDR and CCT (rho = -0.223, p = 0.022). This negative 
correlation reflects the knowledge that a higher age and a large excavation are correlat-
ed with a thinner CCT. Ergo, thin CCT in line with high IOP can be confirmed as a risk 
factor for the development of glaucomatous damage to the optic nerve, with a high risk 
of blindness in the study population at LSFEH in Malawi. 
4.4.4 Influence of thin CCT on IOP measurements 
Many articles discuss the influence of CCT and further corneal parameters on IOP 
measurements. Especially since IOP control at certain individual target pressures is 
crucial for stopping the progress of the disease, accurate IOP determination is of utter 
importance. (Boehm 2011) (Neuburger 2011) (Rosentreter et al. 2011)  
It is a controversy if IOP readings represent true IOPs of individuals, as these are only 
accessible by intracameral measurements. (Boehm 2011) A question is if IOP is really 
higher in people with thicker CCTs or if IOP readings in people with thick or thin CCTs 
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are over- or underestimated, which could be explained by physiology and mechanics of 
ocular applanation used to measure IOPs. Already Goldmann himself described that 
measurement errors are likely to occur in thin or thick corneas, due to the dependency of 
applanation on corneal composition. (Goldmann & Schmidt 1957) Different authors 
describe that more power is needed to applanate a thicker surface than the force neces-
sary for a fine one. Thereby, on thick corneas, IOP is rather measured too high or over-
estimated, whereas in thin corneas, it is rather measured too low or underestimated. 
(Boehm 2011) (Doughty & Zaman 2000) (Hohmann 2011) (Neuburger et al. 2011)  
Hohmann warns that this phenomenon may lead to mistaking people with thick corneas 
as ill due to high IOP levels, but leave others with thin corneas untreated because of 
falsely low IOP readings. This can result in missed opportunities for early glaucoma 
detection. Ignoring those with thin corneas may be most fatal, due to the more aggres-
sive progress of glaucoma development and the higher risk of optic nerve damage, as 
illustrated above. (Hohmann 2011) 
In her Malawian study, she uses a correction formula for ICT and GAT values, as she 
found significant influence of CCT on these parameters, needing correction. (Hohmann 
2011) Many different corrective formulas exist, since GAT is designed for an average 
CCT of 520 µm and a lot of data does not correspond to this average. In the discussion 
of different nomograms, there is neither an agreement which is most adequate, nor if 
correction of measures is useful at all. In accordance with the current state of 
knowledge, a correction formula was not deemed appropriate or necessary and was 
therefore not considered in the presentation of results or the following discussion. Nev-
ertheless, a short discourse follows on how CCT and IOP readings may possibly interact 
and be corrected.  
A well-known table is Kohlhaas’s correction table for GAT. For every 25 µm deviation 
from 550 µm it corrects the measured IOP for 1 mmHg upwards (in thinner corneas) or 
downwards (in thicker corneas). Nevertheless, it is only valid for pachymetry-measured 
readings between 460 to 705 µm and was mainly designed from healthy eyes. Transfer-
ring them onto pathological eyes can be erroneous. (Neuburger et al. 2011) (Rosentreter 
et al. 2011) 
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Feltgen et al. found in a study, in which they actually compared applanation tonometer 
values with those of direct invasive intraocular measurements, that CCT had no relevant 
influence on applanation measurements. (Feltgen et al. 2001) Doughty and Zaman 
discuss that routine correction of tonometry results for CCT differences may not give 
clinicians more certainty in diagnosing or starting treatment of people with conspicuous 
findings. (Doughty & Zaman 2000) It is advised by Doughty and Zaman to use 
pachymetry on corneas of patient eyes with chronic disease, if IOP measurements show 
borderline or suspicious results. They claim, applanation tonometry is not significantly 
influenced by CCT of healthy eyes. (Doughty & Zaman 2000)  
A trend of positive correlation between IOP and CCT is seen in the present studies. 
Higher IOPs were recorded together with higher CCT values. The healthy sample (study 
A), with only 11.5% IOP readings above 21 mmHg, had thinner mean (509.2 µm) and 
median (507.5 µm) CCT values than the sample with 100% IOP readings above 21 
mmHg (study C), where mean CCT was 527.8 µm and median 527 µm. Thus, thicker 
CCT and higher IOP readings can be assumed to be related in this data, which is also 
explained in the following text. In terms of correlation, as mentioned in chapter 3.5, 
CCT and ICT/GAT were only moderately or weakly correlated (rho = 0.35, p = 
0.000/rho = 0.244, p = 0.000) in study A, but not correlated in study C. 
Mohamed et al. found a strong positive correlation between CCT and GAT IOP-
readings with p<0.001, and therefore recommends routine CCT assessment in every 
patient attending a glaucoma practice. (Mohamed et al. 2009) Correspondingly Vijaya 
et al. state, that a 100 µm increase in CCT in their study was found to be associated with 
an increase in IOP of 1.96 mmHg in the rural, as well as 2.45 mmHg in the urban popu-
lation. (Vijaya et al. 2010) Also Hoffmann et al., in a large German cohort study, found 
IOP to be positively correlated with CCT, when using non-contact tonometry, which 
was known and therefore expected to be positively correlated with CCT. (Hoffmann et 
al. 2013) Doughty and Zaman’s meta-analysis of CCT-IOP-associations exposed a 
statistically significant correlation between both parameters with a 10% difference in 
CCT resulting in 3.4+/-0.9 mmHg difference in IOP (p<=0.001, r=0.419). Furthermore, 
they revealed differences between healthy and chronically diseased eyes. The cited 10% 
difference in CCT was smaller for healthy eyes (1.1+/-0.6 mmHg, p=0.023, r=0.331), 
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but for eyes affected by chronic disease (POAG, ocular hypertension (OHT), NTG, 
diabetes, or lens exfoliation syndrome), IOP change for a 10% CCT difference was 
2.5+/-1.1 mmHg (p=0.005, r=0.45). (Doughty & Zaman 2000) 
According to Boehm, it would be most preferable to assess IOPs independent of CCT as 
far as possible, avoiding the need for CCT-correction formula altogether. (Boehm 2011) 
Also Ehrlich et al. suggest using cornea-independent IOP measurements. They used 
an Ocular Response Analyzer (ORA) which provides non-contact, CCT-independent 
IOP (corneal compensated IOP, IOPcc) in addition to the regular Goldmann-IOP 
(IOPg), and is able to measure corneal hysteresis (indicating tissue property by viscosi-
ty) and the total corneal resistance factor (CRF). (Boehm et al. 2011) Thereby they can 
compare IOPcc and IOPg for accuracy. In conclusion, for higher sensitivity, specificity, 
and for better identification of glaucomatous optic neuropathy (GON) they adjusted the 
GAT threshold to 20.9 mmHg and gave the abovementioned recommendation for CCT-
independent IOP measurements. They focused on NTG, which presented with lowest 
CCTs and was thus most likely to lead to erroneous GAT measurements. (Ehrlich et al. 
2012) Nonetheless, ORA measurements, especially for glaucoma patients, are under 
discussion. Since ORA cannot readily applanate the cornea in eyes with high pressure, 
values might be falsely low and must be interpreted with caution. (Neuburger et al. 
2011) 
In a setting such as LSFEH, a CCT-independent method, such as ORA, would be very 
gainful due to the present low CCT values. It is very unlikely to be realizable, though, 
mostly due to financial reasons. Whichever method is used to measure IOP, clinicians 
should take CCT as well as further corneal biomechanical properties which influence 
IOP measurements in consideration when managing glaucoma and ocular hypertensive 
patients. One option is to lower the target pressures of patients with thin CCTs, as also 
suggested for LSFEH in chapter 4.6. The reason for this was the likely underestimation 
of IOP in thin corneas. (Boehm 2011) (Hoffmann et al. 2013) Before proposing a guide-
line for glaucoma management at LSFEH in section 4.6, the next chapter will elaborate 
on glaucoma screening in the developing world. 
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4.5 Glaucoma screening in the developing world  
One of the main objectives of this thesis is to evaluate the present data and draw conclu-
sions regarding the relevance and design of a possible screening programme at LSFEH 
and comparable settings. The principal questions that will be answered throughout this 
chapter are which screening test(s) could be used (chapter 4.5.1), at which age and 
intervals screening should be implemented (chapter 4.5.2), and which target groups 
should be focused on (chapter 4.5.3). During the elaboration on possible screening tests, 
a focus will be placed on IOP assessment with ICT and possible IOP cut-offs. The final 
part of this chapter (4.5.4) points out the special role of non-ophthalmologists in the 
management of glaucoma. 
4.5.1 Screening tests  
In addition to the “Wilson criteria for screening” already outlined in the introductory 
chapter 1.2.7, a screening test in general, as well as for glaucoma, fulfils the following 
preconditions: (Mowatt et al. 2008) 
 Proven to be safe 
 Easy to handle, transport and understand 
 Quick and well-tolerated by subjects 
 Highly sensitive, specific and cost-effective  
In the international community there is no consensus about which screening tests are 
specific and sensitive enough to be acceptable, as neither a single one nor group of tests 
is yet convincing enough to screen for glaucoma. (Cook 2009) (Mowatt et al. 2008) 
(Lawan 2013) Many suggestions are made regarding screening strategies, of which the 
most relevant are described below.   
The first three abovementioned points can be approved for IOP screening by ICT 
measurements. Sensitivity and specificity are questionable. According to Hohmann, 
tonometry-based glaucoma-screening might be suitable for eye hospitals in developing 
countries, as it enables to detect and refer patients with highly elevated IOP levels, who 
possess a realistic risk of developing glaucoma. IOP assessment should be of major 
importance in an eye clinic in developing country settings. (Hohmann 2011) A major 
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challenge though, is the lack of ICT and GAT at eye departments and primary health 
centres, as well as sufficient staff trained to use them. As only few GATs are present in 
southern Malawi, which can be managed only by few staff members, many patients 
leave the eye clinic without receiving IOP-measurements.  
Lawan affirms that IOP seems to be the easiest parameter to assess glaucoma. Further-
more he approves of IOP screening, since IOP is the parameter in glaucoma which is 
most responsive to treatment and thus worth detecting. Yet, if GAT is chosen, equip-
ment and skills levels rise significantly compared to the mobile ICT. (Lawan 2013) 
On the contrary, there are very depreciative opinions about tonometry as glaucoma 
screening tool. Wang et al. declared the handheld tonometer, despite their advantage of 
being easy to handle even by non-eye specialists, not worth their expense, as they are of 
no use in the detection of ocular disorders. (Wang et al. 1998) The AAO concludes 
according to their literature review, that IOP assessment is an ineffective glaucoma 
screening test for populations, because on the one hand too many POAG patients fall 
below the threshold of 21 mmHg and still develop glaucomatous damage. On the other 
hand, too many referrals with increased IOP levels never progress on to glaucoma. 
(AAO 2010b)  
Results from the present studies can also not support the idea of IOP screening by ICT 
alone in a healthy population. By screening 200 healthy people (study A), only 2.5% in 
a basic population of apparently healthy individuals, and 2.4% at the OPD of LSFEH 
(study B) were eventually diagnosed with glaucoma after taking measurements from 
1,112 people. Accordingly, the sensitivity of only ICT readings above 21 mmHg regard-
ing the definitive glaucoma cases was 80% and specificity was 90%, with a PPV of only 
17% and a NPV of 99.4%. These results demonstrate that the ICT method might partly 
be successful in identifying true healthy individuals amongst an entity but not very 
precise in exposing true ill people. Yet, as mentioned before, the differing sample size 
of glaucoma and non-glaucoma must be kept in mind, but also the fact that glaucoma is 
in reality only present in a small percentage of people. The low PPV is a strong indica-
tor that an isolated ICT screening in the study population of Malawi. Thus by using only 
ICT, a very high number of people would need to be screened with only few detected 
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cases and would certainly miss out all those with NTG. A combination with another test 
might be useful, which will further on be elaborated.  
Consequently, a recommendation for a general population-based ICT screening in 
Malawi or for all patients at LSFEH cannot be proposed. It would be too money- and 
staff-consuming in a country which has to tackle many other fundamental and more life-
threatening challenges.   
Wang et al. manifested already in 1998 in their study at a primary care centre with 94% 
black participants aged 40 or older, that no single test can be identified which reliably 
detects glaucoma cases. They recommend a two-stage strategy. Stage one consists of a 
questionnaire (asking for age, history of eye disease, history of diabetes, self-reported 
visual acuity, and new ocular symptoms) to detect patients at high risk, who can then be 
referred to specialist for further examination. For asymptomatic adults, the recommen-
dation is a comprehensive eye examination every two years. The second stage is visual 
acuity testing and thorough fundus examination. Tonometry alone with IOP >21 mmHg 
in either eye had a sensitivity of 27% and specificity of 96%, detecting only 29% of 
glaucoma cases. Visual field testing had a sensitivity of 70% and specificity of 67%. 
The two-stage approach gave the best results. (Wang et al. 1998)  
Comparably, the German BVA and DOG recommend screening for glaucoma by first 
assessing the history of risk factors, to then do stereoscopic assessment of papilla and 
peripapillary nerve fibre layer, followed by slit lamp examination of the anterior or 
medial segments of the eye and GAT. (BVA & DOG 2006) 
Questionnaire, VA plus ophthalmoscopy combined together in Wang et al.’s study 
resulted in sensitivity levels of 83% and specificity of 76%. They come to the final 
conclusion that there is only one, if any, singular screening test able to filter out a good 
proportion of individuals affected by an eye disease with acceptable levels of specifici-
ty, namely ophthalmoscopy. It should be exerted by an experienced clinician on dilated 
pupils, to examine the optic disc and retina. They admit though, that an expert is not 
necessarily available at primary levels. Therefore, they suggest the alternative of digital 
fundus images, which could then be graded by trained personnel at a remote centre. 
(Wang et al. 1998) 
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Also Spry and Sparrow agree on the conclusion that no single test for glaucoma can 
convincingly discern affected from unaffected people. Rather a two- or three-test 
combination is needed. Most efficient is again a combination of optic nerve assessment 
plus visual field testing. Thirdly, IOP could be measured in order to help deciding to 
prioritise treatment among patients, due to an increased risk of people with high IOP 
levels to develop POAG. (Spry & Sparrow 2005) 
These suggestions of test combinations aim for optimum disease detection under opti-
mum conditions. In developing countries, as so often, ideals have to be set into the 
perspective of present conditions. First and foremost, the technical possibilities have to 
be judged realistically. For instance, in the present study, no perimetry was available. 
This is reality in many health care settings around the globe. (Bowman & Kirupanan-
than 2006) Expertise was given at LSFEH, but the density of trained ophthalmologic 
experts in the developing world is low, as mentioned in the introduction. Thus, idealistic 
screening suggestions are put into the light of developing countries.  
Besides being specific and sensitive enough, another aim of screening tests is to detect a 
disease in its early stage. Early detection of glaucoma, though, proves difficult in gen-
eral and especially in developing countries. (Friedman 2007) A realistic goal for the 
developing world would be to detect at least advanced glaucoma stages in patients who 
are most likely to otherwise go blind. (Rotchford 2005) Despite the risk to detect only 
advanced cases by screening in developing countries, positive side-effects may come 
along with any type of screening, which is the existence of the disease in general includ-
ing education of signs and symptoms. (Mansberger 2010)  
The ideal of early detection of glaucoma cases before the stage of optic nerve damage 
and symptoms of visual loss is worthwhile in the long run. For developing countries, it 
should realistically be altered to medium to late cases. Those are easier to detect, pa-
tients are more likely to present to clinics, and can still benefit from treatment. Further-
more, advanced technique and skills are desirable at any location, but a screening test in 
the developing world should first and foremost be simple and easy to administer. 
(Cook et al. 2009) (Hohmann 2011)  
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The fact of late presentation to the hospital can be used effectively in the detection of 
glaucoma, if more ophthalmological experts or health care workers are trained in fundus 
examination. At this specific setting, glaucoma patients were more likely to present with 
highly cupped discs than with visual symptoms. (Kayange et al. 2014)  
Also in the findings of this thesis, many newly detected glaucoma cases did not show or 
complain of any visual symptoms, but had severely cupped optic discs. Thus, cupped 
discs should be the primary target of eye examinations. This was done in a study report-
ed from Nigeria. An expert team screened for glaucoma suspects by first assessing 
CDRs of healthy subjects. IOP measures were only taken of those with suspiciously 
cupped discs or asymmetry between both eyes. Surprisingly, 97.8% of glaucoma sus-
pects (according to their definition of suspects) had normal IOP values. (Pedro-Egbe & 
Waziri-Erameh 2010)  
This leads to the conclusion, that ICT measurements of IOP miss out on many NTG 
cases or cases with normal IOPs at the time of examination plus giving many false 
positives and negatives. But the ICT technique fulfils the precondition of an easy and 
simple test, which is well tolerated by patients. On the other hand, fundus examination 
by an expert team is more likely to detect both NTG and POAG with increased IOP 
levels, as their main focus is optic disc damage, the strongest and safest sign for the 
presence of glaucoma. Slit-lamp funduscopy requires immobile and more expensive 
equipment, more expertise and time. These are unfavourable preconditions for a test to 
be applicable as screening tool in developing countries. Yet, a combination of ICT and 
funduscopy might be most useful in this setting.  
Giving out questionnaires to filter people at high risk appears to be a simple way to do 
efficient referrals at first thought. Yet, in settings in which many people have never 
attended school, many are unaware of the type and concept of diseases which might run 
in their families or affect themselves, such as diabetes or glaucoma. Also reading or 
computer work, which require sharp sight, are not as frequently used as in the western-
ized world. Therefore, lower vision might not disturb the individual as early as else-
where. In such settings, even a five item questionnaire, as suggested by Wang et al. can 
present a big challenge. (Wang et al. 1998) 
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Visual acuity testing is another simple tool which shall be discussed. VA alone is not 
considered a glaucoma screening test. But, according to Bowman, it could be the most 
practical test for the African setting, where advanced stages of glaucoma occur and are 
thus likely to affect VA. He suggests that all patients with visual acuities below 6/18 
could be referred for thorough examination, if spectacles can be provided for refractive 
errors, and high-quality cataract surgery for immature cataracts. Thereby, some glauco-
ma patients may be picked up earlier than is presently the case. (Bowman & Kirupanan-
than 2006) Two preconditions (spectacles and cataract surgery) are assumed here which 
are not readily accessible in all settings. Nevertheless, visual E charts (as used in the 
present studies) or charts with symbols for illiterate patients are a rather simple, porta-
ble, and inexpensive tool for first orientation. 
In the studies of this thesis an ICT cut-off of 21 mmHg was used as a definition of 
elevated IOP (normal range 11-21 mmHg). This cut-off is seen in most literature. Nev-
ertheless, it is worth discussing which, if any, cut-off value should be used to screen 
most effectively for glaucoma. The following section briefly discusses possible IOP cut-
off points. The AAO calls the value of 21 mmHg an “arbitrarily defined level”, because 
different studies give very inconsistent proportions of people with increased levels 
(range 13-71%). This “highlights the poor value of utilizing a specific IOP cut-off as a 
measure for screening and diagnosing POAG.” (AAO 2010b)  
The results of the Bland-Altman analyses in section 3.6 and comparable literature 
showed that there was on average a 1 mmHg overestimation of GAT by ICT. This 
finding was taken as a basis for discussing a suitable cut-off point in this thesis, as 
explained in the following lines. Taken this 1 mmHg overestimation by ICT as given 
hypothesis, the study data was re-evaluated. It was looked at how many people were 
falsely indicated as elevated IOP above 21 mmHg, by changing the cut-off to 22 mmHg 
in ICT values. This implies that values of 21 mmHg in ICT actually present 20 mmHg 
in GAT. Therefore 22 mmHg would represent true 21 mmHg values, given a 1 mmHg 
overestimation of ICT against GAT.  
In study A with a cut-off of 22 mmHg in ICT, 10% (n=20) instead of 11.5% (n=23) 
would have had increased IOP levels. Still all four individuals newly detected with 
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glaucoma (except NTG) would have equally been detected, as their ICT levels were 
above 21 and also above 22 mmHg. In study C, eleven out of all 106 people with levels 
over 21 mmHg in one eye would have been missed with 22 mmHg ICT cut-off. All 
except one patient (96.3%, n=26) of all 27 who were newly diagnosed with glaucoma 
would have been detected. This one missed case, despite his values of ICT 21/22 mmHg 
being on the lower edge of increased pressure, presented with rather advanced deep 
cupping and CDR of 0.8 and 0.7. In the broad IOP assessment study with 1,112 individ-
uals, 12.8% instead of 13.8% would have been declared with raised IOP.  
This result indicates that a cut-off rise of 1 mmHg for ICT would result in approximate-
ly 1% lower prevalence of raised IOP levels in this population, whereas about 1 in 30 
(3.3%) glaucoma cases would have been missed. Most glaucoma cases, though, pre-
sented with IOP levels clearly exceeding 21 and 22 mmHg and would thus be detected 
with either cut-off point. Raising ICT cut-off to 22 mmHg at this setting therefore seems 
inefficient. Only a few at the lower margin to NTG would have been missed. Consider-
ing that CCT values in the respective population were found to be exceedingly low, this 
may result in underestimation of IOP values with wrongly low IOP values. Consequent-
ly, 21 mmHg as cut-off for ICT measurements at this setting seems appropriate. 
Another approach to IOP cut-offs was mentioned in chapter 1.2.4, for which the 99.5
th
 
percentile of the normal population, e.g. for Malawi, could be evaluated. It enables 
practitioners to have a clearer orientation. From the dataset of study A by excluding all 
patients with glaucomatous findings, the 99.5
th
 percentile of the mean ICT measure-
ments of IOP would be 27 mmHg. Taking this cut-off in study A, for example, two out 
of five would have been missed, instead of one of five, which was a NTG. It could be 
reasoned to refer only those patients with IOP levels clearly exceeding 21 mmHg, e.g. 
over 27 mmHg in the case of this study. Ntim-Amponsah et al. came to the conclusion 
that in their Ghanaian sample, people with IOPs above 31 mmHg had a threefold higher 
risk to rapidly progress on to optic nerve damage compared to those with values below 
32 mmHg. (Ntim-Amponsah et al. 2005) Such high cut-off (31 mmHg) certainly de-
creases the number of false positive referrals and increases the number of those in need 
of urgent treatment. At the same time it reduces the chance to detect cases in which 
treatment is not yet too late. It could be considered more an emergency detection instead 
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of screening for preventable, late-stage disease. It might be interesting to conduct a 
study with higher cut-offs. 
After this discourse on possible screening tests in developing countries, age, intervals 
and target groups are specified in the following chapter.  
4.5.2 Screening age and interval 
Presumed as done in the introduction, that screening for the blinding disease glaucoma 
is useful and needed, it is crucial to discuss the age and intervals of the screening pro-
cess. Researchers call for more studies regarding the best age at which to start 
screening, especially in individuals with a positive family history of glaucoma. (Ntim-
Amponsah et al. 2004) 
The German guidelines by BVA and DOG recommend screening with abovementioned 
examinations starting at the age of 40. Intervals should be every three years until the age 
of 64, and every one to two years after 65 years of age. If other risk factors apart from 
increasing age are present, intervals should be shortened. In case of glaucoma suspects 
or OHT patients under treatment, they recommend tonometry check-ups every third 
month. (BVA & DOG 2006) Another example of possible screening age in a high risk 
population is from the US. In 2002, the US Centers for Medicare and Medicaid Services 
initiated coverage for glaucoma examinations for African Americans 50 or older by eye 
care professionals. (AAO 2010b) 
Especially in Africa the combination of two facts leads to specific conclusions regarding 
screening programmes. Firstly, glaucoma is more aggressive, it may occur faster and at 
an earlier age in Africans, as already mentioned in chapter 1.2.6. Secondly, glaucoma in 
general is a disease progressing with age. (Ntim-Amponsah et al. 2004) This leads to 
the conclusion that young AND old people should be considered in screening 
programmes among African populations. One possibility in the African setting is case-
detection in hospitals and eye-camps in which every patient from 35 years onwards 
would receive an IOP measurement. (Hohmann 2011) Rotchford recommends for SSA 
to concentrate on advanced glaucoma stages, and thus do tonometry and disc 
assessment of every adult over the age of 40 who presents to an ophthalmologist. He 
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adds that in certain African populations, the age limit might have to be even lower, 
which is in accordance with abovementioned conclusion, but difficult to implement in 
the setting of low-income countries. (Rotchford 2005)  
In the South-African study evaluating the prevalence of increased IOP and the useful-
ness of tonometry screening in a general practice, authors come to the conclusion that 
routine tonometry should be performed by every general practitioner. Their minimum 
request is once on every patient above 45 years. Ideally, tonometry should be repeated 
after 10 years. In cases of family history of glaucoma, tonometry checks should be done 
annually. Shorter screening intervals are recommended in diabetic or vascular pathology 
affected patients, who have an inert high risk of developing increased IOP and/or glau-
coma. (van Niekerk et al. 2006) This idea stems from a comparably richer African 
country, but cannot be regarded as implementable in poorer countries due to lack of 
resources.  
The findings of the present thesis could support screening at a younger age. Firstly, 
18.2% of all POAG patients were between 25 and 39 years, and 9.1% between 18 and 
24 years, resulting in 27.3% below 40 years. Among those were very young patients 
with rather advanced stages, as described in chapter 4.3.3, e.g. 20, 21, and 27 year olds 
who partly presented with unilateral blindness and large excavations. Nevertheless, the 
great majority (45.5%) was 60 years or older. If screening started at the age of 40, 
younger patients would have clearly been missed. Even screening after 25 years of age 
would have missed very young cases. One interpretation of these findings is that in the 
Malawian setting, and most likely in health centers in other developing countries, 
screening for glaucoma should ideally start early, at the age of 20 or 25 years at latest. 
Realistically though, it might not be realizable due to lack of resources. 
A suggestion which corresponds well to the present findings of this thesis is made by 
Essuman and Ntim-Amponsah. In their hospital-based study from Ghana they 
determined the age, timing, and associated factors for glaucoma evaluation as part of 
medical eye examination in an ophthalmology clinic. They criticise that glaucoma 
screenings often focus on those over 40 years of age, even though it is known that in 
Africans the disease occurs earlier. Further they find fault with the lack of evidence as 
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to when to start screening in African populations. They found an upsurge of glaucoma 
prevalence after the age of 24, which led them to the conclusion that 25 years can be an 
appropriate age to start glaucoma assessment. Their recommendations are visualized in 
Table 15. (Essuman & Ntim-Amponsah 2012)  
Table 15: Screening recommendation for glaucoma in African patients  
attending eye hospital (own illustration modified after (Essuman & Ntim-Amponsah 2012)) 
Age and risk factor Interval 
25-30 
20 and above with eye complaints 
Every 2 years 
31 and above 
Any age with positive family history 
Yearly  
Screening is recommended every two years in people above 25 years. In case of eye 
complaints, screening should start at 20 years. At the age of 31 and above, screening 
intervals should be shortened and therefore yearly screening intervals are suggested, 
and at any age in people with positive family history for glaucoma. In conclusion their 
glaucoma screening guidelines, with routine measurement of IOP and evaluation of the 
optic disc biomicroscopically in the setting of eye hospitals, seems close to ideal but 
highly out of reach in most settings of the developing world. 
In theory, the suggestions could be regarded as transferable to the context of LSFEH, 
Malawi. In reality, less ambitious goals will be more practicable in the actual setting, 
which is dealing with shortness of money, staff and equipment. Screening intervals and 
repeated visits of one and the same individual are highly impracticle and unlikely to be 
successful in financially restricted contexts. Therefore, a modified proposal is 
summarized in chapter 4.6. 
4.5.3 Target groups 
Lawan speaks of a “need” to find definitions on whom to screen, as there is no justifica-
tion to screen the population on a large scale. (Lawan 2013) Rather, target groups 
should be determined to render screening more (cost-) effective. (AAO 2010b)  
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AAO lists “African Americans and Hispanics” as possible target groups. (AAO 2010b) 
Consequently, Africans as such can be considered a target group. As this is not (yet) 
practicable on everybody in an all-African environment, further target groups need to be 
established for Africa. Focusing on late stage disease has already been discussed in 
chapter 4.5.1 as one possibility to channel the process. Further suggestions for target 
groups are:  
 Family history of glaucoma (Wolfs et al. 1998) (AAO 2010b) (Flammer 2001)  
 First degree relatives (Lawan 2013) 
 Older adults (AAO 2010b) 
One target group are people with a positive glaucoma family history. As previously 
mentioned, retrieving information about patient’s family history of certain diseases is 
not an easy task to do, neither in the western nor in any other part of the world. Never-
theless, cultural differences have to be taken into consideration when trying to access 
this data. Patients may not know their own or family’s history of disease, they may not 
be educated about diseases or the modern concept of medicine. It might not be appro-
priate in a certain society to admit and talk about one’s own or family members’ diseas-
es. It further might not be part of family discourse at all, due to stigmatisation or other 
disadvantages to the affected individual. Or traditional beliefs and explanations for an 
individual’s illness might be a patient’s underlying belief, which might not willingly be 
shared with a modern clinician. This “general culture of keeping diseases as personal” 
also between family members and abovementioned reasons, are all possible explana-
tions why low numbers of positive family histories could sometimes be recorded. (Es-
suman & Ntim-Amponsah 2012) This makes positive family history a challenging 
aspect. 
A second difficulty after finding out about patients’ family history is to successfully 
invite family members for (regular) check-ups. Even when contacted through the affect-
ed person and offered free examination, relatives in a rural setting in Tanzania were 
unlikely to report for examination. Those living further away did not present for exam at 
all, and only 10% of those from the same district came for examination, showing that 
costs for transport can be a main burden. The allocation of costs to the high-risk group 
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of family members of glaucoma patients does not seem feasible and free transport and 
examination has to be guaranteed, at best by the state through the clinic. Otherwise, the 
appeal to come for a medical check-up in a poor society is most likely going to fade 
away without consequences. (Munachonga et al. 2007) (Friedman 2007) 
Wolfs et al. advice that glaucoma screenings among relatives of glaucoma patients 
should first and foremost assess CDR, as this was the earliest and most prominent pa-
rameter to detect glaucoma. The lifetime risk to develop glaucoma was 22% in relatives. 
This was ten times higher than in the control group. Their data suggested that one sixth 
of all glaucoma could be due to genetic inheritance. (Wolfs et al. 1998) 
Regarding the target groups suggestion of family history and first degree relatives of 
glaucoma patients, no suggestion can be deduced from the data of this thesis, because 
no applicable results were collected. Even though the question of family history of eye 
disease or vision loss was posed, most people were unable or unwilling to give clear 
information. Research on this topic is currently done at LSFEH and will be worthwhile.  
A supplement on the topic on inheritance is the current trend towards genetic screening. 
Studies from Africa, which analysed e.g. mutations in myocilin, optineurin, or mito-
chondrial DNA, have so far not been convincing. In economically weak areas, it is 
further not a realistic and practicable concept. (Lawan 2013) 
As far as the target group of older aged people is concerned, recommendations have 
already been proposed in chapter 4.5.2. One aspect which is connected to age and 
glaucoma is cataract. In our study 45.5% of POAG patients had bilateral cataract. To 
avoid the risk of missing glaucoma patients due to cataracts every patient diagnosed 
with a cataract should also get an IOP check and a fundus assessment. Therefore, a 
modified version of Table 15 on glaucoma screening recommendations for the context 
of LSFEH is illustrated in Table 16, considering this aspect. One major aspect, though, 
is the fact that a general screening of the population is unrealistic, but a screening of 
those already presenting to the eye clinic due to ocular problems could as well be 
checked for these two diseases. 
A joint screening for both diseases has also been promoted by Cook. He suggests 
screening for cataract and glaucoma together in primary care clinics by visual acuity 
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testing and at secondary level by using a test combination of optic disc and pupil as-
sessment. (Cook 2009) Therefore, one suggestion is to include glaucoma screening in 
general screenings for eye diseases among the elderly. (AAO 2010a) Already Wang et 
al. in 1998 criticised to concentrate on a single disease during screening instead of 
several at once. Screening for several age-related diseases at once, including glaucoma, 
can be of benefit to the individual and to the clinician as it is efficient and time-saving. 
The inevitable precondition would be a test able to detect several diseases at once. 
(Wang et al. 1998) To this date, though, there is no single test, which could meet this 
demand. Only clinicians themselves can achieve this with their visual diagnostic skills.  
One additional factor in screening programmes is gender. In the setting of the present 
thesis, gender imbalance was observed and explained by cultural as well as socio-
economic barriers for women in Malawi. According to Kayange et al., this imbalance 
should be tackled by health intervention programmes, also for glaucoma. (Kayange et 
al. 2014)  
The data collection at the OPD of LSFEH for this thesis showed contrasting figures. 
58% females against 42% males attended the OPD. Women at the OPD were mostly 
below age 60 (84%), of which 58% were between 18 and 39, and only a minority was 
older than 60. Contrarily, 55% of POAG patients were male. Thus, despite a female 
majority at the OPD, POAG was more common among male attendants. Therefore, the 
recommendation given in chapter 4.6 is to address both genders equally during glauco-
ma screening.  
4.5.4 Training (non-)ophthalmologists 
Mermoud, president and founder of the charity “Vision For All” calls for more training 
of eye doctors. (Kingman 2004) Education and awareness is required among ophthal-
mologists as well as clinical officers (specialist nurses) and non-ophthalmologists at all 
levels. At primary and secondary health care centres, personnel, especially in Africa, 
could be trained to detect and refer patients suspicious for glaucoma. As late stages are 
easier to diagnose, non-ophthalmologists can be equipped with skills needed to diag-
nose these stages. Tonometry and optic-disc assessment can be taught and if used rou-
tinely, with clear and easy criteria for referral, higher detection rates of glaucoma can be 
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achieved. (Kayange et al. 2014) (Rotchford 2005) For comparison, in the UK 99% of 
referrals to eye hospitals of glaucoma suspects are initiated by optometrists at primary 
health level. (Spry & Sparrow 2005)  
Cook gives precise suggestions for glaucoma detection in rural Africa. At primary level, 
employees (clinic nurses, community health workers, traditional healers, etc.) should 
screen everyone 40 years or older at least once every two years. In case of reduced VA 
in one or both eyes, plus black pupil (in the sense of non-present cataracts), patients 
shall be referred to secondary level. At secondary level, ophthalmic nurses and oph-
thalmic medical assistants should perform tonometry and funduscopy with CDR as-
sessment on everyone 40 years and older at least once every two years. All glaucoma 
suspects or cases should be seen at tertiary level by ophthalmologists for diagnostic 
confirmation and treatment. (Cook 2001) These ambitious propositions must neverthe-
less be seen in the light of limited resources in rural Africa and the fact that many other 
including life-threatening diseases are often not covered by health programmes.  
Furthermore, if ophthalmologists and any other health worker were sensible to the 
possible joint appearance of the age-related diseases glaucoma and cataract, it could 
lead to higher detection rates of glaucoma. Patients are urged to seek medical help as 
cataract is the “pain”, to recite Lawan’s words, in the sense of blurred or reduced vision 
or photosensitivity. (Lawan 2013) If trained staff jointly looks for cataract and glauco-
ma, every visit to a health centre may lead to the detection of asymptomatic glaucoma.  
Raising the awareness among eye care providers for glaucoma and its detection during 
comprehensive eye exams, especially in high-risk populations, is thus an important step 
towards more effective case detection. In the same manner, education of the general 
population about glaucoma and the meaning of regular check-ups may contribute to 
earlier detection. (Maul & Jampel 2010) 
Another aspect, which respects doing research in a different culture, is the role of tradi-
tional healers. On local levels, they treat many common (eye) diseases and are likely to 
be frequented first by affected individuals. Especially in rural areas, they are regularly 
consulted. It is also for practical reasons, because there are traditional healers in almost 
every village (one healer per 350 people), but only a few health care workers (one 
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health staff member per 2030 people). (Courtright et al. 1994) Even though these fig-
ures are out-dated, the principles are valid in todays, especially rural Malawi. 
In Kayange et al.’s study, 25% of patients admitted the use of traditional medicine 
before attending the eye clinic. This number is estimated to be higher in reality, as 
traditional medicine is possibly denied in the hospital setting. It may be benefitting to all 
parties involved, if there was more communication and collaboration between tradition-
al healers and clinicians. (Kayange et al. 2014) Examples from other health projects 
showed that training and working together with healers generated positive changes in 
attitudes and behaviour among traditional healers and health care employees. An option 
would be to train healers in recognizing emergency cases which should be referred to 
the hospital, and motivate them to use safe, non-harmful traditional practices. For in-
stance support face washes and steam baths, but not the application of plants directly 
into the eye, which are the three common traditional treatments for eye complaints. 
(Courtright et al. 1994) Experiencing interest from (non-) governmental health agencies 
and by positive feedbacks from referred patients, healers are reported to feel more ap-
preciated. (Courtright 1995) 
Suggestions for more effective screening and glaucoma detection were made at all 
levels, from traditional medicine to primary ophthalmic centres, taking into account the 
results of this study as well as opinions and recommendations from other authors. Tar-
get groups, appropriate ages, and screening intervals have been elaborated on. It is 
apparent that international and state money, the effort of health workers and specialists 
and further research are needed for more successful glaucoma detection, and the preven-
tion of blindness.  
4.6 Conclusions for glaucoma screening and detection at LSFEH  
After looking at screening recommendations for developing countries in literature, it 
became evident that glaucoma as such is a disease which is hard but important to screen 
for. Yet, no convincing concepts exist. Taking the right combination of screening tests 
and target groups is important, even more so in the context of Africa. Therefore, chanc-
es and challenges in the clinical practice of the Malawian tertiary eye center LSFEH are 
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specified, recapitulating conclusions of the prior discussion. It has to be stressed, that 
the following recommendations only apply to the setting of a tertiary health institution 
and are not intended for primary or other basic health settings. Eventually, recommen-
dations for better glaucoma detection at LSFEH is established and illustrated in Table 
16 below. 
4.6.1 Guideline proposal for glaucoma screening at LSFEH 
As mentioned in chapter 4.5.1 no recommendation for a general population-based ICT 
screening in Malawi or for all patients at LSFEH can be concluded. Yet, LSFEH is a 
tertiary eye hospital with a highly motivated staff and glaucoma detection is an im-
portant aim. Therefore, recommendations shall be made for better and more effective 
glaucoma screening in the form of a guideline proposal for the practice at LSFEH ac-
cording to the data of this thesis. They are conclusively summarized in Table 16. 
Table 16: Guideline proposal for glaucoma detection at LSFEH 
Age and risk factor Examination Interval*  
 
40 and above 
- if presenting with impaired 
vision at the OPD 
- if cataract present 
 
 
ICT + Funduscopy 
Focused Cataract & 
Glaucoma check-up 
 
Every three 
years**  
* at least one measurement at first visit, interval is recommended if possible 
** if IOP >21mmHg or suspicious fundus   
 
Accordingly, at the OPD of LSFEH, every patient with 40 years and above, presenting 
at the OPD with impaired vision should receive ICT measurements and funduscopy. To 
avoid the risk of missing glaucoma patients due to a fast cataract diagnosis, every pa-
tient with cataract should also get an IOP-check and a fundus assessment. 
Combining ICT and funduscopy can possibly rule out missing NTG, which was one of 
the shortcomings of the present study and avoiding the low sensitivity and specificity of 
ICT alone. During examinations, signs of glaucoma and cataract should be jointly 
looked for.  
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21 mmHg as cut-off point is considered an appropriate ICT value for practice, so pa-
tients above 21 mmHg in three consecutive measures should be considered suspicious. 
It has to be noted though, that very high IOP values could be inaccurate, and should be 
double-checked with GAT.  
In case of suspicious IOP or fundus findings, they should be checked regularly with ICT 
and funduscopy in intervals of two or three years, as indicated above. It is obvious that 
at this setting, the suggestion of intervals is not totally realistic and might not be fol-
lowed by many individuals. Therefore it needs to be stressed again, that abovemen-
tioned target groups should at least get one ICT measurement and funduscopy done at 
their first visit to the OPD.  
It was mentioned in chapter 4.5.2, that especially in Africa, due to the combination of 
the fact that glaucoma is an age-related disease and the special dynamic of glaucoma 
development in African populations, detection should focus on old people. After 40 
years of age, Malawians appear to have an increased risk of glaucoma development, as 
the thinnest CCTs, one potential glaucoma risk factor, were recorded in this age group. 
Further, because in most glaucoma patients, IOP starts rising between 40 and 50 years, 
treatment needs to be initiated at this stage to prevent further damage. (Flammer 2001) 
(Kingman 2004) Also, the detection rate was 4% in the group above 40 years, in com-
parison to 2.5% in the total sample. For all these reasons and realistic purposes, even 
though it would be ideal to also check young patients at the OPD of LSFEH, the cut-off 
point was set at 40 years. 
Special alertness is further recommended when being confronted with elderly patients, 
since every opportunity to examine them should be seized to screen for cataract AND 
glaucoma, especially if patients present with visual complaints. This combination 
should become an automated routine at LSFEH during eye examinations of patients 
above the age of 40.  
Thin CCT in line with high IOP were found as risk factors for the development of 
glaucomatous damage to the optic nerve, with a high risk of blindness in the study 
population at LSFEH. CCT at LSFEH has been found in the conducted study to be 
extremely thin. Yet, it cannot be recommended to do CCT assessment on every patient, 
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as it is very time-consuming and unfeasible. Rather, ophthalmic staff has to be aware of 
this low CCT average, especially among glaucoma patients, because IOP values might 
be underestimated, and thin CCT puts those patients at special risk of developing optical 
nerve damage. It was recommended to measure CCT before setting individual target 
pressures for therapy, as it might have to be targeted lower in case of very thin CCT 
findings. (Boehm 2011) (Hoffmann et al. 2013) Thus, general awareness about thin 
CCTs should to be spread among all ophthalmic staff members at LSFEH to correctly 
interpret their examination results. It would be ideal and advisable to take CCT meas-
urements once before or during treatment of glaucoma patients for appropriate target 
pressure definition. Its practicability needs to be proven. 
In general, increased IOP levels and POAG was slightly more common among males, 
and therefore men above 40 should be looked at carefully. Women were presenting less 
often to the OPD above the age of 60 and more often between the age of 25 to 59 
(66.4%). If women rarely attend the clinic at older ages, they should be examined close-
ly at any time they appear. This fact can be used effectively at the OPD, as this bears the 
chance to find women with earlier glaucoma stages, if examined carefully by well-
trained and sensitised staff. Combining these findings, careful attention should be given 
equally to both sexes between 40 and 60 years of age, as there is a realistic chance to 
not only find late, but also early-to-medium stages.  
After looking at possible target groups and examination methods for reasonable glau-
coma detection at LSFEH, some special challenges at this particular setting shall be 
highlighted.  
4.6.2 Special considerations regarding glaucoma management at LSFEH  
Great challenges in glaucoma assessment at LSFEH are the presence of only one worn-
out ICT and only a few GATs. Perimetry was not available at LSFEH during the time of 
the study and alternatives should be considered and implemented in the meantime. 
Instead of optic nerve photographs, which cannot be taken of every glaucoma patient 
upon every visit, a schematic drawing as recommended by the AAO is a practicable 
measure for better documentation of fundus findings. (AAO 2010b)  
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In order to achieve a higher glaucoma detection rate, it would be ideal to train more 
clinical officers and other appropriate staff members in funduscopy, GAT and ICT. 
ICT is a quick and well-tolerated tool, which can be taught to receptionists and other 
non-ophthalmological staff members. CDR assessment as well as GAT should be taught 
early in ophthalmology education and should be mastered already by junior profession-
als.  
Further, public health education about glaucoma should be promoted, e.g. by national 
campaigns, posters or through health education at schools, communities, and among 
other health care workers, as suggested similarly by Schulze Schwering et al. Major 
burdens were costs for public transport. If transport and examinations cannot be offered 
free of charge, patients or family members of glaucoma patients are unlikely to present 
regularly, if at all, for check-ups. Thus, national efforts should be strengthened to sup-
port these measures for prevention of blindness. (Schulze Schwering et al. 2014) 
Besides strengthening the awareness among health workers, compliance of patients can 
be ameliorated by stressing the seriousness of the disease. It has to be explained that 
even in absence of symptoms or pain, the presence of the disease may be detrimental. 
Painlessness is a feature which makes it difficult to convey the seriousness of glaucoma 
and convince affected people to spend money on treatment. (Kosoko et al. 1998) 
Another challenge in the general management of glaucoma is poor compliance to treat-
ment, apart from a general poor availability of treatment options and provisions. (Kyari 
et al. 2013) In case of apparent inability or unwillingness of patients to comply to or pay 
regular therapy with medication, surgical options should be considered earlier than 
might be the case in settings where medication is readily available. An article on glau-
coma management in Africa states that surgery “is almost always the correct treatment 
in Africa, where medical therapy throughout the patient’s lifespan is impractical”. 
(Bowman & Kirupananthan 2006) Besides the practical fact, surgical solutions can be 
cheaper for individuals, national and global economies, compared to long term glauco-
ma treatment. Especially in economically challenged countries, prevention of high 
treatment costs should be a major concern, since not even developed economies can 
afford the costs of preventable blindness. (Adio & Onua 2012)    
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A big challenge for treatment of glaucoma at LSFEH is the reported fact that medica-
tions are often less effective in individuals of African descent than in other populations. 
(Tielsch 1991) Also surgical outcomes are less successful in Africans as well as in 
Asians, due to a stronger and more rapid scarring process of tissues. (Kingman 2004) 
Also in this respect, further research about treatment options in these populations is 
desirable. 
As previously mentioned in chapter 4.2, 10% prevalence of increased IOP among ap-
parently healthy populations in this African region may be appropriate. A slightly high-
er prevalence of 11-18% among ophthalmologic patients seems to be a realistic approx-
imation, which may be used as a basis for further discussions or consecutive researches.  
As a US professor of ophthalmology expresses, it is very positive that in general, blind-
ness caused by POAG has been reduced. Yet, still too many do suffer this fate, especial-
ly in less developed countries. Therefore, further research on glaucoma is strongly 
supported. (AAO 2014) For Malawi it is desirable that the proposed recommendations 
may stimulate further discussion and verification in theory and practice on-site.       
4.7 Limitations of study design and data collection 
In every clinical study, limitations and controversies are inevitable. Firstly, an absolute 
diagnosis of glaucoma cannot be given due to limitations of examination possibilities. 
The lack of visual field testing devices and regular documentation, e.g. of fundus find-
ings for the estimation of disease progression, are reasons for partly rather subjective 
diagnoses. Even though glaucoma diagnosis by CDR assessment is in itself subjective 
and is different from clinician to clinician, the limited technical possibilities for diagno-
sis and documentation are an added complication. Foster et al. mention the absence of 
perimetry and a diagnosis of glaucoma which is only based on CDR and tonometry, 
may lead to an underestimation of glaucoma cases. (Foster et al. 2002) Nonetheless, the 
presence of the ASOCT due to donation was an important feature to detect possible 
causes of glaucoma. The true prevalence of glaucoma at LSFEH might thus be higher 
than detected throughout the studies. In general terms, it is possible that some cases 
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were missed and others might be diagnosed incorrectly. Nonetheless, the thesis gives an 
approximation to the disease patterns and numbers in this region of Malawi.  
Secondly, a major constraint in producing significant and comparable data is the fact 
that various definitions exist for several of the used parameters. Blindness and glauco-
ma itself are defined differently in existing literature. In developing countries, due to 
limited possibilities, definitions and diagnoses cannot be made in the same way and 
perfection as elsewhere. Different methods are used to record e.g. VA, IOP, or CDR. 
Furthermore, study samples are often small, and especially among the scarce data from 
Africa, samples often represent a rather confined portion of a population. This leads to 
discussions and comparisons of numbers and figures which are often not based on the 
same standards and definitions. (Kyari et al. 2013)   
A third limiting factor was the momentary pressure documentation, as ICT and GAT 
measurements were recorded only at one point in time. Some patients were invited to 
come back for check-ups, of which some did and some did not return. It was not record-
ed in the data of this thesis, as it was not possible to organize and survey it in the limited 
period of time. Furthermore, the detection of NTG was only possible in the study A, as 
people with normal IOP levels were excluded in study C. NTG or those glaucoma pa-
tients who presented with normal IOP values at that specific time, but have e.g. noctur-
nal pressure spikes, will have been missed. This represents a further indication for 
actually higher numbers of glaucoma at LSFEH then detected in this thesis.  
In the discourse on IOP assessment and diagnosis of glaucoma, it has to be added that in 
those cases in which patients presented with very high pressures, their cornea was often 
too hazy to access the fundus. Still they were defined as glaucoma cases, since their 
pressure and thus the likelihood of glaucoma put them at high risk. Often patients with 
hazy corneas, and also those without hazy corneas but high pressures, were sent for 
check-up. As mentioned before, this data, though, has not been recorded.  
Nevertheless, there were cases in which raised IOP levels were detected at first visit, 
and normal values upon the second visit. Still, it was recorded as “raised IOP” due to 
the findings at first presentation. It was not possible to keep track of all patients who 
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returned for check-ups, because second assessments were not always done by the per-
sonnel of the study, but also by other staff at LSFEH. 
All data regarding age has to be looked at in light of the fact that the exact date of birth 
is often not known and not correctly documented. Especially in the older generation, 
only rough estimates about age can be given. A common answer on their age among 
patients was “about 50 years”. For statistical evaluation we had to record this approxi-
mated age with a specific number, which might not represent the true age. In case of the 
female patient with 112 years, it can therefore not be claimed with certainty if this 
information was correct. 
Partial inaccuracies have to be assumed in terms of GAT measurements as well as VA 
assessment. Further, some of the patients were examined for the first time in their life, 
especially as GAT is a procedure which requires training and accustoming on the part of 
patients. Practical application was sometimes difficult, and therefore measurement 
inaccuracies are possible in this respect. As far as VA testing is concerned, it was some-
times difficult to instruct patients correctly, and often they did not fully understand the 
tasks. Thereby, some data on VA might be imprecise.   
On the one hand, the sample selection of the studies cannot be considered to be random-
ized, and does not raise the claim to represent the general Malawian population like a 
population-based epidemiological survey would. On the other hand, this sample pro-
duced a much higher yield of the targeted glaucoma cases than would have been ob-
tained from a broad population screening. The sample is thus partially biased. Firstly, 
because it was hospital-based and even the sample of healthy people was selected on the 
premises of the hospital for practical reasons. Secondly, the sample represents a poorer 
fraction of the population as the hospital is public and frequented more by those who 
cannot afford to pay for private clinics. Blantyre is an urban centre and thus patients 
presenting to LSFEH do not necessarily represent rural populations. 
Many important additional factors for the development of glaucoma have not been 
included in this study. Myopia, vascular pathologies, high blood pressure, diabetes, or 
the use of steroids could have a great influence and more research has to be done to 
evaluate these patients as potential target groups in glaucoma screenings. A possible 
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obstacle to this effort might be that patients often do not know their blood pressure, 
diabetic, or sickle cell status. (Ntim-Amponsah et al. 2005)  
Some glaucoma cases presented with a good CDR of e.g. 0.2 in at least one eye. This 
can be explained firstly by the fact that diagnosis of glaucoma was also given due to 
very high IOP findings only, yet without suspicious CDR. This was justified because 
such high IOP puts those patients at high risk for the future development of glaucoma-
tous changes. Further, in case of secondary glaucoma or POAG which affected only one 
eye, the other, unaffected eye of this patient is also recorded. 
A remark was made by Nangia et al. that large optic discs, commonly found in black 
patients, might lead to an over-diagnosis of glaucoma. (Nangia et al. 2013) The fact that 
all clinicians performing optic disc assessment in the present study are experienced and 
accustomed to the African population, this misjudgement can be regarded unlikely. 
A further comment is dealing with the treatment, which was prescribed to patients 
newly diagnosed with glaucoma. Even though consequences and seriousness of the 
disease were thoroughly explained in local language, it has to be assumed that not eve-
rybody will have bought the needed drugs. The hospital pharmacy was supposed to 
provide glaucoma medications, but they were regularly out of stock. Thus, patients were 
urged to buy it on their own expenses. In many cases, this is unlikely to have happened 
due to lack of financial resources and compliance, particularly since treatment is usually 
necessary for the rest of their lives. The same doubt exists in respect to regular follow-
up visits. 
In terms of statistical analysis it is a limiting factor to the expression of significance that 
for example in the dichotomous variable of glaucoma diagnosis the two groups are 
comprised of very different sample sizes of 1081 healthy against 27 glaucoma cases.  
Lastly, it cannot be anticipated whether the proposed guidelines are workable for glau-
coma detection at LSFEH. They may nevertheless stimulate further discussions, as well 
as verification in theory and practice among ophthalmologists and health care workers 
at LSFEH, elsewhere in Malawi and other countries in the developing world. 
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5 Summary 
Glaucoma is the second leading cause of blindness worldwide, in Africa and also in the 
African country Malawi. It is said to cause 8 to 12% of global blindness. The prevalence 
of glaucoma in Africa is estimated to be about 4.79%. According to the research, there 
is no scientific data for Malawi. This thesis was designed to create a database for this 
African country with information regarding features of healthy and glaucomatous eyes, 
with a focus on intraocular pressure (IOP), optic disc appearance and central corneal 
thickness (CCT). It further analysed the prevalence of increased IOP above 21 mmHg, 
as this is one of the major risk factors for the development of glaucoma. The prevalence 
of glaucoma in Malawi were approximated. 
The clinical research consisted of three cross-sectional studies, carried out between 
August and October 2014 at Lions Sight First Eye Hospital (LSFEH) in Blantyre, Ma-
lawi. The first study (A) comprised 200 people randomly recruited on the hospital 
premises, who were presently not seeking medical help for visual disturbances and 
without a known diagnosis of glaucoma or high IOP. The intention was to gather data of 
the average Malawian population as a basis for further studies. Results indicated the 
prevalence of increased IOP and the number of glaucoma cases among them. The se-
cond study (B) consisted of 1,112 patients at the outpatient department (OPD) of 
LSFEH. It aimed at getting a maximum number of IOP measurements by ICare tonome-
try (ICT), detecting the average IOP and prevalence of increased IOP. The third study 
(C) consisted of 106 patients with increased IOP values in three consecutive ICT meas-
urements in study B. This enabled to detect the actual prevalence of glaucoma among 
those suspicious by ICT values. The data of glaucoma patients was analysed separately 
to describe characteristics of glaucomatous eyes.  
The thesis resulted in conclusions regarding the effectiveness of an ICT screening for 
glaucoma and possible guidelines for glaucoma screening at LSFEH. Results were 
evaluated in mean, median, minimum-maximum-ranges, frequencies, and percentages. 
Subgroups were formed using SPSS, e.g. by glaucoma diagnosis, gender, age above and 
below 40 years or patients with CDR above 0.8 in funduscopy. Correlations were calcu-
lated for all metric variables.  
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The prevalence of increased IOP above 21 mmHg among the non-glaucomatous sample 
(A) was 10%. Among ophthalmologic patients at the OPD (B) the prevalence was 11 to 
18%, depending on gender and age. The general glaucoma prevalence in the healthy 
sample was 2.5%, whereas in the age group above 40 years it rose to 4.6%, which is in 
accordance with prevalence numbers for Africa. Glaucoma prevalence among those 
with increased IOP (C) was 25.5%.  
The main glaucoma type of all examined patients from study A and C was primary 
open-angle glaucoma (POAG) with 60 to over 70%. CCT values were found to be 
thinner than in other data from African populations. Mean CCT of the healthy sample 
was 509.2 µm and among POAG patients it was 516.2 µm. In study C the group with a 
CDR 0.8 or worse had a CCT mean of 501.6 µm. The thinnest corneas were found 
among POAG patients above the age of 40 with a mean of 494.5 µm.  
In study A the ICT sensitivity was 80% with a specificity of 90%, a positive predictive 
value of 17% and negative predictive value of 99.4%. Therefore, ICT alone cannot be 
regarded as a useful screening method. No recommendation for a general ICT screening 
of the Malawian population or all patients at the OPD of LSFEH can be made.  
A guideline for a focused glaucoma screening at the OPD of LSFEH was developed, 
using a combination of screening methods. Accordingly, every patient of 40 years and 
above, presenting at the OPD with visual impairment should receive ICT measurements 
in combination with funduscopy. To avoid the risk of missing glaucoma due to fast 
cataract diagnoses, every patient with cataract should get an IOP and a fundus assess-
ment. In case of IOP above 21mmHg or suspicious fundus findings, patients should be 
checked regularly with ICT and funduscopy in intervals of two to three years. Due to 
financial obstacles, it will most likely be difficult for many patients to follow these 
intervals. Therefore it is recommended, that abovementioned target groups should at 
least get ICT measurements and funduscopy at their first visit. 
This guideline shall encourage a focused glaucoma management at LSFEH and thus 
avoid cases of preventable blindness. 
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German Summary 
Glaukom ist die zweithäufigste Ursache von Blindheit weltweit, in Afrika und in dem 
afrikanischen Land Malawi und ist verantwortlich für 8 bis 12% der globalen Blindheit. 
In Afrika wird die Prävalenz von Glaukom auf 4.79% geschätzt. Wissenschaftliche 
Daten für Malawi sind soweit ersichtlich bisher nicht erhoben. Diese Arbeit diente der 
Erstellung einer Datenbasis für das afrikanische Land und lieferte Informationen bezüg-
lich typischer Charakteristika von gesunden sowie glaukomatösen Augen. Der Fokus 
lag auf intraokularem Druck (IOD), Cup-Disc-Ratio (CDR) und zentraler Hornhautdi-
cke (ZHD). Die Prävalenz von erhöhten IOD über 21 mmHg wurde ermittelt, da dies 
einer der Hauptrisikofaktoren für die Entstehung von Glaukom darstellt. Schließlich 
wurde sich der Prävalenz von Glaukom in Malawi angenähert.  
Die klinische Forschung bestand aus drei Querschnittsstudien, welche zwischen August 
und Oktober 2014 an der Augenklinik „Lions Sight First Eye Hospital“ (LSFEH) in 
Blantyre, Malawi, durchgeführt wurden. Die erste Studie (A) umfasste 200 zufällig 
ausgewählte Personen auf dem Krankenhausgelände, die aktuell nicht wegen Sehbe-
schwerden einen Arzt aufsuchten bzw. kein bekanntes Glaukom oder erhöhten IOD 
hatten. Dadurch sollten Werte der durchschnittlichen Malawischen Bevölkerung erho-
ben werden, die als Basis für weitere Studien dienen können. Die Ergebnisse zeigten die 
Prävalenz erhöhten IODs und der Glaukome in einer gesunden Malawischen Studien-
population. Die zweite Studie (B) bestand aus 1,112 Patienten, die sich in der Ambulanz 
der Augenklinik befanden. Sie zielte auf eine möglichst große Zahl von IOD-
Messungen mittels ICare Tonometer (ICT) ab, um einen Durchschnitts-IOD und die 
Prävalenz erhöhten IODs zu detektieren. Die dritte Studie (C) umfasste 106 Patienten, 
die in drei aufeinanderfolgenden ICT-Messungen im Rahmen der Studie B einen erhöh-
ten IOD hatten. Dies ermöglichte die Glaukomprävalenz unter denen zu bestimmen, die 
suspekte IOD-Messungen aufwiesen.    
In der Arbeit wurde der Nutzen von Glaukom-Screenings mittels ICT ausgewertet und 
eine Screening-Leitlinie für Glaukom am LSFEH erstellt. Die Ergebnisse wurden mit 
Mittelwert, Median, Minimum, Maximum, Häufigkeiten und Prozenten angegeben. Mit 
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Hilfe von SPSS wurden Untergruppen nach z.B. Diagnose, Geschlecht, Alter oder CDR 
erstellt. Korrelationen der metrischen Variablen wurden berechnet.  
In Studie A wiesen 10% der untersuchten Personen einen erhöhten IOD auf. Unter den 
Patienten in Studie B waren es 11 bis 18%, abhängig von Alter und Geschlecht. Die 
Glaukomprävalenz betrug 2.5%.  In der Gruppe der über 40-jährigen waren es den 
Prävalenzzahlen in Afrika entsprechend 4.6%. In Studie C betrug die Prävalenz 25.5%. 
Das primäre Offenwinkelglaukom (POWG) stellte mit 60 bis 70% die Hauptform der 
Glaukome in Studie A und C dar. Die ZHD-Werte waren geringer als in anderen afrika-
nischen Populationen. Sie betrugen unter den Gesunden durchschnittlich 509.2 µm und 
unter POWG-Patienten 516.2 µm. Patienten mit einer CDR von 0.8 oder mehr wiesen 
eine durchschnittliche ZHD von 501.6 µm auf. Die dünnsten ZHD-Werte von 494.5 µm 
wurden unter den POWG-Patienten über 40 Jahren gefunden.   
In Studie A wurde eine ICT-Sensitivität von 80% und eine Spezifität von 90% errech-
net, mit einem positiv prädiktiven Wert von 17% und einem negativ prädiktiven Wert 
von 99.4%. ICT-Messungen allein können nicht als adäquate Screening-Methode ge-
wertet werden. Ein generelles Screening aller in Malawi oder auch aller Patienten im 
LSFEH erscheint nicht sinnvoll. Vielmehr wird ein fokussiertes Screening mit einer 
Kombination von Methoden vorgeschlagen.  
Jeder Patient über 40 Jahre, der sich mit Sehverschlechterung in der Ambulanz vorstellt, 
sollte ICT-Messungen in Kombination mit Funduskopie erhalten. Um Glaukome bei 
Kataraktpatienten nicht zu übersehen, sollten diese ebenfalls IOD-Messungen und 
Funduskopie erhalten. Im Falle von IOD-Werten über 21 mmHg oder auffälligem Fun-
dus sollten Patienten regelmäßig mittels ICT und Funduskopie in Intervallen von zwei 
bis drei Jahren kontrolliert werden. Da dies für viele Patienten voraussichtlich insbe-
sondere aus finanziellen Gründen nicht umsetzbar ist, wird empfohlen, dass die genann-
ten Zielgruppen mindestens bei ihrem ersten Besuch die ICT-Messungen und Fun-
duskopie erhalten. Diese Empfehlungen sollen ein fokussiertes Glaukommanagement 
am LSFEH fördern und somit vermeidbare Fälle von Blindheit verhindern. 
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9.3 Data sheets 
9.3.1 Summary of all study findings 
Table A 1: Comparison of findings, 
study A healthy sample;  study B intraocular pressure (IOP) assessment; 
study C raised IOP sample; 
study A&C Primary open-angle glaucoma (POAG) patients 
 
Study A 
Healthy 
 
Study B 
OPD  
Study C  
IOP >21mmHg 
 
 Study A&C 
POAGs  
 
Total Number 200 1,112 106 22 
Gender distribution     
Female (%) 53.0 58.2 50.9 45.5 
Male (%) 47.0 41.8 49.1 54.5 
Age         
Mean / Median 35.3 / 32 41.2 / 36 46.6 / 43 52.0 / 54 
<40 n (%) 135 (67.5%) 617 (55.5) 44 (41.5%) 6 (27.3) 
>=40 n (%) 65 (32.5%) 495 (44.5) 62 (58.5%) 16 (72.7) 
Age group n (valid %)     
18-24 40 (20.0) 193 (17.4) 14 (13.2) 2 (9.1) 
25-39 95 (47.5) 424 (38.1) 30 (28.3) 4 (18.2) 
40-59 52 (26.0) 283 (25.4) 30 (28.3) 6 (27.3) 
60-79 13 (6.5) 190 (17.1) 31 (29.2) 10 (45.5) 
80-max - 22 (2.0) 1 (0.9) - 
IOP (ICT / GAT)  (only ICT)   
Total Mean  
Median  
16.6 / 15.4                 
16 / 15 
16.6          
15.5 
26.7 / 25.9   
24.5 / 24 
30.2 / 30.3    
27 / 26 
R_Mean 16.5 / 15.3 16.8   26.0 / 25.4 29.0 /29.3 
R_Median 16 / 15 16 25 / 24 27 / 26 
L_Mean 16.6 / 15.5 16.4           27.4 / 26.5 31.4 / 31.3 
L_Mean 16 / 15 15 24 / 24 27 / 26 
IOP >21mmHg no. (%) 23 (11.5) 154 (13.8) all all 
Dx      
Total n (%) 5 (2.5) 27 (2.4) 27 (25.5) all 
POAG 3 (1.5)  19 (17.9) all 
PEX 1 (0.5)  3 (2.8) - 
Secondary glau 0  5 (4.7) - 
NTG 1 (0.5)  0 - 
Suspects 5 (2.5) 20 (1.8) 19 (17.9) - 
CCT (µm)     
Total Mean / Median 509.2 / 507.5  527.8 / 527 504.7 / 505 
R_Mean / Median 508.9 / 506.5  523.8 / 523 514.4 / 504 
L_Mean / Median 509.5 / 508.5  531.7 / 531 518 / 506 
ACD (mm)     
R_Mean 3.0  2.8 2.8 
L_Mean 3.0  2.8 2.7 
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ACA  (°) Mean     
R_nasal / temporal 38 / 37  38 / 38 38 / 36 
L_nasal / temporal 38 / 38  39 / 38 36 / 39 
CDR 
Total Mean / Median 
0.3 / 0.3 
 
0.45 / 0.4 0.7 / 0.7 
R_Mean / Median 0.3 / 0.3  0.4 / 0.4 0.7 / 0.7 
L_Mean / Median 0.3 / 0.3  0.5 / 0.4 0.7 / 0.7 
>= 0.8 min. 1 eye, n (%) 4 (2.0)  20 (18.7) 10 (45.5) 
VA BE blind n (%) 0  4 (3.8) 1 (4.5) 
Cataract n (valid %) BE 31 (16.3)  30 (28.3) 10 (45.5) 
Abbreviations 4: ACA, anterior chamber angle; ACD, anterior chamber depth; BE, both eyes; CCT, central corneal 
thickness; CDR, cup-to-disc ratio; Dx, glaucoma diagnose; GAT, Goldmann-Applanation tonometer; glau, glaucoma; 
ICT, ICare tonometer; IOP, intraocular pressure; L, left eye; n, number; NTG, normal tension glaucoma; OPD, 
outpatient department; PEX, pseudoexfoliation glaucoma; R, right eye; VA, visual acuity;  
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9.3.2 Study A 
Table A 2: Summary of findings study A 
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Abbreviations 5: ACA, anterior chamber angle; ACD, anterior chamber depth; BE, both eyes; cat, cataract; CCT, 
central corneal thickness; CDR, cup-to-disc ratio; Dx, glaucoma diagnose; f, female; GAT, Goldmann-Applanation 
tonometer; glau, glaucoma; HM, hand movement; ICT, ICare tonometer; IOP, intraocular pressure; L, left eye; m, 
male; n, number; max, maximum; min, minimum; ND, normal distribution; NTG, normal tension glaucoma; NPL, no 
perception of light; OPD, outpatient department; PEX, pseudoexfoliation glaucoma; POAG, primary open angle 
glaucoma; R, right eye; SD, standard deviation; secondary glau, secondary glaucoma; VA, visual acuity;   
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9.3.3 Study B 
Table A 3: Summary of findings study B 
 
Abbreviations 6: Dx, glaucoma diagnose; glau, glaucoma; f, female; ICT, ICare tonometer; IOP, intraocular pressure; 
L, left eye; m, male; max, maximum; min, minimum; n, number; ND, normal distribution; R, right eye; SD, standard 
deviation; susp., glaucoma suspect; 
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Abbreviations 7: ACA, anterior chamber angle; ACD, anterior chamber depth; BE, both eyes; cat, cataract; CCT, 
central corneal thickness; CDR, cup-to-disc ratio; Dx, glaucoma diagnose; f, female; GAT, Goldmann-Applanation 
tonometer; glau, glaucoma; HM, hand movement; ICT, ICare tonometer; IOP, intraocular pressure; L, left eye; m, 
male; n, number; max, maximum; min, minimum; ND, normal distribution; NTG, normal tension glaucoma; NPL, no 
perception of light; OPD, outpatient department; PEX, pseudoexfoliation glaucoma; POAG, primary open angle 
glaucoma; R, right eye; SD, standard deviation; secondary glau, secondary glaucoma; SVI, severe visual impairment; 
VA, visual acuity; VI, visual impairment; 
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9.3.5 Primary Open-Angle glaucoma (POAG) sample 
Table A 5: Findings of POAG patients from study A and C, gender and age comparison 
 
POAGs  Women Men <40 years >=40 years 
N 22 10 12 6 16 
Gender distribution 
     female_n (%) 10 (45.5%) all 
 
3 (50%) 7 (43.8) 
male_n (%) 12 (54.5%) 
 
all 3 (50%) 9 (56.3) 
Age             
Mean / Median 52.0 / 54 46.0 / 48.0 57.9 / 68 26.0 / 26.0 63.25 / 66.5 
Min 20 20 21 20 43 
Max 78 73 78 36 78 
<40 6 (27.3) 3 ( 30.0) 3 ( 25.0) all 
 >=40 16 (72.7) 7 (70.0) 9 (75.0) 
 
all 
Age groups (n/valid %) 
     18-24  2 (9.1) 1 (10.0) 1 (8.3) 2 (33.3) - 
25-39 4 (18.2) 2 ( 20.0) 2 (16.7) 4 (66.7) - 
40-59 6 (27.3) 3 (30.0) 3 (25.0) - 6 (37.5) 
60-79 10 (45.5) 4 (30.0) 6 (50.0) - 10 (62.5) 
IOP (ICT/GAT) mmHg 
     Total  Mean (ICT/GAT)  30.2 / 30.3 26.1 / 25.4 28.4 / 28.2 28.3 / 26.8 26.9 / 26.9 
Total Median (ICT/GAT) 27 / 26 25.8 / 24.8 27.5 / 26.5 27.5 / 25.5 26.8 / 26.3 
Right_Mean 29.05 /29.32 27.13 / 26.6 27.89 / 27.78 29.6 / 27.8 26.67 / 27.0 
Right_Median 27 / 26 28.0 / 26.5 26.0/ 25.0 28.0 / 26.0 26.5 / 26.0 
Left_Mean 31.41 / 31.33 25.0 / 24.13 28.9 / 28.56 27.0 / 25.8 27.08 / 26.75 
Left_Median 27 / 26 23.5 / 23.0 29.0 / 28.00 28.0 / 25.0 27.0 / 26.5 
CCT µm 
     Right_Mean / Median 514.43 / 504 504.75 / 504.5 505.56 / 498.0 528.6 / 530.0 495.42 / 494.5 
 Left_Mean / Median  517.95 / 506 511.25 / 514.0 497.78 / 491.0 529.4 / 531.0 493.58/491.5 
CDR      
Right_Mean / Median 0.676 / 0.7 0.663 / 0.65 0.756 / 0.8 0.64 / 0.6 0.742 / 0.75 
Left_Mean / Median 0.711 / 0.7 0.65 / 0.7 0.767 / 0.8 0.72 / 0.7 0.708 / 0.7 
 (at least 1 eye)   >=0.8 10 (45.5%)  
 
3 (30.0) 7 (58.3) 2 (33.4), 
 
8 (50.0) 
Visual acuity  (%) 
     Right eye VI           >= 6/18 16 (72.7) 9 (90.0) 7 (58.3) 5 (83.3) 11 (68.8) 
Blind    <3/60 - >=1/60 1 (4.5) 0 1 (8.3) 0 1 (6.3) 
Blind        <1/60 (HM/NPL) 2 (9.1), 1HM, 
1NPL 
0 2 (16.7) 1 (16.7) (NPL) 1 (6.3) (HM) 
Left eye VI         >= 6/18 15 (68.2) 8 (80.0) 7 (58.3) 6 (100.0) 9 (56.3) 
Blind    <3/60 - >=1/60 1 (4.5) 1 (10.0) 0 0 1 (6.3) 
Blind <1/60 (HM/NPL) 5 (22.7) 1 (10.0) 4 (33.3) 0 5 (31.3) 
bilaterally blind 1 (4.5%) 0 1 (8.3) (B525) 0 1 (6.3) 
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Cat. (n/valid %) 
                       R 12 (54.5) 4 (40.0) 8 (66.7) 0 12 ( 75.0) 
                    L 10 (47.6) 3 (30.0) 7 (58.3) 0 10 (62.5) 
BE 10 (45.5%) 3 (30.0) 7 (58.3) 0 10 (62.5) 
Abbreviations 8: BE, both eyes; cat, cataract; CCT, central corneal thickness; CDR, cup-to-disc ratio; GAT, Gold-
mann-Applanation tonometer; HM, hand movement; ICT, ICare tonometer; IOP, intraocular pressure; L, left eye; n, 
number; max, maximum; min, minimum; NPL, no perception of light; POAG, primary open angle glaucoma; R, right 
eye; VI, visual impairment; 
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9.4 COMREC confirmation letter 
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9.6 Informed consent form including information sheet (English and 
Chichewa) 
Informed Consent Form 
Eye examination for glaucoma detection study including intraocular pressure 
measurements at LSFEH, Blantyre, Malawi 
Introduction  
We are conducting a research study on an eye disease called Glaucoma. You are invited 
to participate in the study but before you decide we ask you to read the information 
below and ask for any clarification.   
Glaucoma is a common eye disease in Malawi and a main cause of blindness. It occurs 
when the pressure in the eye is elevated and damages the nerve carrying image signals 
from the eye to the brain. Glaucoma leads to an in the beginning unnoticed, gradual and 
permanent loss of sight, leading to blindness if not treated. 
 
What is the purpose of the study? 
The aim of this study is to collect data about the prevalence of elevated eye pressure and 
specific types of glaucoma at LSFEH, Blantyre. The results of the research study will 
help us determine how common the disease is in this region of the country and find 
common forms in patients presenting to the clinic. This will contribute to a better 
knowledge and overview of the relevant eye diseases and help nurses and doctors to a 
better diagnose and treatment options for glaucoma.  
 
Do I have to take part? 
You are free to take part or not or to withdraw your consent at any time without giving a 
reason. Your refusal to take part in this study will not affect the standard care you are to 
receive in any way. If you agree to take part, you will be asked to sign this consent 
form. Information about you will be confidential and no participant’s results will be 
identified by name. 
 
If I take part what will happen to me? 
You will be asked some questions about your health and then you will undergo routine 
eye examinations. Eye examination will include testing your vision, measuring your eye 
pressure and looking at different structures of your eye through a microscope. None of 
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these examinations will be invasive or painful to you. The whole procedure will take 
about 30 minutes. 
If there is any relevant finding in our examination, you will be treated for the found 
condition.  
 
What are the risks/potential benefits of taking part? 
Patients in our study are going through a routine eye examination. As part of our re-
search study, we are taking extra time to record observations.  
Our examinations do not have any risks to your health.  
Contrarily, you can benefit from a thorough eye examination which can give you de-
tailed information about the health of your eyes. With this knowledge, you can be sure 
to have a solid examination and a chance for early detection of any irregularity in your 
eyes. If necessary we will give you the right treatment and ask you to come back for 
follow ups. 
 
If I am not pleased with the examinations what can I do? 
Complaints concerning how you have been treated during the course of the study can be 
forwarded to College of Medicine. 
College of Medicine Research and Ethics Committee (COMREC), College of Medicine, 
P/Bag 360, Chichiri, Blantyre 3, Malawi 
. 
When the study is finished what will happen to the results? 
Results of all participants will be combined and can be published in any important 
journal and presented at scientific conferences. You will not be identified individually 
in any report of the study findings. 
For further information, please contact:  
Christine Fertig; Email: christine.fertig@gmail.com 
 
Please read and sign this form if you are taking part in this study 
1. I have read (or have had another person read to me) the attached information 
sheet on this project, and have understood the purpose of the study. 
 
2. I give permission for someone from the research team to look at my medical 
records and I understand that any information will be kept confidential. 
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3. I understand that I will not benefit financially from this study. 
 
4. I know how to contact the research team if I need to. 
 
 
I …………………………… agree / disagree to voluntarily participate in this study 
and be examined by the study team. I understand that I am free to withdraw my consent 
at any time without giving a reason and without my medical treatment or legal rights 
being affected. 
 
……………………………….             …………………………     ……………… 
Patient Name                                       Signature                        Date 
 
In case of illiterate patient: 
........................................       .....................................     ..................................... 
Name of impartial witness        Signature    Date 
 
……………………………….     ………………………….      
…………………………… 
Name of Researcher                  Signature                              Date 
 
Thank you for taking part in this study!!! 
 
Chikalata chopempha chilolezo chanu 
Kuyeza maso komanso kadzadzidwe ka madzi m’maso pofufuza nthenda ya glau-
coma ku chipatala cha maso cha Lions ku Blantyre ku Malawi 
Zokhuzana ndikafukufuku wathu 
Ife tikupanga kafukufuku okhuzana ndi nthenda ya maso yotchedwa glaucoma ndipo 
tikukupemphani kuti mukutenge nawo mbali mukafukufuku wathuyi. Musanapange 
chisankho cholowa mukafukufukuyi, muli opemphedwa kuti muwerenge kaye zokhu-
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zana ndikafukufuku ameneyi pachikalatachi ndipo muli olandiridwa kufunsa mafunso 
kuti mumvetsetse. 
Nthenda ya glaucoma imakhudza anthu ambiri kuno ku Malawi ndipo ndi imodzi mwa 
matenda akulu akulu amene amayambitsa khungu. Glaucoma ndi nthenda imene madzi 
a m’maso amadzadza mopyola muyezo kenako nkumafinya komanso kupha misempha 
imene imanyamula zithunzithunzi kuchokera m’maso kupititsa ku ubongo. Koyambilira 
kwamatendawa, munthu samazindikira kuti mphamvu yakuwona ikuchepa. Koma 
pakapita nthawi opanda chithandizo, mphamvu yakuwona imapitilira kuchepa mpakana 
wodwalayo amagwidwa ndi khungu losachizika. 
Cholinga cha kafukufukuyi ndi chiyani? 
Cholinga cha kafukufukuyi ndi kudziwa za kuchuluka kwa vuto la kudzadza kwa madzi 
mopyola muyezo m’maso komanso kudziwa za mitundu ya matenda a glaucoma ku 
chipatala cha maso cha Lions, ku Blantyre. Zotsatira za kafukufukuyi zizatithandiza 
kudziwa kukula kwa vuto la nthenda ya glaucoma muchigawo chino cha Malawi ko-
manso kudziwa kabweredwe kosiyanasiyana ka matenda a glaucoma. Kudziwa izi, 
kuzathandiza anthu achipatala kuti apite patsogolo ndi njira zopezera komanso 
zothandizira vutoli. 
Kodi ndili wokakamizidwa kutenga nawo mbali? 
Muli ndi ufulu wotenga nawo mbali m’kafukufukuyi kapena kukana kapena kutuluka 
popanda kulongosola chifukwa pa nthawi iliyonse imene inu mwafuna. Kukana kwanu 
sikuzasokoneza munjira iliyonse chithandizo chachipatala chomwe inu mukuyenera 
kulandira. Ngati mwavomera kutenga nawo mbali pa kafukufukuyi, muli opemphedwa 
kusayinira pa chikalata chopempha chilolezochi. Chilichonse chokhuzana ndi inu chi-
zasungidwa mwa chinsinsi ndipo mayina anu sazagwiritsidwa ntchito polongosola 
zotsatira zakafukufukuyi. 
Ndikavomera kutenga nawo mbali, chitandichitikire ndi chiyani? 
Muzafunsidwa mafunso ochepa okhuzana ndi thanzi lanu kenako muzayezedwa maso 
anu. Poyeza maso anu, tizayamba ndikuyeza mphavu yakawonedwe kanu, kenako 
tizayeza kadzadzidwe ka madzi m’maso anu ndipo tizamaliza ndikuwunika maso anu 
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ndi makina woyezera maso. Poyezedwapo, simudzamva kupweteka kuli konse komanso 
simuzavulazidwa mu njira ili yonse ndipo kuyezaku kuzatenga nthawi yosapitilira 30 
minutes. 
Ngati mungapezeke ndi vuto lirilonse poyezedwapo, inu muzalandira chithandizo pavu-
tolo. 
Kodi pali chiwophyezo kapena ubwino uli wonse potenga mbali? 
Anthu olowa mu kafukufuku wathu aziyezedwa maso ngati m’mene wina aliyense 
angayezedwere. Koma poti uyu ndikafukufuku, tizatenga nthawi yowonjezera chifukwa 
chofatsilira pokuyezani masowo. 
Njira zathu zoyezera maso zilibe chiwophyezo chilichonse pa moyo wanu. 
Ku mbali inayi, pali mwayi woti inu mutha kupindula poyezedwa maso anu mofatsilira 
m’kafukufukuyi poti izi zitha kutiziwitsa zambiri za m’mene maso anu aliri. Patati 
papezeka vuto lirilonse lamaso anu, muzalandira chithandizo choyeneracho. 
Ngati ndili ndi dandaulo lokhuzana ndikafukufukuyi, nditani? 
Ngati muli ndi dandaulo lokhuzana ndikafukufukuyi, lemberani kalata ku: 
College of Medicine Research and Ethics Committee (COMREC), College of Medicine, 
P/Bag 360, Chichiri, Blantyre 3, Malawi 
Kafukufukuyi akazatha, zotsatira zake zizapita kuti? 
Zotsatira zakafukufukuyi zizaphatikizidwa nkulembedwa mu m’chikalata cha zachi-
patala komanso zizalongosoledwa ku misonkhano ya anthu ofufuza za sayansi. Dzina 
lanu silizatchulidwa polongosola zotsatira zonse za kafukufukuyi. 
Kuti mudziwe zambiri, mutha kulembera kwa:  
Christine Fertig; Email: christine.fertig@gmail.com 
 
Chonde werengani ndi kusayina pa chikalatachi ngati mwavomera kutenga nawo 
mbali pakafukufukuyu: 
1. Ndawerenga (kapena kuwerengeredwa) chikalata chopempha chilolezochi, 
ndipo ndamvetsa cholinga cha kafukufukuyu. 
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2. Ndikupereka chilolezo kwa anthu amene akupanga kafukufukuyu kuti atha 
kuwerenga zikalata zanga za chipatala ndipo ndamvetsa kuti chilichonse 
chokhudzana ndi ine chizasungidwa mwachinsinsi. 
 
3. Ndamvetsetsa kuti sindizapindula popeza ndalama kuchokera m’kafukufukuyu. 
 
4. Ndikudziwa njira zomwe ndingatsatire nditafuna kulumikizana ndi anthu ochita 
kafukufuku ameneyi. 
 
 
Ine …………………………… ndavomera / ndakana mwakufuna kwanga kuti ndi-
tenge nawo mbali mu kafukufuku ameneyi komanso kuti ndiyezedwe ndi anthu ochita 
kafukufukuyu. Ndamvetsa kuti ndili ndi ufulu otuluka m’kafukufukuyu mopanda ku-
pereka chifukwa ndipo izi sizizakhuza chithandizo chachipatala kapena ufulu womwe 
ndikuyenera kulandira.  
 
……………………………….             …………………………     ……………… 
Dzina                                                Sayini                                Tsiku 
 
Kwa anthu osatha kulemba: 
........................................       .....................................     ..................................... 
Dzina la mboni yapadera     Sayini                    Tsiku 
 
……………………………….     ………………………….      
…………………………… 
Dzina la ofufuza                       Sayini                                 Tsiku 
 
Zikomo kwambiri potenga nawo mbali m’kafukufukuyi!!! 
 
 
